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The demonstration of the etiologic role of oncogenic type HPV infection in 
cervical cancer has led to the development of the prophylactic vaccines Cervarix and 
Gardasil. Despite their licensure, current vaccines do not elicit complete protection 
against all 15 oncogenic HPV genotypes, and the high cost of these vaccines is a major 
hurdle in access to vaccination. During my thesis, I have compared several promising 
technologies as candidate preventive vaccines with the potential to target a broad swath 
of medically significant HPV types using approaches that are simple and inexpensive to 
manufacture, and thus represent potential alternatives to highly multivalent L1 VLP 
vaccines. An initial critical step was the development of pseudovirions derived from 
medically significant HPV types, and examining their assembly and infectious pathway 
for commonalities using inhibitors and antibodies. The HPV pseudovirions were utilized 
for measuring the neutralizing antibody responses to candidate vaccines and for vaginal 
challenge studies in mice. In passive transfer studies neutralizing antibodies by all 
vaccines tested were sufficient to mediate protection against experimental vaginal 
challenge, implying their central role in effecting immunity and their relevance as a 
correlate of protection. We compared four L2-based HPV vaccine candidates: 1. in vivo 
electroporation of a DNA vector expressing a codon-optimized L1 gene, 2. HPV16 L1 
capsomers linked with amino acids 13-47 of HPV18, HPV31, and HPV45 L2 in tandem 
(GST-+39/ǻ-L2x3), 3. A chimeric VLP presenting HPV16 L2 amino acids 17-36 in 
an immunodominant loop of HPV16 L1 (RG1-VLP), and 4. L2 multimer fusions 
comprising L2 protective domains (amino acids 11-88) derived from 8 or 5 different 
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HPV subtypes (11-88×8 and 11-88×5). Electroporation of L1 DNA vector elicited type-
restricted immunity but when different HPV type vectors were co-administered 
heterotypic L1 interactions produced interference. GST-+39/ǻ-L2x3 and RG1-VLP 
induced high titers of HPV16 L1-specific neutralizing antibody but moderate titers of L2-
specific antibody, although sufficient for cross-protection against other HPV types. L2 
multimers induced substantially broader protection against vaginal challenge with 
medically significant HPV types than either Gardasil or Cervarix in the mouse model. 
Our data suggest the potential of L2 multimer and RG1-VLP as next generation 
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a) Human papillomavirus associated cancers 
Like the hepatitis B vaccine, the development of the two licensed HPV vaccines is 
a medical triumph in both infectious disease and cancer prevention because the viruses 
targeted are each responsible for approximately 5% of all cancer cases worldwide. The 
two licensed HPV vaccines, Cervarix® (GSK) and Gardasil® (Merck), are composed of 
virus-like particles (VLPs) derived from the major capsid protein L1 of the most 
prevalent types in cancer, HPV16 and HPV18, and Gardasil also includes L1 VLP of the 
two benign types HPV6 and HPV11 that cause ~90% of genital warts. While L1 VLPs 
are highly immunogenic alone, both vaccines utilize an adjuvant; Gardasil contains 
amorphous aluminum hydroxyphosphate sulfate (AAHS), whereas Cervarix utilizes 
aluminum hydroxide and a toll-like receptor (TLR)-4 agonist, 3-O-desacyl-4’-
monophosphoryl lipid (MPL) A. 
The primary etiologic role of persistent HPV infection in causing ~500,000 
cervical cancer cases worldwide each year is firmly established, and thus with the advent 
of HPV vaccines and continued efforts in cytologic and viral DNA-based screening for 
precursor lesions (Figure 1) and ablative therapy of high grade squamous intraepithelial 
neoplasia (SIL), cervical cancer is a preventable disease [1,2]. Further, 40% of penile 
cancers, 40% of vaginal and vulval cancers, 90% of anal cancers, 3% of mouth cancers, 
and 12% of oro-pharyngeal cancers are also triggered by HPV and potentially 
preventable through vaccination [3]. HPV is a small, non-enveloped DNA tumor virus 
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and over 120 HPV genotypes have been described [2]. With increasingly sensitive new 
technologies investigators continue to find new types, but only approximately a dozen 
sexually transmitted ‘oncogenic’ HPV types are responsible for more than 95% of 











Figure 1.  Localization of capsid protein expression and viral genomes in a productive 
HPV16 lesion (low grade squamous intraepithelial lesion (LSIL/CIN1)).  
(a) Hematoxylin and eosin-stained section of cervical squamous epithelium; 
keratinocytes with markedly enlarged nuclei surrounded by cytoplasmic halo 
(arrowheads) in the upper epithelial layers characteristic of LSIL. (b) In situ hybridization 
for HPV16 genome; discreet nuclear signals (arrowheads) predominantly in the middle 
zone of the epithelium where the proliferating cells are just beginning to differentiate. (c) 
Immunohistochemistry of L1 using monoclonal antibody 1H8. (d) 
Immunohistochemistry for L2 using monoclonal antibody RG-1. Positive 
immunolabeling in the occasional keratinocyte nuclei limited to the upper epithelial 
4 
 
layers (arrowheads). The exquisite temporal/spacial regulation of viral genome copy 
number and late gene expression is apparent in this productive HPV16 lesion. In the basal 
epithelial cells the viral genome copy number is low (~100 episomes/nucleus), but as the 
cells divide and move up through the epithelium their differentiation triggers vegetative 
viral replication (producing a high copy number of ~104 episomes/cell), and in the 















b) Immunodominant and conformationally dependent neutralizing epitopes of L1 VLP 
Since HPV utilizes the host DNA polymerase for replication of its genome at a 
low error rate, HPV sequences have remained very stable, although it is likely that the 
different HPV genotypes have emerged over eons based on distinct tissue tropism (e.g. 
cutaneous versus mucosal epithelia) and to escape immune responses [4]. Indeed, while 
the sequences of the internal regions of L1 are highly conserved, the surface loops are 
hypervariable between HPV types and correspond to type-restricted and 
immunedominant neutralizing epitopes [5]. This suggests that the preferential 
accumulation of these changes in the hypervariable loops may reflect both selection to 
escape protective antibody responses and a lack of structural constraints in these loops. 
Thus L1 VLP-reactive neutralizing antibodies predominantly recognize only the type 
against which they were raised and consequently most genotypes are different serotypes 
[6]. Another notable feature is that the neutralizing antibodies overwhelmingly recognize 
conformational/non-linear epitopes, and this may also contribute to the specificity of 
binding [7]. Thus the licensed vaccines target the two most common HPV types found in 
cervical cancer, HPV16, and HPV18 (and one also targets the two most prevalent types in 
benign genital warts, HPV6, and HPV11) and this produces robust protection against 
persistent infection and intraepithelial lesions caused by these HPV types, but variable 
efficacy of protection of potentially reduced duration for other related HPV types [8,9]. 
For example vaccination with HPV16 L1 VLPs can also provide strong protection against 
HPV31 [10,11]. This is presumably because the sequence of HPV31 L1 is evolutionarily 
most closely related to HPV16 [12]. However the cross-neutralizing antibody titer is 
orders of magnitude lower than to the HPV16-specific response (T Kemp et al., abstract 
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BS2, 26th International Papillomavirus Conference, Montreal, Canada, July 2010). While 
this suggests that low titers of neutralizing antibody are sufficient for protection, it raises 
the question of the longevity of the cross-protective response. Similarly, HPV18 L1 VLPs 
can trigger an HPV45 cross-neutralizing and cross-protective response, but protection 
against other more divergent types is weak [10,11,13]. This contrasts the T cell responses 
to HPV L1 VLP which show some type restriction but in general are very broad, likely 
reflecting recognition of epitopes within the conserved internal portions of the L1 capsid 
[14]. As a consequence of the type-restricted nature of L1 VLP vaccines, there are 
ongoing clinical trials of a highly multivalent vaccine, comprising L1 VLPs of the two 
types found in ~90% of genital warts (HPV6 and HPV11) and the seven most prevalent 
HPV types detected in ~90% of cervical cancer cases (HPV16, HPV18, HPV31, HPV33, 
HPV45, HPV52, and HPV58). While both of the licensed vaccines utilize an adjuvant, 
L1 VLPs are remarkably immunogenic and produce robust neutralizing antibody 
responses even when patients are vaccinated without an adjuvant [15]. Indeed, a single 
dose of the licensed vaccine provides at least short-term protection, although the standard 
regimen is three immunizations (AR Kreimer et al., abstract LBA, 26th International 
Papillomavirus Conference, Montreal, Canada, July 2010). It is likely that several 
features of L1 VLP contribute to this immunogenicity. Firstly, their highly regular and 
close-packed display of neutralizing epitopes on the surface of the VLPs provides 
increased avidity for and crosslinking of reactive B cell receptors lowering the threshold 
for their activation compared to a monovalent antigen [16]. Secondly, L1 VLP can 
inherently activate both immature human myeloid and plasmacytoid dendritic cells (but 
not Langerhans cells) [17-19]. Thirdly, in contrast to typical protein antigens, L1 VLP are 
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rapidly taken up by immune cells facilitating presentation of MHCI and II epitopes, and 


















c) Mechanism of protection and immune correlates 
An important unanswered question is how vaccination with L1 VLP mediates 
protection. This question has been addressed in animal models, notably cottontail rabbit 
papillomavirus (CRPV) challenge of rabbits and canine oral papillomavirus (COPV) 
challenge of dogs. Specifically, passive transfer of sera from L1 VLP immunized animals 
SURWHFWHG QDࡇÕYH DQLPDOV IURP H[SHULPHQWDO YLUDO FKDOOHQJH >@ 7KLV LPSOLHV WKDW
neutralizing antibodies are sufficient to mediate protection, but does not rule out a 
contribution of cell-mediated immunity in protection. However, parenteral vaccination 
with L1 VLP did not impact wart growth in animal models, suggesting minimal impact of 
L1-specific T cell responses on established lesions. It should also be noted that 
vaccination with L1 VLP induced type-specific neutralizing antibodies and protection in 
animals, and that vaccination with denatured L1 failed to induce significant titers of 
neutralizing antibodies and was not protective. 
Clinical studies of potential immune correlates of protection have centered upon 
L1-specific serum antibody responses, as measured by Competitive Luminex-based 
Immuno-Assay (CLIA), L1 VLP ELISA, and in vitro neutralization studies [23]. Each of 
these assays indicates that almost all vaccinated patients generate a robust type-restricted 
serum antibody response to L1 VLP, corresponding with the high efficacy of type-
restricted protection. The serum antibody titers wane to a plateau a few months after the 
final immunization and appear stable thereafter. In one study of the licensed quadrivalent 
HPV vaccine, HPV18 L1 VLP-specific antibody titers determined by CLIA waned below 
the threshold of detection in 40% of patients by 48 months although the titers to the three 
other types in the vaccine remained detectable [24]. Despite the absence of CLIA-
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detectable HPV18 L1 VLP-specific antibodies, no new HPV18 infections were observed, 
suggesting that immunity remained [24]. This suggests that either immunity to HPV18 in 
these patients is cell-mediated, possibly by the reactivation of memory B cells, or the titer 
of neutralizing antibody required for protection is very low and its measurement by CLIA 
lacks adequate sensitivity. Although L1 VLP vaccination induces robust T cell responses 
in patients, the absence of a profound therapeutic effect of the licensed vaccines upon 
established HPV infection suggest that it is unlikely that the protection against HPV18 in 
the absence of a CLIA-detectable antibody response is cytotoxic T cell-mediated. 
Alternatively, it is possible that exposure to the viral inoculums triggers a reactivation of 
the B cell response and local production of neutralizing antibody in time to prevent an 
initial infection. However, several factors point to the limited sensitivity of the CLIA for 
detection of HPV18 L1-specific antibody as an explanation for this observation, and that 
low, but protective levels of neutralizing antibodies are maintained. Firstly, the threshold 
of this assay is set using antibody levels in natural infection, and it is possible that these 
titers are protective. Secondly, CLIA detects responses via competition of patient 
antibodies with a high avidity neutralizing monoclonal antibody to L1 VLP, and thus 
primarily detects high avidity responses to a single epitope. It is known that multiple 
neutralizing epitopes are displayed by L1 VLP, and thus these patients may have 
protective antibodies to other epitopes, and/or protective antibodies of lower avidity that 
are poorly detected by CLIA. 
While the L1 VLP ELISA assay is more sensitive than CLIA, it also detects non-
neutralizing and presumably nonprotective antibodies and may provide false positives. In 
vitro neutralization assays measure functional antibodies, but native HPV virions are hard 
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to generate for all types and in sufficient quantities. Furthermore, the readout of infection 
is early spliced viral mRNA assayed by quantitative RT-PCR, and this is relatively 
cumbersome. A technology based on infection of 293TT cells with HPV pseudovirions 
that carry marker genes has greatly simplified the in vitro neutralization assay [25]. 
Nevertheless, recent passive transfer studies in mice suggest that the in vitro 
neutralization assay may lack the sensitivity to detect the minimal protective level of 
antibody, and that the passive transfer approach may provide a better approach, albeit low 
throughput [26]. This may reflect differing mechanisms of infection and thus 
neutralization in vivo within the genital mucosa [26] as compared to in vitro with 293TT 
target cells [27] (Figures 2 and 3, respectively). In vitro neutralization assays also depend 
upon extensive dilution to measure antibody levels, and it is possible that low avidity 
antibodies are protective and poorly detected by this in vitro assay [28]. Nevertheless, the 
range of HPV types cross-neutralized by the sera of L1 VLP-vaccinated patients appears 
to correspond to the breadth of protection. 
That serum L1 VLP-specific antibody titer better correlates with protection than 
the robust L1-specific cell-mediated response raises several questions. Firstly, why does 
the L1-specific cellular immune response not clear established HPV infections? This may 
be explained in part by the unique biology of HPV [29]. HPV does not produce viremia, 
but rather is confined to epithelial lesions above the basement membrane and systemic T 
cell responses may not reach these lesions or may be suppressed therein. Most 
importantly, while all HPV infected cells express early genes E6 and E7, the capsid 
proteins are only expressed in the upper differentiating and dying layers (Figure 1). 
Consequently, L1-specific cellular immune responses do not target the basal epithelial 
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cells that harbor the infection, unless some type of bystander response can be triggered 
[29]. The second surprise is that serum neutralizing IgG titers are the relevant correlate 
for a purely mucosal infection and begs the question of how these antibodies reach the 
viral inoculum since systemic vaccination typically fails to induce a local IgA response 
(Figure 2). L1 VLP-specific IgG is detected in the vaginal fluid of vaccination patients 
and its level correlates with serum titer, although it varies with the menstrual cycle [30]. 
This indicates the occurrence of either active transport or passive transudation of the IgG 
into the vaginal fluid wherein it neutralizes the viral inoculum. However, it does not 
explain protection at cutaneous sites against HPV6 and HPV11 infections induced by 
vaccination. A second, not mutually exclusive, possibility is that the microtrauma that is 
associated with infection during intercourse and facilitating access for HPV to the basal 
epithelia may trigger a local exudation directly from plasma to the site of infection 
(Figure 2). It is unclear whether a minimal level of neutralizing antibody must be 
maintained sufficient to provide sterilizing immunity, or whether the viral inoculum can 
trigger a rapid anamnestic activation of memory B cells to produce neutralizing antibody 
locally [31]. The slow course of HPV infection and the ability to neutralize the virus 
many hours after binding to cell surfaces suggest that the latter is a possibility [32]. 
Indeed re-vaccination of individuals clearly triggers a robust anamnestic antibody 






Figure 2.  Models for the mechanisms of HPV infection in vivo and antibody-mediated 
protection.  
Day et al. have proposed models of infection and immunity based upon microscopic 
studies of HPV pseudovirions during vagLQDO FKDOOHQJH RI QDÕࡇYH PLFH DQG WKRVH
immunized with L1 or L2 [26]. (a) Infection of vaginal epithelium. Microtrauma to the 
squamous epithelium of the vagina/and or cervix associated with intercourse provides 
HPV access to the basement membrane. HPV binds to the basement membrane via 
heparan sulfate glycosaminoglycans (HSPGs) and this triggers a conformational change 
in the capsid exposing L2 for N-terminal clipping by secreted furin. The furin-cleaved 
HPV binds to a viral receptor on the surface of basal epithelial cells during wound 
healing to initiate infection. (b) L1 VLP-specific antibody-mediated protection against 
vaginal infection. In hosts vaccinated with L1 VLPs, neutralizing IgG passively 
transudates from the capillaries into the cervical/vaginal fluid and/or is actively 
exchanged. If the trauma is sufficient, direct exudation from plasma is possible at the site 
of wounding. High concentrations of L1 VLP-specific antibodies can prevent virions 
binding to the basement membrane. In the presence of lower antibody levels the binding 
of HPV to the basement membrane, and the cleavage of L2 by furin still occurs, but the 
virions are unable to transfer to the viral receptor on the basal epithelial cells and the 
virion-antibody complexes are released. (c) L2-specific antibody-mediated protection 
against vaginal infection. In the presence of L2-specific antibody, the binding of HPV to 
the basement membrane and the exposure of L2 occur. However, the antibodies bind to 
epitopes in the N-terminus of L2 after its cleavage by furin and the virions are unable to 















Figure 3.  Model of In vitro infection of 293TT and HaCaT cells by HPV (based upon 
[26,27]).  
(a) In vitro infection of 293TT cells. Early studies of in vitro infection by HPV utilized 
293TT or other transformed cell lines as target cells. HPV binds directly to the 293TT 
cell surface via HSPGs which triggers a conformational change in the capsid such that the 
amino terminus minor capsid protein L2 becomes exposed. Exposure of L2 renders it 
accessible to cleavage by furin [50]. Furin-cleavage of L2 is essential to infection and is 
associated with escape of L2 and the viral genome from the endosome. g secretase 
activity is also required for infection, but it is unclear what it cleaves [51]. The viral 
genome–L2 complex is too large to cross the nuclear envelope, but gains access to the 
nucleus as during mitosis while its membrane has dissolved [52]. (b) In vitro infection of 
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HaCaT cells or primary keratinocytes. In contrast to 293TT cells, HPV binds first to the 
laminin-5 associated extracellular matrix via HSPGs secreted upon the culture surface 
before infection of the immortalized keratinocyte line HaCaT or primary keratinocytes. 
Upon attachment to the extracellular matrix, the HPV virions undergo a conformational 
shift that exposes L2 for cleavage by secreted furin. Only then can the virions bind to a 
secondary receptor on the keratinocyte surface for subsequent uptake. Antibodies 
reacting with particular loops on the capsid surface (e.g. H16.V5 and H16.E70 
monoclonal antibodies) can prevent virions binding to the extracellular matrix, but these 
antibody-bound virions can still bind the cell surface, although infection does not occur. 
In the presence of antibodies reacting with other surface L1 loops (e.g. H16.U4 
monoclonal antibody), the binding of HPV to the basement membrane, and the cleavage 
of L2 by furin still occur, but the virions are unable to transfer to the viral receptor on the 
basal epithelial cells [27]. Likewise, L2-specific antibodies (e.g. RG-1 monoclonal 
antibody) allow the binding of HPV to the basement membrane, and the exposure of L2. 
The antibody binds to the exposed L2 after its cleavage by furin and the virions are 








d) Candidates for second generation HPV vaccines 
The identification of a correlate of protection is important to identify whether an 
individual immunization is successful, to validate batches or sources of L1 VLP vaccine 
produced by different manufacturers and/or in different systems (e.g. bacteria or plants 
[34,35]) and also in the development of second generation preventive HPV vaccines. One 
such potential second generation vaccine comprises L1 capsomers (the pentameric 
subunit of the VLP) that can be readily produced in bacteria [36]. The L1 capsomer-
based vaccine offers potential advantages of reduced cost, stability at ambient 
temperature that could facilitate introduction into low resource settings where HPV 
vaccines are most needed. Although L1 capsomers induce lower neutralizing antibody 
titers than VLP, protection is robust even without adjuvant and the use of an adjuvant can 
potentially close this gap [36,37]. Another approach of HPV vaccination is the use of 
naked DNA vectors, which are simple to manufacture, heat stable and delivered by gene 
gun, tattoo or electroporation to express codon-modified L1 in vivo [38]. The use of 
needles for immunization also provides a barrier to widespread use, and there are efforts 
to use live recombinant vectors, such as an L1 recombinant version of the orally 
administered typhoid vaccine Salmonella typhi [39]. The VLP vaccine could also be 
combined with other vaccines, either by mixing them together or by introducing the L1 
gene, for example into measles vaccine, or the tuberculosis vaccine BCG to deliver L1 
[40,41]. 
In selecting a correlate of protection, it should be both simple to use, readily 
standardized into predefined international units and ideally not specific to L1. The latter 
point is relevant because of several efforts to second generation HPV vaccines based 
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upon the minor capsid antigen L2 [42]. Vaccination with L2 protects animals from 
experimental viral challenge, but this immunity lacks the type restriction associated with 
L1 VLP vaccines [43,44]. The protection is mediated by broadly neutralizing antibodies 
that recognize conserved linear epitopes in the N-terminus of L2 [43,45]. Residues within 
the protective region of L2 play a critical role in viral infection and thus their sequence is 
conserved even in diverse HPV types [46,47] (Figure 3). The L2 cross-neutralizing 
epitope appears to be displayed on the capsid surface only during infection, and thus 
vaccination with virions or L1/L2 VLPs induces limited, if any, L2-specific antibody 
[27,44]. Unfortunately L2 does not form a particulate structure alone and therefore is 
significantly less immunogenic than L1 VLP, suggesting the need for an adjuvant for 
vaccination or for multimeric display of L2 in an immune-dominant epitope of a 













I) Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and 




Human papillomaviruses (HPV) comprise a family of at least 120 non-enveloped 
epitheliotropic viruses which contain a double-stranded circular DNA genome and are 
phylogenetically classified into five genera; alpha, beta, gamma, mu and nu [12]. 
Papillomavirus infections generally produce benign papillomas or warts of either skin or 
mucosa, such as condylomata accuminata (anogenital warts) associated with ‘low-risk’ 
types HPV6 and 11. However, the sexually transmitted ‘high-risk’ members of the alpha 
genus mucosal HPVs are essential etiological agents in cervical cancer, and also in a 
significant fraction of anal, penile, vaginal, vulval and oropharyngeal cancers [2,53]. 
HPV16 and HPV18 are the most impactful high-risk HPV types, together causing 70% of 
cervical cancer, with a dozen or so other alpha HPVs associated with the remaining cases 
[3,54], although it is important to recognize that the majority of infections are cleared by 
patients. The beta HPVs infect skin beginning early in childhood and are associated with 
non-melanoma skin cancer in sun-exposed areas of immunocompromised patients or 
those with the rare hereditary disease epidermodysplasia verruciformis (EDV), notably 
HPV5 and HPV8 [55]. Conversely, beta HPV infections are generally clinically 
inapparent in immune competent patients, but may cooperate with UV-induced DNA 
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damage in the development of cutaneous squamous cell cancers [55]. Infections with 
HPV of the gamma, mu and nu genera typically produce benign and self-limiting skin 
warts [12]. 
Papillomavirus virions have a non-enveloped 60nm diameter capsid with T=7d 
iscosahedral symmetry [56]. The capsid is formed from 360 molecules of the major 
capsid protein L1 via assembly of 72 star-shaped capsomers or pentamers, each 
comprising five L1 molecules. The capsid also contains as many as 72 molecules of the 
minor capsid protein L2 and, while its location is not totally clear, at least a portion of L2 
is buried at the base of central cavity at the center of each capsomer [57]. Five surface 
loops of L1 with high variation in amino acid sequence among different types contain the 
immunodominant neutralization epitopes and act as domain linkers for the conserved 
internal jelly roll structure [5]. 
Recombinant expression of L1 is sufficient to form virus-like particles (VLP) that 
mimic native virus morphologically and immunologically. Similar to infectious virions, 
VLP can bind to heparan sulfate proteoglycans (HSPG) on the cell surface, and HSPG 
mimetics such as soluble heparan sulphate or carrageenan compete this interaction [58-
64]. Indeed, consistent use of the carrageenan-based vaginal microbicide, Carraguard, 
with condoms was negatively associated with the acquisition of high-risk HPV infections 
in a randomized, double-blind and placebo controlled trial [65]. L2 facilitates viral 
genome encapsidation during virion assembly and is critical for infection [6,66]. At the 
initiation of infection, virions undergo a conformational change that reveals the amino 
terminus of L2 on the capsid surface such that it is cleaved by the cellular protease furin 
[50,67]. Furin cuts L2 at residue 11 in HPV16 and this cleavage is required for infection 
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[50]. L2 interacts with several cellular components, including cyclophilin, annexin, 
syntaxin-18 and sorting nexin 17, believed to contribute to infectious cell entry, although 
the mechanisms are not fully elucidated [68-71]. L2 also enables virion egress from the 
endosome and translocates with the viral genome to the nucleus to establish infection 
[72]. The regulated intra-PHPEUDQH SURWHDVH Ȗ-secretase is required for endosomal 
escape, but its cellular target remains to be defined [51,73]. 
The licensed HPV vaccines, Cervarix and Gardasil, were both developed to 
prevent HPV16 and HPV18 associated persistent anogenital infection and disease, in 
particular epithelial dysplasias and cancers, and Gardasil to also prevent benign genital 
warts associated with HPV6 and HPV11 [74]. Vaccination elicits type-restricted 
neutralizing antibodies and protection due to immunodominant epitopes formed by 
hyper-variable surface loops of the L1 VLP antigens [5]. Both vaccines provide limited 
cross-protection, particularly toward HPV31 or HPV45, close phylogenetic relatives 
ofHPV16 and HPV18, respectively [11,75,76]. However the duration of cross-protection 
is unclear, and is weak to ineffective for more distantly related types [77]. A nonavalent 
L1 VLP vaccine is currently in development to broaden protection among the high-risk 
mucosal alpha HPV types. Another approach is vaccination with the amino terminus of 
L2 including residues 11-88 [48,78,79]. This region of L2 is well conserved and can elicit 
broadly neutralizing antibodies, although at lower titer than L1 VLP, because L2 does not 
form an immunogenic VLP structure. However, because L2 protective epioptes are 
linear, those derived from multiple HPV types can be concatenated into a single antigen, 
e.g. Į-88×8 that compromises a fusion of the 11-88 region of the eight medically 
significant alpha HPV types 6, 16, 18, 31, 39, 51, 56 and 9DFFLQDWLRQZLWK/Į-
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88×8, or passive transfer of its antiserum, provides broad immunity against vaginal 
challenge with alpha HPV, but its activity against other genera has not been examined 
[78]. 
Our mechanistic understanding of papillomavirus infectious process(es) is based 
on studies generally performed with only a few HPV types. Here we examine if 
medically significant HPV types of different genera, carcinogenic potential and tropism 
share a common infection mechanism. As the known inhibitors and vaccines have also 
been tested predominantly against a limited number of HPV types, their breadth of 
activity cannot be fully appreciated. Further, several studies indicate differences in 
receptor usage and uptake pathways by different HPV types [62,80,81]. Because of the 
technical difficulties of culturing and measuring the infectivity of papillomaviruses in 
vitro, PsV are used as surrogates for biologic studies of native virions, particularly given 
their capacity to deliver a reporter construct upon its encapsidation by over-expression of 
L1 and L2 [82]. In light of this, we generated PsV for 34 HPV types from the alpha and 
beta genera to better understand the commonalities and differences in the infectious 










b) Materials and Methods 
 
1) Pseudovirion (PsV) production 
L1/L2 expression plasmids were provided by Martin Müller and Lutz Gissmann 
(DKFZ, Heidelberg, Germany), Christopher Buck and John Schiller (NCI, Bethesda, 
MD), and Helena Faust (Lund University, Malmö, Sweden) and Joakim Dillner 
(Karolinska Institutet, Stockholm, Sweden). Additional constructs were synthesized by 
Biobasic (Supplementary Table 1). Briefly, the L1 and L2 genes for individual isolates of 
HPV genotypes documented in Genbank were codon-optimized for expression in human 
cells and cloned with a 5’ Kozak sequence (GCCACC) and two 3’ stop codons 
(TAATAG) into the mammalian double expression vector pVITRO1-neo-mcs 
(InvivoGen) as listed in Supplementary Table 1. The L1 gene flanked by BamHI-XbaI 
was cloned into the BglII-NheI region of MCS2, followed by the L2 gene flanked by 
BamHI-XbaI which was cloned into the BamHI-AvrII region of MCS1. All HPV PsV 
were produced as described in 
http://home.ccr.cancer.gov/Lco/pseudovirusproduction.htm. Briefly, plasmids containing 
L1 and L2 late genes of different HPV types were transfected with plasmid expressing 
luciferase reporter gene into 293TT cells utilizing TransIT-2020 transfection reagent. 
Cells were incubated for 48 h at 37°C, harvested, washed with DPBS-Mg (DPBS 
supplemented with 9.5 mM MgCl2), and lysed with equal volume of lysis buffer (DPBS 
supplemented with 0.5% w/v Brij58 and 0.2% v/v benzonase). For PsV maturation, cell 
lysates were incubated for 24 h at 37°C and adjusted to 850mM NaCl. For extraction 
lysates were centrifuged at 10,000 x g for 10 min, and clarified supernatants loaded onto 
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a 12mL step gradient of Optiprep (39, 33, 27% w/v), and spun at 40,000 rpm in a SW40 
rotor for 15 h at 16°C. After centrifugation, 1mL fractions were collected from the top 
layer and the fraction demonstrating the highest infectivity was selected for further 
experiments. 
 
2) HPV Infectivity assays 
1.5 × 104 293TT, HeLaT or HaCaT cells in 100 µL DMEM-10 or KH-SV cells in 
100 µL KSFM were infected with 250, 500, 1000, or 2000 million particles of each HPV 
types in 100 µL medium in triplicate and incubated for 72 h at 37°C. Luciferase activity 
was measured as described in inhibition assays. All experiments were performed in 
triplicate. 
 
3) HPV Inhibition assays 
293TT cells were seeded at 1.5 × 104 cells in 100 µL 10% FBS DMEM (DMEM-
10) per well in 96-well plates and allowed to attach overnight. For heparin and 
carrageenan inhibition studies, heparin (Sigma H-4784) and carrageenan (Sigma C1138) 
were serially diluted in DMEM-10 and incubated with 250 million PsV particles of 
different HPV types in 100 µL DMEM-10 for 1 h at 37°C. Mixtures were added to 
293TT cells and incubated at concentrations of 64, 128, 256, 512 µg/mL of heparin or 
carrageenan for 72 h at 37°C. For furin inhibition studies, furin inhibitor 1 (Decanoyl-
RVKR-CMK) was mixed with 250 million particles of each HPV type in 100 µL 
DMEM-10 and the mixtures were immediately transferred to 293TT cells and incubated 
at 20 µM conceQWUDWLRQRI IXULQ LQKLELWRU IRUKDW&)RUȖ-secretase inhibition 
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studies, XXI was mixed with 250 million particles of each HPV type in 100 µL DMEM-
10 and the mixtures were immediately transferred to 293TT cells and incubated at a final 
concentration of 500nM XXI for 72 h at 37°C. As a positive control, 4 µL of L1 
antiserum from mice vaccinated i.m. with L1 DNA utilizing electroporation in 50 µL of 
culture medium was mixed with 250 million particles of each HPV type in 50 µL. 
Mixtures were transferred to 293TT cells and incubated for 72 h at 37°C. Following 
infection cells were washed with 1X PBS, and lysed with 30 µL of Cell Culture Lysis 
Reagent on rocking shaker for 15 min at room temperature. Lysates were transferred to 
96-well black plate and luciferase activity was measured by GloMax®-Multi Detection 
System after adding 50 µL of luciferin substrate to each well. All experiments were 
performed in triplicate. 
 
4) Neutralization assay 
293TT cells were pre-plated at 1.5 × 104 cells per well in 96-well plate and 
incubated 24 h at &/RIUDEELW/Į-88×8 antiserum [78] was serially diluted 
two-fold in 50 µL of culture medium. As a negative control, pre-immune serum was 
applied. 250 million particles of each HPV type in 50 µL of culture medium were mixed 
with serially diluted serum in triplicate and then transferred to pre-plated 293TT cells and 
cultured for 72 h at 37°C. Luciferase activity was measured as described above.  
 
5) SDS-PAGE and Western blotting 
Each HPV PsV preparation was normalized by the amount of L1 protein. Samples 
were boiled for 5 min with reducing gel sample buffer, subjected to SDS-PAGE analysis 
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using 4-20% Tris-HCl gels, and proteins were transferred to PVDF membrane. The 
membrane was blocked with 5% non-fat milk in PBST (PBS containing 0.1% Tween-20) 
at room temperature for 1 hour, inFXEDWHGZLWKDUDEELW/Į-88×8 antiserum at room 
temperature for 1 hour and binding detected with HRP-conjugated goat anti-rabbit IgG 
secondary antiserum. 
 
6) Quantitative real time PCR measurement of luciferase reporter plasmid 
Reporter plasmid was extracted from 20 µL of each HPV PsV preparation using 
PureLink Viral RNA/DNA extraction kits. The real time PCR was performed with 25 µL 
of universal PCR Master Mix, 900 nM of forward and reverse primers (TTG ACC GCC 
TGA AGT CTC TGA and ACA CCT GCG TCG AAG ATG TTG), 250 nM of TaqMan 
probe (6FAM-CCG CTG AAT TGG AAT CCA TCT TGC TC-TAMRA), and 5 µL of 
extracted reporter plasmid in 50 µL final volume using an I-Cycler IQ (Bio-Rad). Each 
sample was conducted in duplicate. 
 
7) Data analysis and Statistics 
To calculate the neutralization titer value (the reciprocal of the dilution that causes 
50% reduction in luciferase activity), the non-linear model Y=Bottom + (Top-Bottom) 
/(1+10^((LogEC50-X)*HillSlope)) was fitted to the log10 transformed neutralization data 
using Graphpad Prism 6 and the estimated EC50 [with 95% confidence intervals] is 
reported as the titer.  Comparisons between the infectivity of members of papillomavirus 
species was determined by the Mann Whitney test, and means ± standard error are 





1) Generation and characterization of 34 HPV PsV types 
PsV are useful surrogates for biologic studies of native virions, particularly given 
their capacity to recapitulate early events of papillomavirus infection and neutralization, 
deliver a reporter gene of choice and their relative ease of production [82]. Here we 
encapsidated a vector expressing firefly luciferase (pY-luc) into HPV PsV because of this 
reporter’s low background, high sensitivity and utility in the mouse challenge model [78]. 
Recombinant mammalian expression of papillomavirus capsid genes is dramatically 
enhanced by their codon modification [83,84], presumably reflecting the disruption of 
negative regulatory sequences [85]. Several PsV vectors have been previously described 
[25,82,86-88] and we generated constructs for additional HPV types that were not 
previously available (Sequences in Supplementary Table 1 and constructs may be 
obtained from Addgene (www.addgene.com)). HPV PsV were prepared by co-
transfection of 293TT cells with pY-luc and the L1/L2 expression vectors per standard 
methodology [82]. 
We first tested infectivity of each HPV PsV type normalized to 250 million 
particles (as estimated based on L1 concentration) by measuring luciferase activity 
(relative light units, RLU) 72 h post-infection in 293TT cells. The HPV PsV infected 
cells showed dramatic differences in reporter expression (Figure 4A). Overall, the 
cutaneous HPV type PsV showed lower infectivity compared to mucosal tropic types 
(p<0.0001), and the PsVs derived from alpha species HPV showed greater infectivity that 
those derived from beta HPV types (p=0.01). However, even for the weakest PsV types, 
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the signal observed was still more than 100-fold higher than background signal. 
Furthermore, pre-incubation of the PsV with rabbit antiserum raised against the cognate 
L1 VLP prevented reporter delivery, consistent with antibody-mediated neutralization of 
an infection rather than a non-specific transfection. Rabbit antiserum to L1 VLP was not 
available for a number of HPV types. Instead, sera were harvested from mice two weeks 
after electroporation i.m. three times at two week intervals with the an HPV L1 
expression vector [89].  Pre-incubation of the HPV PsV with these mouse antisera 
similarly inhibited reporter transfer (Figure 5)  
It is possible that the weak infectivity of the PsV derived from cutaneous HPV 
types reflects use of 293TT cells a target cell line, rather than one derived from skin cells. 
Therefore we also tested infectivity of diverse alpha and beta HPV PsV in HeLaT clone 4 
cells, a human cervical cancer line transduced with SV40 large T antigen [90], as well as 
in the spontaneous immortalized human keratinocyte cell line HaCaT [91], and KH-SV, a 
human keratinocyte line immortalized by transduction with SV40 large T antigen [92]. In 
both human skin keratinocyte-derived lines (HaCaT and KH-SV), the cutaneous HPV 
PsV demonstrated minimal or undetectable signals, whereas mucosal HPV PsV showed 
more robust infectivity.  Similar findings were seen for infection of HeLaT cells, 
implying that the weaker infectivity of the cutaneous HPV PsV does not reflect the use of 
293TT as target cells or the need to infect a line derived from skin keratinocytes (Figure 
6). 
L2 is known to play several important functions during virion assembly and 
infection, and therefore differences in the incorporation of L2 may account for the wide 
range of PsV infectivity by HPV type. Thus, the level of L2 incorporation into the 
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gradient-purified preparations of HPV PsV was analyzed by Western blot (Figure 4B) 
using a broadly reactive rabbit antLVHUXPWRWKH/DQWLJHQĮ-88×8 [78]. This Western 
blot analysis suggested that the PsV preparations of several cutaneous HPV types that 
exhibited low infectivity (Table 1) also contained low levels of L2, notably HPV23, 27, 
38 and 57 (Figure 4B). This does reflect the failure of the antiserum to recognize the L2 
of these HPV types because this antiserum, but not the pre-immune serum, can neutralize 
their infection. Furthermore, the L2 band was not apparent on Coomassie-stained SDS-
PAGE analysis of these PsV. Rather, this reflects poor expression of L2 and thus low 
incorporation into the PsV, as Western blot analysis of 293TT cells transfected with these 
constructs shows low levels of L2 (data not shown). 
Differences in the infectivity of each type of HPV PsV might also reflect variable 
efficiency in reporter plasmid encapsidation. Therefore the number of copies of 
benzonase-resistant, and therefore presumably encapsidated, reporter plasmid DNA 
present within 315ng of each gradient purified HPV PsV preparation was measured by 
quantitative real time PCR. The lowest levels of reporter DNA encapsidation were 
observed for PsV of HPV27, 57, and 34 (Figure 4C). Since L2 has been shown to 
facilitate genomic DNA encapsidation, the low DNA encapsidation by HPV types 27 and 
57 may reflect the low levels of L2 incorporated in these PsV. However the amounts of 
encapsidated plasmid and/or L2 were not always proportional to the relative infectivity 






Figure 4.  Assessment of infectivity, L2 incorporation, and reporter DNA encapsidation 
by PsV preparations of 34 HPV types. 
(A) 250 million particles (as estimated based on L1 concentration) of HPV PsV were 
transferred to 293TT cells, incubated at 37°C for 72 hours before cell lysis. Luciferase 
activity was measured in cell lysate (n=4). (B) Western blot analysis detecting L2 in 
100ng of each HPV PsV preparation using rabbit antLVHUXPWR/Į-88×8. (C) Reporter 
plasmid copy number of each PsV preparations for each HPV type sample was measured 
by quantitative real time PCR. Black and blue bars represent alpha and beta type, 








Figure 5.  Neutralization of PsV by L1 VLP antiserum 
PsVs of each indicated HPV type, each carrying a luciferase reporter gene, were mixed 
with mouse or rabbit L1 VLP antiserum or their respective pre-immune serum (each at 
1:50 dilution) for two hours at 37°C, then the mixtures were transferred to 293TT cells 
and cultured for 72 hours (n=3). Cells were then lysed and luciferase activity was 
measured. Percent neutralization by L1 VLP antiserum was plotted. Pre-immune serum 
was non-neutralizing in all cases. Red and blue bars represent mucosal and cutaneous 









Figure 6.  Infectivity of diverse HPV on mucosal and skin cell lines. 
HeLaT (A), HaCaT (B), KH-SV (C) cells were treated with titrations of diverse HPV 
PsV from alpha and beta subfamilies and incubated at 37°C for 72 hours. Cells were 
lysed after incubation and luciferase activity was measured. Red and blue bars represent 


















at pH 7.4 
Neutralization 





Į 32 M 5.2 3,360 2,225 to 5,074 
42 M 3.4 11,450 9,456 to 13,865 
Į 3 C 2 11,140 7,314 to 16,967 
Į 27 C -4.2 3,942 350 to 44,402 
57 C 1 3,440 858 to 13,789 
Į 26 M 5.2 11,223 7,786 to 16,177 
51 M 5.2 4,420 3,755 to 5,202 
Į 53 M 6.3 352 208 to 595 
56 M 5.2 1,536 1,243 to 1,898 
66 M 7.2 870 517 to 1,465 
Į 18 M 5.9 12,422 10,780 to 14,312 
39 M 5.1 6,216 3,798 to 10,174 
45 M 5.9 4,913 3,021 to 7,991 
59 M 7.1 8,214 7,255 to 9,300 
68 M 3.1 1,403 980 to 2,008 
70 M 4.1 2,359 1,382 to 4,027 
Į 40 M/C 4.2 834 380 to 1,830 
43 M/C 6.2 1,580 1,063 to 2,349 
Į 16 M 2 31,266 28,513 to 34,284 
31 M 8 2,212 940 to 5,207 
33 M 4.8 16,207 9,942 to 26,420 
35 M 7 7,458 5,151 to 10,800 
34 
 
52 M 5.9 927 651 to 1321 
58 M 4.5 14,807 8,904 to 24,622 
Į 6 M 7.1 5,553 4,315 to 7,146 
11 M 7.2 27,760 23,455 to 32,855 
44 M 7 5,041 2,716 to 9,358 
Į 34 M 5.7 13,140 11,689 to 14,770 
73 M 4.9 8,810 6,853 to 11,325 
ȕ 5 C -4.7 3,561 492 to 25,770 
8 C -2.8 17,679 7,256 to 43,073 
ȕ 38 C -4.8 1709 489 to 5976 
23 C -3.9 2475 834 to 7347 
ȕ 76 C -4.9 2110 1154 to 3861 
 
 
Table 1. Summary of the phylogeny, tropism, charge and in vitro neutralization by L2 11-
88×8 antiserum of the 34 HPV genotypes tested.  
Phylogeny and tropism were taken from de Villiers et al, [99] predicted net charge of L1 
at pH7.4 was calculated as described in [80]. PsVs of each indicated HPV type carrying a 
luciferase reporter gene were mixed ZLWKWLWUDWHGUDEELW/Į-88×8 antiserum for two 
hours at 37°C, then the mixtures were transferred to 293TT cells and cultured for 72 
hours. Cells were then lysed and luciferase activity was measured. Neutralization titer 





2) Inhibition of HPV infection by Heparin and ܼ-carrageenan 
CHO cells deficient in heparan sulfate proteoglycan (HSPG) production are no 
longer infected by HPV PsV [58], suggesting that HSPG is an important entry factor. 
Further soluble heparan sulfate can bind to capsids and is an inhibitor of infection for at 
least some HPV genotypes, but not all [62]. To explore the generalizability of these 
observations, we tested if heparin universally inhibited infection by PsV of all 34 HPV 
types within the alpha and beta HPV subfamilies. Ten-fold serial dilutions of heparin 
(Sigma H-4784), ranging from 10 to 1000 µg/mL, were incubated with the PsV of each 
HPV type for 1 hour at 37°C prior to transfer to 293TT cells to assess infectivity. Near 
complete inhibition was observed for PsV of all 29 alpha HPV types at 1000 µg/ml 
heparin, including HPV 31 (Figure 7A) for which the role of HSPG in infection is 
controversial [93]. With the exceptions of HPV8 and HPV23, infection by PsV of the 
beta HPV types was not impeded even at the highest concentration of heparin tested 
(1000 µg/mL), and paradoxically several demonstrated increased levels of infectivity 
[94]. Notably, the addition of 10 or 100 µg/mL heparin profoundly increased infectivity 
of HPV5, HPV57 and HPV76 PsV, slightly increased the infectivity of HPV38 PsV, but 
inhibited HPV8 and HPV23 PsV (Figures 7A and C). In contrast, even at 10 µg/mL 
heparin, most alpha HPV type PsVs exhibited significant inhibition. 
Carrageenan is also a potent inhibitor of HPV infection via a mechanism 
resembling that of heparan sulfate [60-63], although the breadth of its activity has been 
questioned recently [81]. It is currently being tested as a vaginal microbicide, and may be 
broadly protective against genital HPV transmission [65]. Therefore, we also tested the 
impact of carrageenan on in vitro infectivity of PsVs of diverse HPV types. The findings 
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resembled the inhibitory profile of heparin [62,80,95]. PsV of most alpha types were 
inhibited except HPV27 and HPV57, but carrageenan had limited impact on beta types 
(Figure 7B, D). Carrageenan was more potent in inhibiting alpha HPV PsV infection than 
heparin at 10 µg/mL (Figure 7), consistent with earlier findings [60]. Carrageenan also 
showed some differences in inhibitory efficacy against PsV of beta HPV types compared 
to heparin. For example, carrageenan did not inhibit HPV27 infection whereas heparin 
did, suggesting subtly distinct mechanisms of inhibition by carrageenan and heparin. 
Taken together, the results imply that different HPV subfamilies bind HSPG differently 
during infection, which may contribute to their differing tropism [62]. Further, heparin 
and carrageenan are broadly inhibitory against PsV of most alpha species of HPV 
(including all of the high-risk mucosal HPV types tested), but not against PsV infection 




Figure 7.  Inhibition of HPV PsV infection by titrations of heparin and carrageenan. 
PsVs of each HPV type carrying a luciferase reporter gene were incubated with 1000 
µg/mL, 100 µg/mL, 10 µg/ml or 0 µg/ml heparin (A) or carrageenan (B) at 37°C for 1 
hour. The mixtures were transferred to 293TT cells for 72h. After incubation cells were 
lysed and luciferase activity was measured, and percent infection compared to control 
was calculated (n=3). The percent inhibition of infection by each HPV PsV in the 
presence of 100 µg/mL of heparin (C) or carrageenan (D) was also plotted separately. 




3) Conservation of furin cleavage as an essential step for infection 
After binding to HSPG on extracellular matrix, HPV16 undergoes a 
conformational change and exposes the previously buried amino terminus of L2 on the 
capsid surface prior to cell entry [50,67]. The exposed amino-terminus of L2 is sensitive 
to furin cleavage as it contains a conserved consensus cleavage site, Arg-X-(Arg/Lys)-
Arg, and mutation of this site prevents HPV16 PsV infection. The furin inhibitor 
decanoyl-RVKR-cmk also can prevent HPV16 infection, suggesting cleavage of L2 by 
furin is a critical step for infection [50]. However, only a few HPV types have been tested 
and overall significance of furin cleavage among diverse HPV types has not been 
thoroughly addressed so far. Sequence alignment indicated that the furin target sequence, 
RX(R/K)R, is present in the L2 of all the HPV types for which we developed PsV, 
suggesting that the function provided by furin cleavage is conserved (data not shown). 
Therefore we tested whether application of the furin inhibitor at 20 µM (a concentration 
at which no cell toxicity was observed by XTT assay, data not shown) inhibited infection 
of 293TT cells by PsV of all 34 HPV types. Infection of 293TT cells by PsV of every 
alpha HPV was strongly inhibited, although it was less effective against some beta types 
such as HPV5  (Figure 8). Nevertheless, it is clear that the requirement for furin cleavage 




Figure 8.  Impact of furin inhibitor on infection by PsV of diverse HPV. 
PsVs of each indicated HPV type carrying a luciferase reporter gene were transferred to 
293TT cells for 72 hours in the presence or absence of 20 µM furin inhibitor. After 
incubation, cells were lysed, luciferase activity was measured and percent inhibition of 
infectivity compared to control calculated. Red and blue bars represent mucosal and 











4) &RQVHUYDWLRQRIQHHGIRUFOHDYDJHE\Ȗ-secretase during infection 
7KHȖ-secretase inhibitor XXI potently blocks HPV16 infection, and homozygous 
GHOHWLRQRIȖ-secretase component subunits nicastrin or presenilin-1 also prevents HPV16 
infection [51]7RGHWHUPLQHZKHWKHUWKHQHHGIRUȖ-secretase function during infection is 
conserved across diverse HPV types, we examined the impact of 500nM XXI upon 
LQIHFWLRQRI77FHOOVE\HDFK3V9W\SHV7KHȖ-secretase inhibitor XXI dramatically 
reduced the infectivity of the PsV of all 34 HPV types tested (Figure 9), LPSO\LQJWKDWȖ-
secretase is a key cellular factor that diverse genotypes utilize during infection and its 










)LJXUH,PSDFWRIȖ-secretase inhibitor on infection by PsV of diverse HPV. 
PsVs of each indicated HPV type carrying a luciferase reporter gene were transferred to 
77FHOOVIRUKRXUVLQWKHSUHVHQFHRUDEVHQFHRIQ0Ȗ-secretase inhibitor XXI 
(n=3). After incubation, luciferase activity was measured and percent inhibition of 
infectivity compared to control calculated. Red and blue bars represent mucosal and 











5) Neutralization of diverse HPV by DQWLVHUXPWR/DQWLJHQĮ-88×8  
The amino terminus of L2 contains a protective epitope and it is also 
evolutionarily highly conserved between types and even different species. We previously 
described that rabbit antiserum WDUJHWLQJWKH/DQWLJHQĮ-88×8 can neutralize a broad 
spectrum of mucosal HPV types, notably those associated with cervical cancer and 
benign genital warts, and that passive transfer of this antiserum protects mice from 
genital HPV PsV challenge [78]. While this candidate vaccine antigen was designed to 
broadly protect against mucosal HPV that are associated with cervical cancer and genital 
warts, it may also protect against cutaneous HPV types as there is considerable sequence 
conservation in the 11-88 region. Cutaneous HPV types have been associated with non-
melanoma skin cancers and benign skin warts that are costly to treat or a common 
nuisance, particularly for immunocompromised patients [55]. To examine the breadth of 
cross-neutralization against diverse HPV types, we tested antiserum from a rabbit 
vaccinDWHG ZLWK WKH / DQWLJHQ Į-88×8. PsV from each of the 34 HPV types was 
incubated with 2-fold serially diluted rabbit serum and the mixture was then transferred 
to 293TT cells to DVVHVVLQIHFWLYLW\7KHĮ-88×8 antiserum detectably neutralized PsV 
of all alpha and beta HPV types tested (Table 1), whereas the pre-immune serum did not.  
Likewise, this antiserum reacted with L2 in PsV preprations of all 34 HPV types tested in 
a Western blot analysis (Figure 4B). These observations suggest the potential of this 
candidate vaccine antigen to protect against diverse beta types associated with non-







The two licensed vaccines safely provide robust protection for men and women 
against acquiring infections by the two most potent oncogenic types, HPV16 and HPV18, 
and Gardasil also protects against the two most common types associated with genital 
warts, HPV6 and HPV11. In spite of their effectiveness, there is still a demand for new 
approaches for the prevention of HPV infection due to the high cost and type-restricted 
protection afforded by the licensed vaccines and also the need for immunization [96]. 
Aside from HPV16 and HPV18, about a dozen other oncogenic alpha HPV types are 
associated with cervical cancer, although each contributes only a minor fraction. 
Although the licensed vaccines provide varying degrees of cross-protection against 
closely related oncogenic HPV types, the extent and duration of cross-protection remain 
controversial [77]. Consequently, there are ongoing efforts to develop a nonavalent L1 
VLP vaccine to target the seven oncogenic HPV types most commonly detected in 
cervical cancer, as well as HPV6 and HPV11. However, inclusion of 9 HPV VLP types 
into a single vaccine formulation will most likely increase the cost of vaccine production, 
which is one of the main limitations to global implementation of HPV immunization. 
Moreover, there has been little focus on vaccination against cutaneous HPV types, 
notably the beta species. While the beta HPVs typically have minimal clinical impact 
among patients with intact immune systems, immunocompromised patients (i.e. HIV-
positive patients or those receiving immunosuppressive treatment following solid organ 
transplantation) and those with the rare hereditary syndrome EDV are vulnerable to non-
melanoma skin cancers caused by these beta types, notably HPV5 and HPV8  [55]. It is 
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unlikely that the licensed vaccines or even the new nonavalent vaccine will impact 
infection by the diverse beta HPV types, and therefore there is interest in alternative 
approaches to provide coverage against beta HPV. 
More than 120 HPV genotypes has been completely characterized so far, but 
studies of the mechanisms of infection have been focused only on a very limited number 
of HPV types of the greatest medical significance, mainly due to restricted availability of 
PsV of a few HPV types. Therefore to assist in understanding the biology of HPV as well 
as assessing the breadth of protection provided by new vaccine and microbicide 
candidates, we generated and tested a diverse set of 34 PsV including 29 alpha types and 
5 beta types (Table 1). The mechanisms underlying the different tropism of HPV are not 
understood. The alpha HPV types, with the exception of alpha2 and alpha4 subgroups, 
preferentially infect the genital mucosa and are sexually transmitted, whereas the beta 
HPV types infect the keratinizing squamous epithelium of the skin, typically starting 
during childhood. The distinct tropism may be governed by differences in entry into the 
cell, or viral transcription or replication, or a combination of these functions. To initially 
examine whether there are differences in the uptake processes of the predominantly 
mucosatropic alpha and cutaneotropic beta HPVs we tested the potency of known 
inhibitors of infection against PsV of the diverse range of HPV types. Use of PsV 
delivering a luciferase reporter for these studies eliminates any influence of viral tropism 
that would be conferred by the native viral genome with respect to viral transcription or 
replication. 
The initial studies focused on HSPG because it is the most studied cell surface 
receptor for HPV, and there is evidence of differential utilization by different genotypes 
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[62,80,81,93]. We verified that the two HSPG mimetics heparin and carrageenan are 
inhibitors of diverse mucosatropic HPV PsV infection. This is significant because of 
ongoing efforts to develop carrageenan as a vaginal microbicide and its use as an 
ingredient in many sexual lubricants. Both compounds completely inhibit infection by 
most alpha types at high and intermediate concentrations (Figure 7), although most alpha 
types demonstrated partial inhibition by 10 µg/mL heparin, the lowest concentration 
tested (Figures 7A and 7). However, while infection by HPV27 was blocked by heparin 
at 1000 µg/mL, carrageenan did not inhibit even at the highest concentration of 1000 
µg/mL (Figure 7B), possibly reflecting their different structures and mechanism of 
particle binding [80,95]. Notably, the alpha4 viruses HPV27 and HPV57 are capable of 
infecting cutaneous sites. A previous study suggested that cutaneous types tended to have 
negatively charged L1 at pH 7.4 and lower surface net charge compared to mucosal types 
[80]. We calculated a net charge for L1 of 34 HPV types at pH 7.4 and beta types (Table 
1). Interestingly HPV27 and HPV57 L1 display the lowest net charge at pH 7.4 among 
the 29 alpha types and they were not inhibited effectively by carrageenan at a 
concentration of 1000 µg/mL, 100 µg/mL and 10 µg/mL like most beta types and HPV57 
was not inhibited by heparin at 100 µg/mL and 10 µg/mL. These net charge differences 
may contribute to the distinct response of HPV27 and 57 PsV to the HSPG mimetics as 
compared with the other alpha types [80,95].  
When the concentration of heparin or carrageenan was reduced to 10 µg/mL, PsV 
of some cutaneous HPV types demonstrated enhanced infectivity (Figure 7A, B). This 
result was unexpected because heparin and carrageenan are inhibitors of mucosatropic 
HPV infection, although low amounts of heparin increased HPV infectivity in a recent 
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report [62,94,97]. It is possible that when virion surface is partially coated by heparin or 
carrageenan, it can trigger a conformational change which, in turn, enhances infectivity 
perhaps by rendering L2 more accessible to furin cleavage [94]. Conversely, if the virion 
surface is completely coated by heparin or carrageenan due to high affinity, and if the 
binding groove and charged residues on the capsid surface that interact with the HSPG 
cellular receptor are masked completely[58], this can potentially prevent cell binding and 
infection.  
Despite efficiently blocking infection by the mucosatropic alpha types, neither 
heparin nor carrageenan were consistent inhibitors of the cutaneous types, and indeed 
frequently promoted infection. This failure of heparin to inhibit infection by one beta type 
was also observed previously for HPV5 [62]. Several studies suggest that key surface 
exposed positively charged lysine residues in L1 are important for interaction of HPV16 
PsV with heparan sulfate, and mutation of these lysine residues resulted in reduced cell 
binding and infectivity. We aligned L1 of 34 HPV types tested and noted only one of 
these lysine residues, HPV16 L1 278K, is highly conserved in alpha types but not beta 
types (data not shown). Differences in interaction with HSPG-like molecules on the cell 
surface may account in part for the tropism of HPVs for cutaneous versus mucosal 
epithelia [62]. However, the relationship is not straightforward; heparin inhibited HPV3, 
HPV23 and HPV27, and carrageenan inhibited HPV3 and HPV23 infection (Figure 7). It 
is unclear whether heparin and carrageenan fail to inhibit most beta HPVs because they 
simply cannot bind to the virion, or they do bind but cannot block receptor interaction. A 
failure to bind beta HPV particles is unlikely since many PsV showed increased 
infectivity with addition of heparin and carrageenan. A potential concern with these 
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observations is that low numbers of infectious particles in the PsV preparation of the 
cutaneous HPV types could have led to an artifact, although L2 incorporation and 
encapsidation of reporter plasmid was similar to the alpha types. It is also important to 
recognize considerable variability in L2 incorporation, genome encapsidation and 
infectivity for PsV preparations of different HPV types when using them as a model for 
native virions assembled in warts [81]. 
We expected to observe broad spectrum blockade of HPV infection by furin 
inhibitor because the furin cleavage consensus sequence RX(R/K)R in L2 was conserved 
for all HPV types examined herein. This sequence and the requirement for furin cleavage 
is also conserved in bovine (BPV) and other animal papillomaviruses [50]. Furin 
inhibitor blocked infection by all HPV types tested although not completely for some 
beta PsV. This may reflect use by the beta types of protein convertases other than furin 
that are partially inhibited by furin inhibitor [50], or possibly an artifact relating to the 
lower signal to noise ratio for the less infectious types.  
7KHȖ-secretase inhibitor XXI also effectively inhibited PsV infection for all HPV 
types tested (Figure 9). Beta types, which tend to exhibit somewhat lower sensitivity than 
alpha types to the furin inhibitor, were strongly inhibited by XXI. The data suggest that 
all the HPVs follow a common entry pathway dependent upon both furin- DQG Ȗ-
secretase-dependent proteolysis, despite potential differences in interactions with cell 
VXUIDFH +63*V EHWZHHQ WKH PXFRVDO DQG FXWDQHRXV W\SHV +RZHYHU ZKLOH VHYHUDO Ȗ-
secretase inhibitors that have been tested clinically for prevention of Alzheimer disease 
might be re-tasked for broad prevention of HPV infection, they have also been associated 
with squamous cell cancer [98]. 
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Although the amino terminus of L2 is a weaker immunogen compared to L1 VLP, 
it is considered to provide broader protection [74]. In particular, the concatenated fusion 
SURWHLQ/Į-88×8 comprising residues ~11-88 of L2 derived from eight alpha HPV 
types [78] has been shown to induce cross-neutralizing antibodies that broadly protect 
against the HPV types most commonly found in cervical cancer and benign genital warts. 
+HUH ZH DOVR H[DPLQHG / Į-88×8 antiserum for its capacity to cross-neutralize 
cutaneous beta HPVs that are also associated with cancer, particularly among 
immunocompromised and EDV patiHQWV 5HPDUNDEO\ WKH / Į-88×8 antiserum 
neutralized all beta HPV types tested (Table 1). The result implies that the neutralizing 
epitopes at the amino terminus of L2 are highly conserved and play an important role in 
both alpha and beta HPV iQIHFWLRQDQG WKDWDQ/Į-88×8 vaccine might potentially 
provide broad protection against the diverse alpha and beta HPV family. Serologic 
studies suggest that beta HPV infections are acquired throughout life, beginning in 
childhood [55]. Therefore, optimally vaccination against beta HPV would need to begin 
early. 
In conclusion, we have considered agents that block infection via inhibiting 
UHFHSWRU LQWHUDFWLRQ IXULQ FOHDYDJH RU Ȗ-secretase function as alternative approaches to 
vaccination to broadly prevent both mucosal and cutaneous HPV infections. At present, 
carrageenan shows promise as a vaginal microbicide to broadly prevent infection by 
mucosatropic high-risk papillomaviruses [65]. However our results show that it is 
unlikely to prevent cutaneous HPV transmission. Further, it would need to be regularly 
DSSOLHGDWKLJKDPRXQWVWRHQVXUHIXOOSURWHFWLRQ$VERWKIXULQDQGȖ-secretase contribute 
to numerous cellular processes, systemic use of their inhibitors are also likely to have 
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significant side effects rendering them impractical despite broad anti-HPV activity, 
although topical application might be feasible. Nevertheless, our study with 34 medically 
significant HPV types indicates that there is a conserved infection pathway once the virus 
enters its host cell, and thus targeting conserved residues of the capsid proteins that 
interact with the key cellular entry factors has potential for broad protection. Indeed, 
rDEELWDQWLVHUDWRWKH/Į-88×8 antigen provided broad protection against alpha HPV 
challenge via cross-neutralizing antibodiHV>@+HUHZHILQGWKDW/Į-88×8-specific 
antibodies also cross-neutralize diverse beta papillomaviruses, suggesting the potential to 
protect against types associated with non-melanoma skin cancer in immunocompromised 
or EDV patients (should they mount a sufficient response after vaccination) or the 
potential of herd immunity in the general population to limit their circulation. Taken 
together, this study supports the possibility of vaccination with L2 candidate vaccines for 

















Persistent infection by oncogenic human papillomavirus (HPV) drives the 
development of cervical cancer [1]. HPV infection also causes subsets of other cancers 
such as vulvar, vaginal, penile, anal, and oropharyngeal cancers [3,100,101]. The 
importance of preventing HPV infection drove the development of two commercial 
viruslike particle-based (VLP) vaccines, Gardasil® by MSD and Cervarix® by GSK, 
respectively. These two L1 VLP-based vaccines elicit robust type-restricted neutralizing 
antibodies that effectively inhibit HPV infection [7,6,13,102-105]. However, Gardasil® 
and Cervarix® each contain L1 VLP derived from only two high risk genotypes, HPV16 
and HPV18, although Gardasil also contains L1 VLP derived from the two most common 
genotypes causing benign genital warts, HPV6 and HPV11. Since HPV16 and HPV18 
cause 50% and 20% of all cervical cancers [54,106], the two licensed vaccines are 
potentially able to prevent most but not all cases of cervical cancer because of the type-
restricted immunity [11,107]. However, HPV16 causes, 90% of cases of HPV-associated 
vaginal, vulval, anal and oropharyngeal cancers, suggesting a distinct type distribution at 
these anatomic sites [3,100,101]. Passive transfer studies in animal models of HPV 
infection suggest that the type-restricted neutralizing antibodies induced by L1 VLP 
vaccination effect protection, although a role for cellular immunity has not been excluded 
[108]. The breadth of protection may be expanded by simply increasing the number of L1 
VLP of different HPV genotypes, although this increases the cost and complexity of 
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production. Merck is currently testing a nonavalent L1 VLP vaccine that targets the seven 
most common HPV genotypes found in cervical cancer and two types that cause most 
cases of genital warts [109].  
The minor capsid protein, L2, harbors several conserved neutralizing epitopes at 
its amino terminus that elicits cross-protection among diverse HPV types [44,46,110,111]. 
However, by comparison to L1 VLP, weaker immunogenicity is an obstacle L2 vaccine 
development [44,112]. Several attempts have been made to enhance immunogenicity of 
L2 conserved epitopes and create a single vaccine protective against most high-risk HPV 
types. For example, L2 epitopes have been displayed repetitively by generating L2 
multimer fusion proteins, or insertion into the immunodominant neutralizing epitope of 
VLPs of HPV and other viruses [48,49,113,114].  
Cost and the need for a cold chain are barriers to global implementation of HPV 
immunization. Unfortunately, 85% of cervical cancer cases occur in women in 
developing countries and even the tiered pricing for the two licensed vaccines is beyond 
the reach of many lower income countries [115]. The L2 multimer vaccine can be 
manufactured as a single protein in the E. coli system lowering its cost compared to 
multivalent L1 based vaccines produced in yeast or insect cells [34,116,117]. However, 
protein-based vaccines are prone to degradation at ambient temperature and typically 
require refrigeration such that development of heat-stable formulations is needed to 
facilitate implementation in low income and remote populations [117].  
Naked DNA vaccines encoding vaccine antigens have several potential 
advantages. Production of DNA vaccines does not require culture, inactivation of 
infectious pathogens, and their purification from bacteria is well standardized and 
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comparatively inexpensive [118]. Importantly, naked DNA can be readily stored at 
ambient temperature. Moreover, the antigenic structure of the vaccine antigen produced 
by DNA vaccination likely closely resembles the appropriate native structure with the 
correct posttranslational modifications. Indeed, L1 expressed in E. coli does not form 
regular VLPs and requires in vitro disassembly and reassembly [34,119]. Furthermore, 
the DNA vector itself can have an adjuvant effect via its inherent immunostimulatory 
elements. Unmethylated CpG dinucleotide motifs can be sensed by Toll-like receptor 
(TLR)-9 [120], a microbial pattern recognition receptor (PRR), and trigger innate 
inflammatory responses [121-123]. DNA in the cytoplasm can be recognized and 
stimulate Absent In Melanoma 2 (AIM2) [124], and STimulator of IFN Genes (STING) 
pathways [125]. DNA vaccines also provide sustained antigen expression for a prolonged 
immune stimulation compared to the short half-life of protein antigens [126]. Despite 
many advantages over protein vaccines, low immunogenicity is a major shortcoming of 
DNA vaccines, and is believed to reflect inefficiency of delivery of the vaccine to the 
host nucleus. 
There are several alternative modes of DNA administration that can overcome 
inefficient delivery. The gene gun provides ballistic delivery of gold particles coated with 
DNA to cells in the skin including professional antigen presenting cells, termed 
Langerhans cells [127,128]. While the method is more efficient than i.m. injection, only a 
limited amount of DNA can be used due to technical issues. A second improved method 
of DNA delivery via in vivo electroporation elicits robust immune responses as a 
consequence of increased transfection of somatic cells and inflammation caused by 
localized cell death [129-131]. The potential of electroporation in clinical trials has 
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recently been demonstrated with DNA vaccines targeting hepatitis B virus [132], HIV 
[133,134] and HPV oncoproteins, E6 and E7 [135]. 
Here we show the potential of L1-expressing DNA vaccines administered with 
electroporation as a prophylactic vaccine. In addition, our results also demonstrate 
interference between L1 DNA vaccines administered at the same site with electroporation, 
likely reflecting co-assembly of different L1 into chimeric particles rather than 
immunologic competition. Finally, we find that this interference can be eliminated if L1 
DNA vaccines of different HPV genotypes are spatially separated upon administration, or 

















b) Materials and Methods 
 
1) Ethics Statement 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All animal studies were performed with the prior approval of the Animal Care and Use 
Committee of Johns Hopkins University (protocol MO08M19). 
 
2) Vaccine Preparation 
Codon optimized capsid genes, L1 and L2, of HPV6, HPV16, HPV18, HPV26, 
and HPV51 were sub-cloned into double expression vector, pVITRO1-neo-mcs 
(Invivogen, San Diego CA) or pcDNA (Invitrogen, Carlsbad CA), for DNA vaccination. 
HPV16 L2 multimer expression construct encompassing residues íRI+39W\SHV
(L2×8) was sub-cloned into pcDNA 3.1 for mammalian expression, and L2 a11-88×8 
polypeptide was produced, purified, and dialyzed as previously described [79]. All 
plasmids employed for the immunization were purified and endotoxins were removed 
with UltraClean® endotoxin free kit (Mo Bio, Carlsbad CA). 
 
3) Pseudovirus (PsV) Production 
Codon optimized L1 and L2 capsid genes of HPV6, 11, 16, 18, 26, 31, 45, 51, 
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were sub-cloned into double expression vector, pVITRO1-neo-mcs (Invivogen, San 
Diego CA). Pseudovirions (PsVs) were generated in 293TT cells following the standard 
PsV production protocol (http://home.ccr.cancer.gov/Lco/pseudovirusproduction.htm). 
Firefly luciferase expression plasmid was employed as a reporter for PsV infection in 
neutralization assays and for vaginal challenge studies. 
 
4) Immunoprecipitation 
293TT cells grown in DMEM-10 medium were transfected with empty vector, a 
single expression vector for only HPV6, 16, or 18 L1, or mixture of L1 DNA of HPV6, 
16, 18 in equal parts using transit 2020 (Mirus Bio LLC, Madison WI), and harvested in 
48 hours. Cells were lysed with non-denaturing lysis buffer containing 20 mM Tris HCl 
pH 8, 137 mM NaCl, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 2 mM EDTA, and a 
protease inhibitor cocktail (Roche). mAb H18.F8 [9] was added to whole cell lysate (0.5 
mg) and tumbled end-over-end overnight at 4°C. Protein G Sepharose (GE healthcare, 
Waukesha WI) was added and mixed for an additional 4 hours at 4°C. Resins were 
harvested by centrifugation at 14,000 × g at 4°C for 1 min and supernatants were 
discarded. Resins were washed three times with 1 ml lysis buffer, resuspended in 2× 
sample loading buffer, and boiled for 5 min. 
 
5) Western blot analysis 
Western blotting was performed with standard protocols 
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(http://www.abcam.com/ps/pdf/protocols/WB-beginner.pdf). Primary antibodies used 
were H6.C6, H16.O7, and H18.E20 [9], and secondary antibody used was HRP-goat anti-
mouse IgG light chain (Jackson ImmunoResearch, West Grove PA). 
 
6) Vaccination 
Groups (n=5) of 3–4 week old female Balb/c mice were vaccinated s.c. three 
times at two week intervals with 25 ug of L2×8 multimer polypeptide formulated with 
alum (50 ug), or 50 ul of Gardasil, or i.m. with 10 ug of L2 11-88×8 multimer expression 
plasmid, or i.m. utilizing in vivo electroporation with PBS, 10 ug of L2×8 multimer 
expression plasmid in pcDNA 3.1, 2 ug or 10 ug of HPV6, 16, 18, 26, 51 L1 expression 
plasmid in pVITRO1-neo-mcs, 20 ug of HPV6, 16, 18 L1 expression plasmid in 
pVITRO1-neo-mcs, 10 ug of HPV11, 16, 18, 26, 31, 45, 51 L1+L2 expression plasmid in 
pVITRO1-neo-mcs, 20 ug of HPV6, 16, 18 L1+L2 expression plasmid in pVITRO1-neo-
mcs, 10 ug of mixed (HPV 6, 16, 18, 26, 51 L1, 2 ug each) plasmids in pVITRO1-neo-
mcs, 60 ug of mixed (HPV6, 16, 18 L1, 20 ug each) plasmids in pVITRO1-neo-mcs, 60 
ug of mixed (HPV6, 16, 18 L1+L2, 20 ug each) plasmids in pVITRO1-neo-mcs, or 20 ug 
of HPV6, 16, 18 L1 expression plasmids in pVITRO1-neo-mcs at different sites. Blood 
samples were collected two weeks and three months after the last vaccination. Serum was 
separated by centrifugation at 2,000 g for 10 min at 4°C after the blood had congealed 





Mice were injected with DNA in 30 ul water i.m. into the gastrocnemius muscle, 
or biceps femoris muscle of hind leg. A pair of electrode needles was inserted into the 
muscle flanking injection site and electrical pulses were delivered utilizing an ECM830 
electroporation generator (BTX Harvard Apparatus company, Holliston MA). Eight 
pulses of 106 V each were delivered for 20 ms pulse duration at 200ms intervals. 
 
8) ELISA 
For analysis of antibody response against HPV16 L2 protein, microtiter plates 
were coated with L2 protein at 500 ng in 100 ul PBS/well overnight at 4°C, and blocked 
with PBS/1% BSA for 1 hour at 37°C. Plates were incubated with serum samples diluted 
1:50 in PBS/1% BSA for 1 hour at 37°C. After 3 washes with washing buffer (0.01% v/v 
Tween 20 in PBS), HRP-sheep anti-mouse IgG diluted in 1% w/v BSA at 5000-fold was 
added to each well as a secondary antibody, and incubated for 1 hour at 37°C. After 3 
further washes, 100 ul of ABTS solution, 2,2ƍ Azinobis [3-ethylbenzothiazoline-6-
sulfonic acid], Roche, (Basel Switzerland) was added to each well for developing color 
and read by an ELISA reader, Benchmark Plus (Bio Rad, Hercules CA) at 405 nm. 
 
9) In vitro Neutralization Assays 
Serum samples (4 ul) were serially diluted two-fold in culture media, and mixed 
with 0.03 ul of HPV PsV carrying luciferase reporter plasmid. Mixtures were incubated 
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at 37°C for two hours, added to 3 × 104 of 293TT cells, and incubated at 37°C for 72 
hours. Cells were washed with 1× PBS, lysed with 30 ul of Cell Culture Lysis Reagent 
(Promega, Madison WI) for 15 min at room temperature on a rocking platform. Lysates 
were transferred to 96-Well black plate, and luciferase activity was measured by 
GloMax®-Multi Detection System (Promega, Madison WI) after adding 50 ul of 
luciferin substrate (Promega, Madison WI) to each well. 
 
10) Vaginal Challenge Studies 
Mice were subcutaneously injected with 3 mg of medroxypro-gesterone (Depo-
Provera, Pfizer, New York NY) four days before vaginal challenge to synchronize their 
estrus cycles. Viral challenge was performed by delivery of 10 ul of HPV PsV (HPV6: 
135 billion, HPV16: 189 billion particles in total) mixed with 10 ul of 3% carboxymethyl 
cellulose (CMC) into the vagina before and after cytobrush treatment (15 rotations, 
alternating directions) while the mice were under isoflurane anesthesia. Three day after 
challenge, mice were anesthetized by isoflurane, and 20 ul of luciferin substrate (7.8 
mg/ml, Promega, Madison WI) was delivered into the vaginal vault before imaging. 
Bioluminescence was acquired for 10 min with a Xenogen IVIS 100 (Caliper Life 
Sciences, Hopkinton MA) imager, and analysis was accomplished with Living Image 2.0 
software. For imaging of passively immunized mouse groups, mice were injected i.v. 




11) Statistical analysis 
Exploratory statistical analyses are performed to analyze the observed titer data. 
Square-root data transformations were used to achieve normality in residuals for titer 
data. One-way ANOVA and pair wise multiple comparisons with Bonferroni adjustment 
were performed using SAS 9.3. When the overall significance test is not significant, the 
pair wise comparisons are not conducted. To claim significance, we use alpha level 0.1 



















1) In vivo electroporation with HPV L1 DNA vaccines elicits robust type-restricted 
neutralizing antibody titers in mice  
Vaccination of rabbits with naked DNA expressing CRPV L1 either via i.m. 
injection or ballistic delivery on gold beads (gene gun) protects rabbits from experimental 
viral challenge [136,137]. The initial enthusiasm for naked DNA vaccination based on 
animal data has been tempered by a low efficiency of delivery by i.m. injection of 
patients. However, recent clinical studies suggest that in vivo electroporation of naked 
DNA vaccines can induce robust humoral responses in patients [134,135,138-140]. 
Furthermore, codon optimization appears to be important for robust expression of the 
HPV capsid proteins [83,84,141]. Therefore we sought to determine whether a strong 
neutralizing antibody response could be elicited in mice with codon optimized HPV16 L1 
capsid gene-expressing naked DNA constructs utilizing i.m. injection as compared to i.m. 
injection with in vivo electroporation, or i.d. delivery via gene gun. We utilized HPV 
pseudovirion infection of 293TT cells to examine neutralization by serum antibody as a 
surrogate of wart-derived virions infecting primary human keratinocytes [25]. 
Vaccination of mice three times at 2 week intervals with 40 ug of HPV16 L1 DNA by 
i.m. injection resulted in a weak HPV16 neutralizing antibody response as compared to 
s.c. administration of 1/10th of a human dose of Gardasil for which the serum titer was 2 
log10 greater (Figure 10A). The response was greater when this HPV16 L1 DNA vaccine 
was administered i.d. via gene gun at a dose of 2 ug (the maximum that can be applied by 
this method), but the titer was still a log10 below that obtained with Gardasil. When the 
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HPV16 L1 DNA vaccine was injected i.m. followed by in vivo electroporation, doses of 
10 ug or greater elicited an HPV16 neutralizing antibody titer approaching that of 
Gardasil, whereas the response to the 2 ug dose was weak. A one-way analysis of 
variance (ANOVA) shows that there is significant difference among 2 ug, 10 ug, 20 ug 
and 40 ug HPV16 L1 electroporation (EP) groups (p-value = 0.0347). With Bonferroni 
multiple comparison adjustment, at a level 0.1, we find a significant difference between 2 
ug and 10 ug HPV 16 L1-EP groups (adjusted p-value 0.0991) and between 2 ug and 40 
ug HPV 16 L1-EP groups (adjusted p-value = 0.0582). A significant difference is also 













Figure 10.  Impact of DNA vaccine dose and delivery method on the induction of type-
restricted neutralizing antibodies.  
(A) Balb/c mice were vaccinated three times at two week intervals with HPV16 L1 DNA 
expression vector via i.m. injection alone (40 mg)(i.m.), i.m. injection and in vivo 
electroporation (0, 2, 10, 20 or 40 mg)(EP) or i.d. ballistic delivery on gold particle via 
gene gun (2 mg)(GG). Vaccination with Gardasil s.c. was included as a positive control. 
Serum samples were collected two weeks after the third vaccination, and tested for in 
vitro neutralization assay against HPV16. (B) Mice were vaccinated with DNA vector 
expressing L1+L2 of the genotypes indicated (see line labeled ‘Vaccine’) i.m. utilizing 
electroporation. Neutralizing antibody titer against PsV of the indicated genotypes (see 







2) In vivo electroporation with L1 only or L1+L2 DNA vaccines elicits a similar antibody 
response 
The co-expression of the minor capsid protein L2 with L1 can enhance the 
efficiency of VLP assembly [142]. Therefore, we explored whether a higher titer 
antibody response could be achieved upon vaccination with a DNA vaccine expressing 
both L1 and L2 versus L1 alone. However, vaccination three times i.m. using in vivo 
electroporation with 10 ug of a DNA vaccine expressing HPV16 L1+L2 elicited a similar 
neutralizing antibody titer to HPV16 L1 alone. Further, vaccination three times i.m. using 
in vivo electroporation to deliver 10 ug of a DNA vaccine expressing L1+L2 derived 
from HPV11, HPV18, HPV26, HPV31, HPV45 or HPV51 each elicited a similar 
neutralizing antibody titer against PsV of the same type utilized for vaccination (Figure 
10B). The titers of neutralizing antibodies induced upon vaccination three times i.m. 
using in vivo electroporation to deliver 10 ug of a DNA vaccine expressing L1+L2 were 
similar to, but still lower than those elicited by Gardasil. Since the responses to 
electroporation of 10 ug of a DNA vaccine expressing L1+L2 appeared more variable 
than for Gardasil, the homogeneity of variances among L1 DNA EP, L2×8 Protein and 
Gardasil groups was examined with Levene’s test. While the difference is not significant 
(p-value = 0.0556), this may reflect the rather limited sample size (5 mice in each group). 
L2 contains cross-neutralizing epitopes, and therefore we tested whether in vivo 
electroporation of mice with 10 ug of the DNA vaccine expressing HPV16 L1+L2 
induced antibodies that cross-neutralized PsV of HPV31, the genotype most closely 
related to HPV16, or vice versa. However, no significant cross-neutralization was 
observed between these two types (Figure 10B), and no L2-specific antibody response 
64 
 
was observed (despite robust L2 expression, Figure 11C) indicating that L2 is not 
immunogenic in the context of the capsid. These findings suggest that a multivalent L1-
based DNA vaccine approach or vaccination with L2 (in the absence of L1) would be 











Figure 11.  Neutralizing antibody titer and antibody response of sera from mice 
vaccinated with L1 or L2×8 delivered as protein or a DNA vaccine via electroporation.  
Balb/c mice were vaccinated three times at two week intervals with PBS, 10 mg L2×8 
DNA vaccine i.m. with electroporation three times, or twice utilizing 10 mg HPV16 L1 
DNA vaccine i.m. with electroporation followed by a single boost with 25 ug L2×8 
protein in alum s.c., 10 mg HPV16 L1 DNA vaccine i.m. with electroporation three times, 
three times with 10 mg L2×8 DNA vaccine i.m., or 25 ug L2×8 protein in alum s.c., or 
Gardasil s.c.,,. Serum samples were collected two weeks after the third vaccination, and 
were tested for in vitro HPV16 neutralization titer (A) and antibody response to HPV16 
L2 (B) as measured by ELISA. (C) To assess relative levels of expression, 293TT cells 
were transfected with no plasmid, HPV16 L1+L2 DNA in pShell, full length HPV16 L2 
DNA in p16L2h, bacterial codon optimized L2×8 DNA in pcDNA, or human codon 
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optimized L2×8 in pcDNA. 293TT cells were lysed two days after transfection. Western 


















3) In vivo electroporation with an L2 multimer DNA vaccine failed to elicit neutralizing 
antibodies 
Prior studies by Hitzeroth et al suggest that i.m. vaccination of mice with 100 ug 
DNA expressing codon-optimized full length HPV16 L2 induces a T cell response but 
only a very weak antibody titer, whereas vaccination with the amino terminus of L2 may 
be more immunogenic [143,144]. Vaccination of mice with a multimer peptide 
comprising L2 residues 11-88 amino acids derived from 8 HPV types (L2×8) induced 
broadly neutralizing antibodies, although at a titer, 30-fold lower than for L1 VLP [79]. 
Therefore we compared the HPV16 neutralizing antibody titers induced upon vaccination 
via in vivo electroporation with codon-optimized HPV16 L1 DNA versus L2×8 multimer 
DNA. While the L1 DNA construct elicited very high neutralization titers approaching 
those induced by Gardasil vaccination (Figure 11A), L2×8 multimer DNA vaccination 
failed to induce neutralizing antibody against HPV16 pseudovirions, even with a single 
L2×8 protein in alum boost (although the latter did induce an L2-specific response 
detectable by ELISA with a titer of 400). Vaccination with L2×8 multimer DNA failed to 
induce a neutralizing antibody response either with or without electroporation, and 
whether the codon optimization of the L2×8 construct was biased for bacterial expression 
or mammalian expression (not shown). Similar levels of expression of L2×8 protein were 
detected in 293TT cells 48 h post transfection with the L2×8 constructs codon optimized 
for bacterial or mammalian cell expression (Figure 11C). The levels of L2×8 were 
substantially lower than for full length codon-optimized HPV16 L2 and there was 
evidence of a greater extent of degradation, possibly contributing to the poor immune 
response (Figure 11C). 
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Vaccination with antigen delivered first via DNA vaccine and then boosting with 
protein has been suggested to enhance humoral immunity as compared to DNA 
vaccination or protein alone [145,146]. We tested the sera of mice vaccinated twice with 
L2×8 multimer DNA followed by a third immunization of L2×8 multimer peptide mixed 
with alum adjuvant. Surprisingly, we were not able to detect an HPV16 neutralizing 
antibody titer with the L2×8 multimer DNA vaccine prime and protein boost combination 
regimen (Figure 11A), although antibody response to full length HPV16 L2 was detected 
(Figure 11B) with an ELISA titer of 400. In contrast, vaccination three times with L2×8 
protein in alum elicited L2-specific antibody (ELISA titer of 12,800) and significant titers 
of HPV16 neutralizing antibody (a mean titer of 1600, Figure 11A), although the latter is 
30-fold lower than for L1 DNA vaccination or Gardasil. This suggests that even 
vaccination twice with L2×8 multimer DNA was inadequate for priming a neutralizing 
antibody response prior to a single L2×8 protein boost, and this may reflect poor 
expression, protein instability, insensitivity of the neutralization assay, weak 
immunogenicity for L2×8 vaccination via DNA vector, and/or the preferential induction 









4) Vaccination with a mixture of L1 DNAs of multiple HPV types exhibits interference 
Since L1-based DNA vaccine electroporation successfully induced a robust but 
type-restricted neutralizing antibody response, we evaluated the potential for a 
multivalent vaccine in which L1 DNAs of several HPV types are mixed prior to i.m. 
injection and in vivo electroporation. Our initial study suggested that a 2 ug dose of 
HPV16 L1 DNA vaccine induces a suboptimal neutralizing antibody response, but 10 ug 
produces the maximal response. To examine if the 2 mg L1 DNA vaccine dose provided 
a consistent response regardless of HPV type, and whether the response to a pentavalent 
vaccine would be additive or synergistic, we performed a pilot experiment in which five 
different DNA vaccines expressing L1 of HPV6, HPV16, HPV18, HPV26, and HPV51 
respectively were mixed (2 ug each) and delivered i.m. by electroporation for comparison 
to vaccination with each type singly at doses of 2 ug or 10 ug. HPV6, HPV16 and HPV18 
are each members of difIHUHQW SDSLOORPDYLUXV VSHFLHV Į Į DQG Į7 respectively), 
whereas HPV26 and +39DUHERWKPHPEHUVRI WKHĮ5 species. The latter two types 
were included to determine if interference in the response to mixtures of L1 expression 
constructs occurred intra-species or inter-species or both [12]. After three immunizations, 
mice vaccinated with the pentavalent L1 DNA mixture exhibited distinct neutralizing 
antibody responses compared to mice vaccinated with L1 DNA of single HPV type 
(Table 2). The 2 ug dose of a single L1 DNA vaccine gave an inconsistent response for 
HPV16 and between different HPV types, whereas the response to 10 ug was consistent 
across all 5 types tested. The variable response at the 2 ug dose of a single L1 DNA 
vaccine did not reflect L1 expression level alone. Indeed, the relative number of particles 
produced using these codon-optimized L1 genes to produce pseudovirions in 293TT 
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cells, as estimated by Coomassie-stained SDS-PAGE gel studies of purified 
pseudovirions and normalized to HPV16 are: HPV6 L1: 15.5%, HPV16 L1: 100%, 
HPV18 L1: 1%, HPV26 L1: 119%, HPV51 L1: 147%. Thus despite significantly lower 
production of particles by HPV6 and HPV18, both of these constructs elicit a robust 
neutralizing antibody response. Serum from the L1 DNA mixture group showed no 
detectable neutralizing titer against HPV6 and HPV16 PsVs, the expected titer for 
HPV51 but an increased titer against HPV18 and HPV26 PsVs (Table 2). This finding 
suggested that the DNA constructs may not act independently when mixed together and 
that increasing the dose of L1 DNA vaccine from 2 ug to 10 ug improves the level and 












Table 2.  Neutralizing antibody titers induced upon vaccination of mice with a 
pentavalent HPV L1 DNA vaccine 
Balb/c mice were vaccinated i.m. three times at two week intervals with a mixture of L1 
vectors of HPV6, HPV16, HPV18, HPV26, and HPV51 (2 mg each), L1 vector of single 
HPV type (2 mg or 10 mg) utilizing electroporation. Gardasil vaccination was included as 
a positive control. Sera from 5 mice were pooled together, and in vitro neutralizing 
antibody titer (IVNT) was measured with HPV6, HPV16, HPV18, HPV26, and HPV51 









5) Spatial separation of L1 DNA vaccines of different types, but not L2 co-expression, 
fully restores independent neutralizing antibody responses upon multi-type vaccination 
In a follow-up study (Figure 12), several changes were made in order to address 
interference when L1 DNA vaccines are mixed. First, the dose of each L1 DNA was 
increased from 2 ug to 20 ug to enhance the level and consistency of the neutralizing 
antibody response, and the number of HPV types decreased from five to three (HPV6, 
HPV16 and HPV18) to minimize the potential for interference and because vaccination 
with Gardasil suggests limited or no immunologic interference in the antibody responses 
to L1 VLPs these three types (Table 2). Furthermore, these types are the most common 
causing genital warts (HPV6) and squamous cell (HPV16) and adenocarcinoma (HPV18) 
of the uterine cervix, suggesting their likely inclusion in future vaccines as compared 
with HPV26 and HPV51 that are infrequently found in cervical cancer [147]. It is 
possible that the immunologic interactions between the L1 vaccines when administered 
as a mixture reflect heterotypic binding and inappropriate co-assembly and/or 
immunologic dominance of particular construct(s). Therefore, to prevent co-assembly of 
L1 of different types into a chimeric VLP, we tested the impact on the humoral response 
of administering the three L1 DNA constructs each at a different site (HPV6 L1 DNA 
was injected into the left biceps femoris muscle, HPV16 L1 DNA was injected into the 
right gastrocnemius muscle, and HPV18 L1 DNA was injected into the left 
gastrocnemius muscle) versus mixed together and delivered at the same site. In addition, 
L2 exhibits some type-restriction for interaction with L1 [148-150], and facilitates VLP 
assembly by ~4-fold [142]. Therefore, mice were vaccinated with a mixture of three 
DNA vaccines expressing L1+L2 of HPV6, HPV16 and HPV18 based upon the 
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hypothesis that the presence of the cognate L2 would both increase the assembly of VLPs 
four-fold and the specificity of co-assembly with the homotypic L1, thus limiting 
heterotypic VLP production. Two weeks after three vaccinations i.m. with the DNA 
constructs indicated, the in vitro neutralization titer of the serum of each mouse was 
tested against HPV6, HPV16 and HPV18 PsV. Vaccination with 20 ug of each L1 DNA 
vaccine individually induced a robust homotypic neutralizing antibody response and an 
equivalent titer was observed when utilizing DNA vaccines expressing L1+L2 (Figure 
12A–C) as the Bonferroni adjusted pair wise comparisons are not significant in all cases 
at alpha level 0.1. Despite reducing the number of HPV L1 DNAs to three types, (HPV6, 
HPV16, and HPV18), there was still some interference in production of neutralizing 
antibody, most noticeably for HPV16 (Figure 12B) for which ANOVA analysis results 
show that there is significant difference among groups (p-value = 0.0030), to a lesser 
extent for HPV18 (Figure 12C) (p-value = 0.0243), but not significantly for HPV6 
(Figure 12A) (p-value = 0.5577). As seen in figure 12A, the HPV16 neutralizing serum 
antibody titer induced by vaccination with HPV16 L1 alone was significantly higher than 
when the HPV6, HPV16 and HPV18 L1 constructs were mixed together and injected at 
the same site (the Bonferroni adjusted t- test p = 0.0038), but not when given at different 
sites (p = 0.6893) or when L2 was co-expressed in the constructs (p = 0.7567). This 
pattern was also observed for sera harvested 3 months post vaccination (Figures 12D-F) 
as ANOVA analysis results show that there is again significant difference among groups 
for HPV16 (Figure 12E, p-value = 0.0005), and HPV18 (Figure 12F, p-value = 0.0027), 
but not for HPV6 (Figure 12D, p-value = 0.6497). Specifically, in figure 12E, the HPV16 
neutralizing serum antibody titer induced 3 months after vaccination with HPV16 L1 
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alone was significantly higher than when the HPV6, HPV16 and HPV18 L1 constructs 
were mixed together and injected at the same site (the Bonferroni adjusted t-test p = 
0.0394), but not when given at different sites or when L2 was co-expressed in the 
constructs. Importantly, when the three L1 DNA vaccines were each administered at a 
physically separate site, robust homotypic neutralizing antibody titers were observed, 
consistent with those obtained when administering each construct alone for all three virus 
types. This observation suggests that the interference does not reflect immunologic 
competition, but rather suggests that co-expression of L1 of HPV6, HPV16 and HPV18 
in the same cells might result in aberrant VLP assembly as a consequence of heterotypic 
binding. While vaccination at different sites resolved interference completely, 
electroporation of mice with a mixture of three DNA vaccines co-expressing both L1 and 
L2 of HPV6, HPV16 and HPV18 only partially reduced interference in the responses to 
HPV16 and HPV18 (Figure 12B and C). This phenomenon was preserved when 
analyzing sera harvested at 3 months after the final vaccination (Figures 12D–F). We also 
tested whether vaccination with L1+L2 DNA of a single type or a mixture of three types 
can generate an L2-specific antibody response but no consistent antibody response 
against HPV16 L2 was observed (Figure 12G). These results imply that formation of 
chimeric VLP still occurs when the valency of the L1 multitype vaccination is reduced, 
and this problem can be ameliorated by co-expression of the cognate L2 proteins, but is 






Figure 12.  A comparison of antibody responses of mice vaccinated with DNA expressing 
L1 or L1+L2 of HPV6, 16, or 18, either singly or together at the same or different sites.  
Balb/c mice were vaccinated i.m. with electroporation three times at two week intervals 
with 20 mg each of DNA expressing L1 or L1+L2 of HPV6, HPV16, and HPV18, either 
individually, or together at the same site or each at a different site (DS), or s.c. with 
Gardasil. Serum samples were harvested at two weeks after the third vaccination (A–C) 
or 3 months after the third vaccination (D–F), and neutralizing antibody titers were 
measured with HPV6 (A,D), HPV16 (B,E), or HPV18 PsV (C,F). Antibody response to 
L2 was measured by ELISA against full length HPV16 L2 with serum samples collected 















6) Electroporation of L1 DNA vaccines induces type-restricted protective antibody 
responses 
As the titers of neutralizing antibodies induced upon vaccination three times i.m. 
using in vivo electroporation to deliver 20 ug of an L1 DNA vaccine were similar to, but 
still lower than those elicited by Gardasil, we therefore tested whether they are still 
sufficient to protect against vaginal challenge with the homologous type HPV. Although 
HPV does not produce disease in mice, the host restriction in HPV infection is 
determined after delivery of the viral genome to the nucleus, and thus infection of the 
vaginal tract of mice with HPV pseudovirions carrying a luciferase reporter can be 
detected by imaging bioluminescence [61]. Passive transfer of 20 ul of serum from mice 
vaccinated i.m. three times with in vivo electroporation to deliver 20 ug of DNA vaccine 
H[SUHVVLQJHLWKHU/RQO\RU//FRPSOHWHO\SURWHFWHGQDࡇÕYHPLFHIURPH[SHULPHQWDO
vaginal challenge with the homologous genotype (Figure 13A). This was also shown for 
HPV6 (Figure 13B), and the protection was maintained when using sera harvested at 3 
months post vaccination for the passive transfer study (Figure 13C). Thus the data 
suggest that the neutralizing antibody titers induced by in vivo electroporation with an L1 
DNA vaccine, although lower than for Gardasil, are sufficient for complete protection 




Figure13.  Comparison of protective antibody responses.  
Balb/c mice were vaccinated i.m. with electroporation three times at two week intervals 
with 20 mg each of DNA expressing L1 or L1+L2 of HPV6, HPV16, and HPV18, either 
individually, or together at the same site or each at a different site, or s.c. with Gardasil. 
Serum samples were collected two weeks (A,B) and three months (C) after the last 
vaccination to test their protective efficacy in vivo and in vitro1DࡇÕYH%DOEFPLFHSHU
group) were passively immunized i.v. with 20 ml of pooled serum. Mice were challenged 
intra-vaginally with HPV16 (A,C) or HPV6 (B) PsV carrying a luciferase reporter 
construct. Three days later, luciferin was administered intra vaginally, and 
bioluminescence imaging was performed. 
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7) L2 co-expression is sufficient to restore protection using multivalent L1-based DNA 
vaccination 
The host restriction in HPV infection is determined after delivery of the viral 
genome to the nucleus, and thus infection of the vaginal tract of mice with HPV 
pseudovirions carrying a reporter gene such as luciferase whose expression can be 
detected by imaging bioluminescence [61]. This provides a useful model to examine in 
vivo protection RI QDࡇÕYHPLFH DIWHU SDVVLYH WUDQVIHU RI QHXWUDOL]LQJ DQWLERGLHV >26,46]. 
Passive transfer of 20 ul of serum of mice electroporated i.m. with a mixture of three 
DNA vaccines expressing L1 of HPV6, HPV16, and HPV18 provided complete 
protection against intra-vaginal challenge with HPV6 PsV (Figure 13B). In contrast, 
when 20 ul of serum of mice electroporated i.m. with a mixture of three DNA vaccines 
expressing L1 of HPV6, HPV16, and HPV18 was injected into naive mice, significantly 
weaker protection against intra-vaginal challenge with HPV16 PsV was observed (Figure 
13A). Interestingly, the sera from mice that were electroporated i.m. with a mixture of 
three DNA vaccines expressing both L1 and L2 of HPV6, HPV16, and HPV18, were 
completely protective by passive transfer. This finding suggests that although the co-
expression of L2 does not completely recover the humoral response obtained by 
vaccination with a single L1 DNA vaccine, nevertheless the titers induced are sufficient 
for complete protection upon passive transfer of 20 ul of serum (which corresponds to 
~1:50 dilution in the mouse). As expected, passive transfer of sera from mice 
electroporated i.m. at different sites with the three DNA vaccines expressing L1 of 
HPV6, HPV16, and HPV18, were also completely protective against HPV16 challenge. 
Importantly, these phenomena were consistent when testing for protective capacity 
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DJDLQVW YDJLQDO+39 FKDOOHQJH RI QDࡇÕYHPLFe after passive transfer of 20 ul of sera 
obtained three months after active vaccination (Figure 13C). These data suggest that the 
protective responses elicited by multivalent vaccination are durable if the L1 DNA 
vaccines expressing individual types are injected in different locations or L2 is co-
















8) Immunologic interference is associated with heterotypic interactions between L1 
proteins 
The reduction in neutralizing responses observed when the DNA vaccines 
expressing L1 of different types are injected into the same site but not different sites 
suggests that it is direct interaction between L1 of different types rather than 
immunologic competition that this responsible for this interference. It has been 
previously described that HPV6 and HPV16 L1 subunits co-assemble together generating 
hybrid VLPs in yeast [73] and co-expression of either HPV11 or BPV1 L1 with HPV16 
L1 reduces the assembly of HPV16 L1 VLPs [74]. In addition, it is known that 
neutralizing epitopes on VLPs are conformationally dependent and type-restricted 
[75,76,77]. Therefore, to test for direct interaction between L1 of different HPV types, 
293TT cells were transfected with the three DNA vaccines expressing L1 of HPV6, 
HPV16, and HPV18 either individually or simultaneously, and immunoprecipitation 
experiments were performed on cell lysates using the H18.F8 monoclonal antibody that 
recognizes a conformational and type-specific HPV18 L1 epitope [78]. The presence of 
HPV6 L1, HPV16 L1 and HPV18 L1 in the immunoprecipitates was detected by Western 
blot analysis with type-restricted monoclonal antibodies H6.C6, H16.O7 and H18.E20 
[78], respectively (Figure 14). H18.F8 immunoprecipitated HPV18 L1, but not HPV6 L1 
or HPV16 L1 from lysates of cells transfected with only a single L1 DNA vaccine 
(Figure 14). By contrast, H18.F8 immunoprecipitated HPV6 L1, HPV16 L1 and HPV18 
L1 from the lysates of cells co-transfected with the three DNA vaccines expressing L1 of 
HPV6, HPV16, and HPV18 L1. These results demonstrate that HPV18 L1 can bind to 





Figure14.  Interaction between HPV18 L1 with L1 of both HPV6 and HPV16.  
To test for interaction between L1 proteins of different HPV genotypes, 293TT cells were 
transfected with empty DNA vector (V), or vector expressing HPV6 L1, HPV16 L1, or 
HPV18 L1 individually (6L1, 16L1, 18L1, respectively), or all three together (Mix). Two 
days later, the cells were harvested and lysed. HPV18 L1 was immune-precipitated from 
lysates using the conformationally-dependent and neutralizing monoclonal antibody 
H18.F8. The presence of HPV6 L1, HPV16 L1 and HPV18 L1 in the immune-
precipitates was detected by Western blotting with H6.C6 (left panel), H16.O7 (middle 













L1 DNA vaccines have potential as an alternative prophylactic HPV vaccine that 
is simple and inexpensive to produce and heat stable, properties that would facilitate 
widespread immunization in low resource and remote settings. However, delivery of 
DNA vaccines in vivo has been limited by the efficiency of transfection in vivo. Several 
approaches including ballistic delivery via gene gun, in vivo electroporation devices, and 
tattooing have been developed to improve in vivo delivery. Here, we have tested two of 
these approaches previously tested clinically for DNA vaccine delivery; gene gun and in 
vivo electroporation. While gene gun vaccination demonstrated strong neutralizing 
antibody responses with only 2 mg of HPV16 L1 DNA vaccine, this was the highest 
amount of DNA that could be loaded onto the gold particles. The in vivo electroporation 
approach required 10 mg of HPV16 L1 DNA vaccine to achieve a consistent and robust 
neutralizing antibody response (that was not significantly higher with 20 mg or 40 mg 
doses), and these titers were higher than for 2 mg maximal dose of HPV16 L1 DNA 
vaccine delivered via gene gun. Although electroporation clearly enhances the efficiency 
of in vivo transfection of cells with the DNA vaccine, it may also trigger local 
inflammation, cell death and recruitment of immune cells to enhance the immune 
response [129-131]. While L1 DNA vaccination clearly has potential as a heat stable and 
low cost vaccine, a requirement for in vivo electroporation would raise the cost and 
complexity of vaccination because of the need for an electroporation device and access to 
electricity. Delivery via a self-contained gene gun device like PD-10 is another option, 
but the DNA dose is much more limited than for in vivo electroporation. 
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Hitzeroth et al observed a very weak (titer of 1:50) and non-neutralizing antibody 
response to vaccination of mice i.m. twice with 100 mg of DNA expressing full length 
codon-optimized HPV16 L2 [143]. The L2×8 DNA vaccination failed to elicit a 
detectable neutralizing antibody titer (Figure 11). A possible reason for the lack of 
response is poor expression by the L2×8 construct as compared with full length HPV16 
L2 is incorrect codon optimization resulting in poor expression. However, when we re-
optimized codon usage in the L2×8 construct for mammalian expression and compared 
expression levels to the previous bacterial codon optimized construct there was no 
significant improvement in expression. There are negative transcription and translation 
regulating sequences in the L2 gene, and the L2×8 DNA constructs may therefore still 
contain 8-fold more negative regulatory sequences than HPV16 L2, even after the 
nucleotide sequence changes resulting from codon optimization. In addition, recent 
studies suggest the presence of a transmembrane-like domain within this region of L2 
that may limit expression and/or antigen release [157]. The L2×8 protein exhibited 
extensive degradation when expressed in mammalian cells (Figure 11C), which may also 
contribute to its low level and immunogenicity. Finally, it is clear that L2×8 is 
substantially less immunogenic than L1 VLP as the L2×8 protein vaccine induces, 30-
fold lower neutralizing antibody titers than Gardasil [79]. 
Previously it was shown that HPV6 L1 and HPV16 L1 can co-assemble forming 
hybrid VLP in yeast [151] and that co-expression of either BPV1 or HPV11 L1 with 
HPV16 L1 reduces HPV16 L1 VLP assembly in 293T cells [152]. We also showed that 
HPV18 L1 binds to both HPV6 L1 and HPV16 L1 when co-expressed in 293TT cells 
(Figure 14). The interaction between L1 of different HPV types, i.e. heterotypic binding, 
85 
 
likely reflects the high degree of sequence conservation of the internal L1 structure, and 
has a deleterious effect upon multivalent L1 DNA vaccination. Indeed, mice vaccinated 
with a mixture of three DNA vaccines expressing L1 of HPV6, HPV16 and HPV18 
showed relatively reduced protection against HPV16 compared to the group vaccinated 
with single HPV16 L1 DNA. This was also the case for HPV18 L1, but not for HPV6 L1. 
Thus the interference was inconsistent, possibly reflecting different L1 expression levels 
and affinity for heterotypic L1 interaction. Vaccinating at different sites completely 
restored the induced neutralization titer to the levels obtained when vaccinating with a 
single construct (Figures 12 and Figure 13). This observation suggests that spatial 
separation of individual type L1 DNA vaccines during vaccination prevents the formation 
of heterotypic L1 interactions and aberrant assembly of chimeric VLP. Three HPV types 
were used in our experiments, but more HPV types covering most of oncogenic types 
could potentially be delivered by a multi-microneedle injector to spare the patient from 
receiving multiple injections at each visit. 
The co-expression of the cognate L2 in each construct is a possible alternative to 
spatial separation of the L1 DNA vaccines of different genotypes during multivalent 
vaccination. While this approach enhanced the neutralizing antibody responses relative to 
a mixed multivalent L1 DNA vaccine, it did not achieve in all cases the titers obtained 
upon vaccinating with a single type or spatial separation with multivalent L1 DNA 
vaccination (Figure 12). Nevertheless, the titers achieved with a mixed multivalent 
L1+L2 vaccine were completely protective against vaginal HPV16 challenge upon 
SDVVLYH WUDQVIHU WR QDࡇÕYH PLFH ZLWK  PO RI VHUXP ZKHUHDV DQWLVHUXP IURP PLFH
administered with the mixed multivalent L1 vaccine was only partially protective (Figure 
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13). This protection data is consistent with the in vitro neutralization titers and suggests 
that only a low neutralizing antibody titer is required for complete protection. Further the 
protective response to the electroporation of the mixed multivalent L1+L2 vaccine was 
durable at 3 months after the final vaccination, suggesting that co-expression of L2 might 
be an alternative to administering each construct at a different site. 
Both of the licensed HPV vaccines utilize an alum-based adjuvant and Cervarix 
also includes a TLR4 agonist, MPL. Naked DNA vaccines, delivered appropriately, can 
potentially activate TLR9 via CpG islands as well as cytoplasmic DNA sensors such as 
DAI and AIM2 to enhance the immune response. However, we have not examined L1 
DNA vaccination with alum and utilizing electroporation. Previously, it was found that 
mixing a hepatitis B DNA vaccine with aluminum phosphate improved the antibody titers, 
10-fold relative to DNA alone injected i.m. without electroporation [158]. While the titers 
of neutralizing antibody induced by L1 DNA vaccines might be improved with adjuvant 
and utilizing electroporation to reach the levels produced by Gardasil, it is clear that the 
L1 DNA vaccines elicit completely protective responses. Passive transfer of 20 ml of 
serum from either L1 DNA or Gardasil vacFLQDWHGPLFHUHQGHUHGQDࡇÕYHDQLPDOVLPPXQH
to vaginal challenge. This corresponds to a, 1:50 dilution in the mouse, indicating a 
robust response. Furthermore, while the studies demonstrate that neutralizing antibody is 
sufficient to mediate protection, it does not rule out a contribution of L1-specific T cell 
immune responses to protection in actively vaccinated mice. Further study is warranted to 
determine the relevance of L1-specific T cell immune responses to preventing HPV 
infections and the relative levels induced by L1 VLP protein and L1 DNA vaccination. 
Safety issues and practical considerations surrounding the use of DNA as a 
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vaccine need further consideration. Although it has not been an issue in clinical studies of 
naked DNA vaccines to date, the potential for a low frequency of integration of the 
vaccine DNA into the host chromosome or the induction of anti-DNA antibodies to cause 
disease remains a concern. Standard i.m. injection of naked DNA is very inefficient 
because only a small fraction of DNA is taken up by cells and expressed, but advances in 
delivery technologies such as ballistic delivery and electroporation are beginning to 
overcome this barrier. Indeed, our results suggest that vaccinating at different sites with 
multi-type L1 or L1+L2 DNA vaccines and using electroporation to enhance delivery 


















Persistent infection by high risk HPV types is a necessary, but not sufficient cause 
of cervical cancer, as well as a significant fraction of other anogenital cancers and subset 
of head and neck cancers [2]. Two licensed HPV vaccines, Gardasil® (Merck) and 
Cervarix® (GSK), are derived from the viral major capsid protein L1, which assembles 
into virus-like particles (VLPs) when expressed in eukaryotic cells [74]. Gardasil® is 
derived from L1 expression in yeast and Cervarix® from expression in baculovirus 
infected insect cells. In Gardasil®, L1 VLPs derived from HPV6 (20 mg), HPV11 (40 
mg), HPV16 (40 mg) and HPV18 (20 mg) are formulated using an amorphous aluminum 
hydroxyphosphate sulphate adjuvant (225 mg). In Cervarix®, HPV16 and HPV18 L1 
VLPs (20 mg each) are adjuvanted with aluminum hydroxide (500 mg) and 3-O-desacyl-
4’-monophosphoryl lipid A (MPL, 50 mg). Both vaccines have demonstrated remarkable 
protective efficacy against infection by the specific HPV types present in each vaccine 
[8,10,75,159]. Importantly, efficacy has been demonstrated against the development of 
low and high grade intraepithelial neoplasia at the cervix, vaginal, vulva and anus that are 
associated with HPV16 and HPV18 infection [160]. Vaccination with HPV6 and HPV11 
VLPs also prevents the occurrence of benign genital warts caused by these types [161]. 
Vaccination with L1 VLPs induces type-restricted immunity, i.e., near absolute 
protection against the type utilized to generate the vaccine, significant but weaker cross-
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protection for the most closely phylogenetically-related types (e.g., HPV16 and HPV31, 
or HPV18 and HPV45), and partial to no protection against more distantly related types 
or types from other species [11,75]. HPV16 and HPV18 are associated with 50% and 
20% of cervical cancer cases, respectively. Because more than a dozen high risk types are 
associated with cervical cancer and benign genital warts cause significant morbidity, 
there is an effort to develop a nonavalent L1 VLP vaccine targeting the seven most 
common oncogenic HPV types and the two most common types in genital warts, HPV6 
and HPV11 [42,54]. 
High-risk HPV infection causes <5% of all cancer worldwide, but <85% of 
cervical cancer cases occur in low income countries, reflecting their lack of resources and 
infrastructure to support national cytologic screening efforts [115]. Therefore, the 
potential benefits of HPV vaccination are likely to be greatest in low resource settings, 
highlighting the need to develop inexpensive and broadly protective HPV vaccines that 
can be delivered globally [74]. 
VLPs are formed by the assembly of seventy two capsomers, and each capsomer 
is comprised of five L1 molecules [5,162]. L1 capsomers are potential low cost 
alternatives to VLPs because they can be purified after expression in bacteria in high 
yields [34,116,117]. Deletion of the N-terminal 9 amino acids and the C-terminal 29 
amino acids from L1 (herein abbreviated as L1ǻ) enhances the yield of capsomers 
[34,119]. 
Vaccination of dogs with GST-fused canine oral papillomavirus (COPV) L1 
capsomers protects against experimental oral challenge with COPV [36]. Vaccination 
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with COPV L1 is completely protective without an adjuvant using only 400 ng 
capsomers or 50 ng VLPs. Passive transfer of serum immunoglobulins from COPV L1 
VLP-YDFFLQDWHGGRJV WRQDࡇÕYH UHFLSients protected the latter from experimental COPV 
challenge, indicating the capacity of neutralizing antibody to mediate protection. 
Capsomers display comparable type-restricted neutralizing epitopes to L1 VLPs [37,163], 
but low avidity and broadly reactive L1 epitopes have been described [164]. Because they 
are not coordinated with other capsomers and are deleted at both termini, we 
hypothesized that L1ǻ capsomers potentially may display cross-protective epitopes that 
are otherwise hidden in VLPs and trigger low avidity broadly protective antibodies 
difficult to detect by neutralization assays [165]. Herein we examine the potential of L1ǻ 
capsomers to generate antibodies that are both broadly neutralizing and protective against 
vaginal challenge. 
The need for broad protection against high-risk HPV types can potentially be 
provided by multivalent combinations of capsomers, but this formulation complicates 
manufacture. As an alternative, we explored the C-terminal fusion of the minor capsid 
protein L2 to L1ǻ a site on the capsomer that tolerates such additions without adversely 
affecting its structure. Residues at the amino terminus of L2, including amino acids 13–
47 [46,166,167], contain broadly protective epitopes [45,46,111], but they are weakly 
immunogenic in comparison to L1 [44,112]. Indeed, when L2 is co-assembled with L1 in 
a VLP, L2 is unrecognized by the immune system either because of its internal 
positioning or the context of L1 dominant epitopes [112]. We hypothesized that the 
tandem fusion of L2 residues 13–47 from three different and common high-risk HPV 
types (derived from HPV18, HPV31 and HPV45 that cause 17.2%, 2.9% and 6.7% of 
91 
 
cervical cancer cases respectively [54]) to the C-terminus of HPV16 L1ǻ (the type 
responsible for 53.9% of cervical cancer cases) would enhance the immunogenicity of L2 
by displaying a dense and regular array of epitopes [168], and thus provide broad 





















b) Materials and Methods 
 
1) Ethics Statement 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All animal studies were performed with the prior approval of the Animal Care and Use 
Committee of Johns Hopkins University (protocol MO08M19). 
 
2) Cells, plasmids, media and growth conditions 
Plasmid pGEX-HPV16 L1ǻ (encoding amino acids 36–502 from GenPept 
accession number NP_041332.1) was constructed for the expression of the deletion 
mutant HPV16 L1ǻN9ǻC29 with an N-terminal GST tag. The HPV16 L1 gene was 
codon optimized for expression in Escherichia coli and synthesized by Genscript with a 
BamHI site at its 59 end, and two stop codons and an XhoI site at its 39 end. It was then 
cloned into the BamHI/XhoI sites of pGEX-4T-2 (GE Healthcare) and verified by 
sequencing. 
Plasmid pGEX-+39 /ǻ-L2×3 was constructed by amplifying HPV16 
/ǻ1ǻC29 from the aforementioned plasmid and reinserting the L1 segment into 
pGEX-4T-2 using the BamHI and EcoRI restriction sites. The L2 segment of this plasmid 
was created synthetically using overlapping oligonucleotides that were assembled and 
amplified using PCR. A sequence containing amino acids 12–46 from HPV18 L2, amino 
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acids 13–46 from HPV31 L2 and amino acids 12–46 from HPV45 L2 (GenPept 
accession numbers AAP20600.1, AAA92893.1 and AAY86493.1, respectively) in 
tandem were submitted to the online program DNAWorks 
(http://helixweb.nih.gov/dnaworks/). This sequence also contained five glycines 
preceding the HPV18 L2 sequence and two glycines in between the HPV18 and 31 and 
HPV31 and 45 sequences. The DNAWorks output included 16 oligonucleotides 
optimized for expression in E. coli. These oligonucletoides were assembled by PCR in a 
reaction containing 100 ng of each oligo, 200 mM of each dNTP, 1x PfuTurbo reaction 
buffer and 2.5 U PfuTurbo (Stratagene). The assembly reaction was performed as 
follows: 2 min at 95°C, 25 cycles of 30 sec at 95°C, 30 sec at 55– 65°C and 1 min at 
72°C followed by 10 min at 72°C. Each of these reactions (1 ml as a template) was then 
amplified using the outermost oligonucleotides as forward and reverse primers (100 ng 
each). The amplification reaction was performed as follows: 2 min at 95°C, 25 cycles of 
30 sec at 95°C, 30 sec at 62°C and 1 min at 72°C followed by 10 min at 72°C. The 
assembly reactions performed between 60 and 65°C resulted in the appropriately sized 
product. This product was digested and ligated into the pGEX-4T-2 vector containing 
+39 /ǻ between the EcoRI and NotI sites. The plasmid was verified by DNA 
sequencing. 
 
3) Purification of capsomers 
Truncated HPV16 L1 was expressed as a GST fusion protein either alone or with 
the tandem HPV L2 epitopes in BL21(DE3) E. coli (Stratagene). A single colony of 
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transformed bacteria was inoculated into 50 ml of Terrific Broth (TB) (1.2% Tryptone, 
2.4% yeast extract, 0.5% glycerol, 17 mM KH2PO4 and 72 mM K2HPO4) containing 
100 ug/ml ampicillin and grown overnight at 30°C. The 50 ml overnight culture was then 
used to inoculate 500 ml of fresh selection medium to an optical density (OD)595 of 0.1, 
and this culture was grown at 37°C until the OD595 reached 4.0. The temperature was 
decreased to 25°C, 200 ul of 0.5 M IPTG was added and the culture was grown to an 
OD595 of 8. The cultures were then split into two bottles of 250 ml each, and the cells 
were harvested by centrifugation at 5000 rpm for 15 min at 4°C. The cell pellets were 
frozen at -20°C until use. 
The cells were lysed, and the fusion proteins were purified via affinity 
chromatography. Each cell pellet was resuspended in 100 ml of ice-cold buffer L (50 mM 
Tris-HCl pH 8.0, 0.2 M NaCl, 1mM EDTA) with 5mM DTT, 1mM PMSF and 1x 
complete protease inhibitor cocktail (Roche). The cell suspension was homogenized 
using a French pressure cell (Thermo Scientific) at 2,000 psi to complete cell lysis. 
DNase I (40 U/ml), 2 mM ATP and 10 mM MgCl2 were added to the lysed bacteria, and 
the lysate was rocked for 1 h at room temperature. Solid urea was then added to a final 
concentration of 2.3 M, and the lysate was again rocked for 1 h at room temperature. The 
lysate was dialyzed overnight at 4°C into two changes of buffer L/5 mM DTT without 
urea, centrifuged at 25,000 × g for 20 min at 4°C and passed through a 0.2 mm filter. A 
volume of 50 ml of clarified lysate was applied to a glutathione sepharose column 
(GSTrap FF 5 ml column, GE Healthcare) at 0.5 ml/min using an ÄKTA FPLC system 
(GE Healthcare). The column was washed with four column volumes each of buffer L 
with 2 mM DTT and buffer L with 2 mM DTT and 0.01% Tween 80. The GST-tagged 
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proteins were eluted with buffer L with 2 mM DTT, 0.01% Tween80 and 10 mM reduced 
glutathione. SDS-PAGE analysis of the eluted fusion protein demonstrated GST-
HPV1/ǻ RU *67-+39/ǻ-L2×3 and free GST as the major components. The 
concentration of the GST-/ǻDQG*67-/ǻ-L2×3 proteins in the samples used for 
vaccination were estimated by SDS-PAGE in comparison to BSA standards. The 
conformation of these proteins was verified by ELISA with the H16.V5 antibody [156], 
which specifically reacts with a conformationally-dependent neutralizing epitope on the 
L1 surface. 
 
4) Generation of HPV pseudoviruses (PsV) 
Pseudoviruses were generated as previously described [82]. Briefly, plasmids 
pshellHPV16L1L2, pVitroHPV18L1L2, pVitroHPV31L1L2 or pVitroHPV45L1L2 were 
transfected with either a luciferase or alkaline phosphatase (SEAP) reporter gene plasmid 
into 293TT cells [82] using TransIT-2020 transfection reagent (Mirus). Three days after 
transfection, cell pellets were collected and rinsed with DMEM and Dulbecco’s PBS. The 
pellets were resuspended in a small volume of DPBS-Mg (DPBS supplemented with 9.5 
mM MgCl2) and then transferred into siliconized tubes. Cells were pelleted by low speed 
centrifugation, and the supernatant was discarded. For PsV maturation, an equal volume 
of lysis buffer (DPBS-Mg supplemented with 0.5% of Brij 58 and 0.2% benzonase) was 
added to the cell pellet, which was allowed to incubate at 37°C for 24 h. After 
maturation, lysates were adjusted to 850 mM NaCl and extracted with high salt buffer 
(DPBS with 0.8 M NaCl). Lysates were clarified by centrifugation at 10,000 × g for 10 
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min, loaded onto an Optiprep step gradient (27, 33 and 39%) and spun at 40,000 rpm in a 
SW40 rotor for 16 h at 16°C. After centrifugation, 0.5 ml fractions were collected from 
the top of the gradient. A sample representing each fraction was diluted and tested on 
293TT cultures [82] for reporter gene expression. Fractions with highest reporter gene 
expression were pooled and used for the serum neutralization assay and the in vivo 
challenge experiments. 
 
5) Immunization of mice 
Inbred 4- to 6-week old female BALB/c mice (NCI) in groups of five or 10 were 
immunized subcutaneously three times at two-week intervals. The immunogens used 
were 25 ug of GST-HPV16L1ǻ, 25 ug of GST-+39/ǻ-L2×3 or the indicated doses 
of the 11-88×5 HPV L2 fusion peptide. Each dose of immunogen (50 ul) contained 
comparable adjuvant (50 ug aluminum hydroxide and 5 ug 3-O-desacyl-4’-
monophosphoryl lipid A [MPL]) to 1/10th of a human dose of the Cervarix® vaccine. 
 
6) Measurement of neutralization antibody titers 
Serum samples collected from each mouse two weeks after the final 
immunization were serially diluted two-fold in culture medium, mixed with an equal 
volume of HPV pseudovirions containing either luciferase or SEAP reporter genes, and 
incubated at 37°C for 2 h. These samples were each added to 293TT cell cultures (3×104 
cells/well), which were then incubated for 72 h [82]. To measure luciferase expression, 
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culture media were removed from each well and 1x Cell Culture Lysis Reagent (CCRL, 
Promega) was added to lyse the cell monolayer for 15 min at room temperature on a 
rocking platform. A volume of 20 ul of the lysate from each well was transferred to a 
black microtiter plate followed by the addition of 50 ul/well of 1× luciferase substrate 
(Promega). The plates were scanned with the GloMax®-Multi Detection System 
(Promega). For SEAP measurement, 40 ul of cell-free supernatant was collected from 
each well, mixed with 20 ul of 0.05% CHAPS, heated at 65°C for 30 min and then cooled 
on ice. A volume of 200 ul/well of p-nitrophenyl phosphate (pNPP) substrate (2 M 
diethanolamine with 1 mg/ml of pNPP) was added to each well for color development at 
ambient temperature, and absorbance data was collected with an automatic ELISA plate 
reader (Bio-Rad). Data was collected when the absorbance from the wells incubated with 
only PsV (ODpsv) had an OD405>1. The highest dilution of serum that resulted in 50% or 
more reduction in ODpsv was defined as the endpoint neutralization titer and expressed 
as its reciprocal value. 
 
7) Determination of ELISA antibody titers 
L2 antigens (HPV16 L2 amino acids 11–200 or full length HPV18 L2 or HPV31 
L2 were generated in E. coli as 6×His fusions [170], or L2 amino acids 17–38 of HPV16, 
17–36 of HPV31, 17– 36 of HPV35, 16–35 of HPV45 or 16–35 of HPV58 chemically 
synthesized as a peptide) were coated onto an ELISA plate (MaxiSorp; Thermo 
Scientific) at 100 ng of protein or 500 ng of peptide per well and incubated at 4°C 
overnight. Coated plates were blocked with PBS-BSA (1× PBS supplemented with 1% 
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BSA) at 37°C for 1 h and then incubated with 100 ul of the diluted serum samples (two-
fold serial dilution from 1:50) at ambient temperature for 1 h. Plates were then washed 
three times with PBST (1× PBS with 0.01% Tween 20), and bound antibody was 
detected with horseradish peroxide-conjugated sheep anti-mouse IgG antibodies (GE 
Health) followed by further washes with PBST and development with the 2,2ƍ-azinobis[3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) substrate (Roche). The 
cutoff OD value (ODcutoff) for the ELISA assay was set at three times the average 
DEVRUEDQFH GHWHFWHG IURP ILYH QDࡇÕYH PRXVH VHUXP VDPSOHV 7KH KLJKHVW GLOXWLon of 
serum sample that had an OD value equal to or above the ODcutoff was defined as the 
endpoint ELISA titer. 
 
8) In vivo PsV vaginal challenge 
Four days before challenge, female Balb/c mice were injected subcutaneously 
with 3 mg of medroxyprogesterone (Depo-Provera; Pfizer) to synchronize their estrus 
cycles [61]. Each challenge dose was comprised of 10 ul PsV mixed with 10 ul of 3% 
carboxymethyl cellulose (CMC). The dose was delivered twice into vaginal vault, the 
first 10 ml just prior to and the second 10 ul just after treatment with a cytobrush cell 
collector. The cytobrush cell collector was inserted into the vaginal vault and turned both 
counter-clockwise and clockwise 15 times while the mice were anesthetized. Three days 
after PsV delivery, the mice were again anesthetized and 20 ul of luciferin (7.8 mg/ml) 
was deposited in the vaginal vault. Luciferase signals were acquired for 10 min with a 




9) Statistical analysis 
Data were analyzed with one-way ANOVA, or the Kruskal-Wallis test and 





















1) Capsomer construction and vaccination 
The generation of the HPV16 L1 deletion mutant (GST-+39/ǻ) and its 
purification after expression as a GST fusion protein in bacteria have been previously 
described [34]. A second construct (GST-+39/ǻ-L2×3) was prepared for this study 
by fusing a bacterial codon-optimized sequence encoding L2 amino acids 13–47 of 
HPV18 with the corresponding sequences of HPV31 and HPV45 in tandem to the C-
terminus of GST-+39/ǻ. Both constructs were used for the expression of high levels 
of soluble protein in bacteria. These proteins were purified from lysates by affinity FPLC 
chromatography with glutathione sepharose. A ~5-fold lower dose of L1 as VLP 
compared to capsomers is sufficient to induce immunity [22,36]. Therefore, to assess the 
immunogenicity of the GST-+39/ǻDQG*67-+39/ǻ-L2×3 capsomers, groups 
of Balb/c mice were immunized three times at two-week intervals with 25 ug of 
capsomers formulated in 50 ug alum and 5 ug MPL per dose. For comparison, an 
additional group of mice was vaccinated with 1/ 10th of a human dose of Cervarix®, 
which was comprised of 2 ug each of HPV16 and HPV18 L1 VLPs formulated in 50 ug 






2) Serum neutralization antibody titers 
Two weeks after the third immunization, serum samples from each immunized 
group were tested for neutralizing antibody titers against the four HPV types most 
commonly found in cervical cancer [53]. HPV16-specific serum neutralization titers were 
detected in all groups of mice except IRU WKH QDࡇÕYH JURXS )LJXUH ). Animals 
immunized with Cervarix® showed a very high mean serum titer of HPV16 neutralizing 
antibodies (53,120), whereas the GST-HPV16-/ǻ DQG *67-HPV16-/ǻ-L2×3 
capsomer-immunized groups exhibited mean titers of 7520 and 6160, respectively 
(Figure 15A), suggesting that the greater immunogenicity of VLP may provide dose 
sparing as compared with capsomers. However, the average anti-HPV18, HPV31 and 
HPV45 neutralization titers were below the limit of detection (<100) for both groups that 
received capsomer vaccines, which is consistent with type-restricted neutralization 
(Figures 15B-D). Serum samples from the Cervarix®-immunized group exhibited an 
average neutralization titer of 34,720 against HPV18, whereas average neutralization 
titers against HPV31 and HPV45 were below the limit of detection (<100). The latter 
finding is surprising because vaccination with Cervarix® protects patients against HPV31 
and HPV45 [75] and modest titers of neutralizing antibodies for these types were 
detected in some vaccinated patients [169], indicating that even very low titers of 




Figure 15.  Neutralizing antibody responses of mice vaccinated with capsomers.  
Two weeks after the third immunization with GST-HPV16/ǻ, GST-HPV16/ǻ-L2×3 
or Cervarix®, two-IROGGLOXWLRQVRIVHUXPIURPQDࡇÕYHRULPPXQL]HGPLFHZHUHWHVWHGIRU
in vitro neutralization activity against pseudovirions derived from HPV16 (A), HPV18 
(B), HPV31 (C) or HPV45 (D) starting at a dilution of 1:100. The reciprocal of the 
KLJKHVW VHUXP GLOXWLRQ ZLWK  UHGXFWLRQ LQ UHSRUWHU JHQH H[SUHVVLRQ VLJQDO ZDV
defined as the serum virus neutralizing antibody titer, and <100 was considered not 





3) Serum anti-HPV L2 ELISA titers 
Serum samples from each immunized group taken two weeks after the third 
immunization were tested for L2 specific antibody titers by ELISA against either HPV16 
L2 11–200 or HPV16 L2 17–36, conserved neutralizing and protective epitopes [46,170]. 
Sera of mice vaccinated with GST-+39/ǻ-L2×3 exhibited mean ELISA titers of 545 
and 230, respectively, against HPV16 L2 11–200 and 17–38 (Figure 16). Since the GST-
+39/ǻ-L2×3 contains L2 sequences derived from HPV18, 31 and 45, we examined 
the reactivity of the sera to full length HPV18 L2 protein, HPV31 full length L2 protein 
and 17–36 peptide, and HPV45 L2 16–35 peptide. The GST-+39/ǻ-L2×3 antisera 
reacted specifically with the HPV18 and HPV45 L2 polypeptides, but not with either the 
HPV31 full length protein or the 17–36 peptide. The GST-+39/ǻ-L2×3 antisera also 
failed to react with HPV35 L2 17–36 or HPV58 L2 16–35 peptides, two types that were 
not included in the vaccine construct. 
We previously showed that the L1 and L2-specific antibody responses to 
vaccination with L1 capsomers mixed with multimeric L2 protein 11-88×5 (a fusion of 
L2 amino acid residues 11–88 derived from HPV1, 5, 6, 16 and 18) were independent 
(i.e., no interference was noted) [37]. Although fusion of L2 with L1 capsomers did not 
significantly impact the neutralizing antibody response, surprisingly, no neutralizing 
antibody titers were detected for HPV18, HPV31 or HPV45, indicating that the L1-
specific response might dominate the L2 specific response to GST-/ǻ-L2×3 
vaccination. GST-+39/ǻ-L2×3 is a fusion peptide that contains GST, an L1 deletion 
mutant and three copies of L2 amino acids 13 to 47 derived from HPV types 18, 31 and 
45, while 11-88×5 is a fusion of L2 amino acids 11 to 88 from five different HPV types 
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(HPV1, 5, 6, 16 and 18) [48]. Thus, vaccination with 4 ug of the latter would provide a 
similar amount of L2 for comparison. Serum collected from mice immunized with 4 ug 
of 11-88×5 had a mean HPV16 L2 17–36 peptide (/,6$WLWHURIZKLFKLV§12-fold 
higher than the mean serum titer of the GST-+39/ǻ-L2×3-immunized group (230) 
(Figure 16B). As compared with GST-+39/ǻ-L2×3 antisera, the antisera to the 11-
88×5 fusion was also more cross-reactive with L2 neutralizing epitopes of HPV types not 








Figure 16.  L2-specific antibody titers induced by vaccination of mice with capsomers.  
Two weeks after the third immunization with GST-HPV16/ǻ, GST-HPV16/ǻ-L2×3 
or Cervarix®, two-fold dilutions of serum from immunized mice were tested by ELISA 
for L2 specific antibodies. Microtiter plates were coated with either HPV16 L2 amino 
acids 11–200 (A), or the 17–38 L2 peptide (B), or HPV18 L2 full length protein (C), or 
HPV31 L2 17–36 peptide (D), or HPV31 full length protein (E) or HPV35 L2 17–36 
peptide (F), or HPV45 L2 16–35 peptide (G), or HPV58 L2 16–35 peptide (H), and then 

















4) In vivo PsV vaginal challenge of capsomer-immunized mice 
Because vaccination with both capsomer vaccines elicited robust HPV16 
neutralizing antibody titers, the mice were subjected to vaginal challenge with HPV16 
pseudovirus carrying a luciferase reporter to facilitate the measurement of infectivity in 
vivo. Three days after intravaginal challenge with HPV16 PsV, the non-immunized 
animals exhibited a high mean luciferase activity (Figure 17A). Conversely, mice 
immunized with either GST-+39/ǻ RU *67-+39/ǻ-L2×3 exhibited 
background levels of luciferase reporter gene activity similar to that of Cervarix®-
immunized mice, which is consistent with complete protection. The background 
luciferase levels in the mice immunized with GST-+39/ǻ*67-+39/ǻ-L2×3 
or Cervarix® were not significantly different (Figure 17A). 
Vaccination with GST-/ǻ-L2×3 elicited L2 specific antibody responses, but 
no cross-neutralizing antibody responses were detected for HPV18, HPV31 or HPV45. 
However, previous studies indicate that the antibody levels necessary for protection are 
low and that the current neutralization assay may lack sensitivity for L2 specific 
neutralizing antibodies [26]. In order to determine if vaccination with GST-HPV/ǻ 
can induce cross-protection, or if fusion of L2×3 to the C-terminus of GST-+39/ǻ 
can enhance cross-protection, immunized mice were vaginally challenged with HPV18. 
Despite using a greater challenge dose of HPV18 PsV (8.3 ug of L1) than HPV16 PsV (1 
ug of L1), it is noteworthy that HPV16 PsV are dramatically more infectious in mice than 
HPV18 PsV (Figure 17%1HYHUWKHOHVVQDࡇÕYHPLFHH[KLELWHGDFOHDUVLJQDODIWHU+39
PsV challenge, while mice vaccinated with Cervarix® that contains HPV18 L1 VLPs, 
exhibited background levels, which is consistent with complete protection (Figure 17B). 
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Vaccination with GST-+39/ǻ capsomers failed to provide significant protection 
against HPV18 challenge, suggesting that capsomers, like L1 VLPs, trigger a type-
restricted protective immune response. Conversely, vaccination with GST-/ǻ-L2×3 
provided robust protection against HPV18 challenge, which was not significantly 









Figure 17.  Vaginal challenge of mice with HPV PsV after immunization with capsomers.  
Mice were subcutaneously immunized with GST-HPV16/ǻ, GST-HPV16/ǻ-L2×3 or 
Cervarix® three times at two-week intervals. Three and five weeks after the last 
immunization, the mice were challenged with either HPV16 (A) or HPV18 (B) PsV 
carrying a luciferase reporter, respectively. Three days after challenge, the mice received 
an intravaginal instillation of 20 ml of D-luciferin and were imaged with a Xenogen IVIS 
100 system (image captured for 10 min post-installation of luciferin). Image analysis in 
each experiment was based on the average measurement (photons/s/cm2) collected from 





Vaccination with GST-HPV16L1ǻ was as effective as Cervarix® in protecting 
mice against vaginal challenge with HPV16, although inducing neutralizing antibody 
titers approximately seven-fold lower than Cervarix®. However a more optimized 
capsomer formulation may reduce or negate this difference, and the difference with 
Gardasil® may be less [171]. It should be noted, however, that very low titers of 
antibodies appear to be sufficient to protect mice from vaginal challenge [26], as 
illustrated by the cross-protection of mice against HPV18 by vaccination with GST-
16/ǻ-L2×3. In this case, the mean titer of HPV18 neutralizing antibodies was below the 
threshold of detection, yet a similar level of protection was observed in mice vaccinated 
with Cervarix®, which exhibited very high titers of antibodies. It is possible that the 
difficulty in detecting L2-specific protective antibodies reflects differences in the 
exposure of L2 during in vitro infection of 293TT cells as compared with in vivo 
infection of the genital mucosa, or dramatically lower levels and/or avidity as compared 
to L1-specific neutralizing antibodies. The presence of L2-reactive antibodies in the sera 
of mice immunized with GST-HPV16/ǻ-L2×3 was detectable at low titer by ELISA, 
suggesting the latter possibility. The antibody responses to the conserved L2 neutralizing 
epitope comprising residues 17–36 [46] were approximately 12-fold lower in mice 
immunized with GST-HPV16/ǻ-L2×3 as compared mice immunized with L2 11-88×5. 
This result suggests that fusion of L2 with L1 does not enhance, and may compromise the 
response to L2. When L2 is simply mixed with L1 capsomers, no interference is observed 
[37], whereas L2 is subdominant to L1 when they are co-assembled into VLPs [44]. Thus 
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there are several efforts to substitute the immunodominant L1 epitopes with a cross-
neutralizing L2 epitope to render L2 more immunogenic like L1 [49,172,173]. Because 
vaccination with GST-16/ǻ protected against challenge with HPV16 but not HPV18 
PsV, the protection provided by L1 capsomers appears to be type-restricted as seen for 
L1 VLPs, and exposure of the sides of the capsomers by preventing assembly does not 
uncover cross-protective L1-specific epitopes. Clearly, the alternate approach to achieve 
broad protection is to generate a highly multivalent L1 capsomer-based vaccine, and 
capsomers have already been produced for HPV11, HPV16, HPV18 and HPV35 [155]. 
Nevertheless, the fusion of an L2 multimer to the C-terminus of L1 did not negatively 
impact the L1 responses, and it provided broader protection. 
The cost of manufacture remains a major, although not the only, barrier to global 
implementation of HPV vaccines [74]. The ability to produce very high yields of 
capsomers in a low cost bacterial expression system suggests the potential for cost 
reduction. The N-terminal deletion in L1 enhances production, and fusion to GST 
facilitates capsomer purification. The C- terminal deletion removes the arm that 
otherwise coordinates with adjacent capsomers within a VLP as well as the L1 DNA-
binding domain, thereby obviating the need for disassembly/reassembly to remove 
contaminating host DNA during VLP purification [174-176]. 
Herein we examined the immunogenicity of L1 capsomers on which the GST was 
retained. Although a tag such as GST would typically be removed from an antigen being 
considered for clinical application, the GST was retained because it has potential as an 
anti-schistosome immunogen [177,178]. Schistosomiasis is the second major parasitic 
disease after malaria and is an important public health problem in many non-
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industrialized countries. Furthermore urinary schistosomasis is a trigger for bladder 
cancer. The GST used in this study for affinity purification is derived from S. japonicum. 
GST derived from S. hematobium is currently in phase III testing (clinicaltrials.gov; 
identifier NCT00870649) to examine its value as a therapeutic vaccine (Bilhvax) in 
children exposed to urinary schistosomiasis [178]. Therefore, the inclusion of GST in the 
capsomer vaccine not only facilitates the purification process, it also confers the potential 
to trigger immunity at low cost against both papillomavirus and schistosome infections, 




















Human papillomaviruses (HPVs) are species-specific, epitheliotropic DNA 
viruses with over 120 types completely characterized today [12]. Infections are 
widespread and induce lesions from benign papilloma to intraepithelial neoplasia to 
carcinoma, the latter representing 5% (Parkin et al., 2005) of the global cancer burden. 
Persistent infection with a subset of mucosal HPVs causes high-grade intraepithelial 
neoplasias that eventually progress to invasive cancer of the cervix (CxCa) and of other 
anogenital and oropharyngeal sites. More than 15 high-risk (HR) types are found in 
almost all CxCas, causing 250,000 deaths in women worldwide every year [54,179]. 
Low-risk (LR) mucosal HPVs cause anogenital warts in 30 million patients. Common 
cutaneous HPVs induce skin warts with substantial impact on high-prevalence groups 
such as children or immunocompromised individuals [180,181]. Moreover, a distinct 
group of cutaneous (genus b) types have been implicated as subsidiary causative factor of 
nonmelanoma skin cancers, although this remains controversial for those other than 
patients with the rare genodermatosis Epidermodysplasia verruciformis [182,183] 
Recombinantly expressed major capsid protein L1 of papillomaviruses self-assembles 
into virus-like particles (L1-VLPs) [7,22,102,142,184] that have been introduced as 
prophylactic vaccines. Both (bivalent Cervarix and quadrivalent Gardasil) licensed 
vaccines comprise VLPs of HR HPV16/18, which cause 70% of cervical disease. One 
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(quadrivalent) vaccine additionally contains VLPs of LR HPV6/11, causing 90% of 
genital warts. Prophylactic vaccination confers enduring yet predominantly vaccine type–
restricted protection mediated by high-titer neutralizing antibodies. To target HPVs 
responsible for the remaining third of CxCas [54], a nonavalent vaccine including 7 HR 
types is in clinical trials (http://clinicaltrials.gov). However, the complexity of such a 
vaccine is unlikely to reduce the already very high costs of current HPV vaccines, which 
may impede delivery to the developing world with the highest CxCa burden. Furthermore, 
a vaccination strategy against the many types causing skin papillomas (warts) has not 
been established [153,185]. Papillomavirus minor capsid protein L2–based immunogens 
represent an alternative strategy to multivalent L1-VLP vaccines. The amino (N) 
terminus of L2 contains highly conserved motifs that are buried in native virions and 
become exposed only shortly during the infectious process. However, immunization with 
L2 peptides alone can induce low-titer antibodies, which mediate cross-neutralization 
[44,45,111,186] in vitro and cross-protection in animal models in vivo [170,187]. An 
HPV16 L2 peptide comprising amino acids (aa) 17–36 is a broadly cross-neutralization 
B-cell epitope recognized by mAb RG1 [46]. Owing to its essential role for viral 
infectivity and its high conservation within many types, the RG1 epitope may represent 
an attractive target to develop a broad-spectrum HPV vaccine. We have previously 
introduced chimeric RG1-VLP as a possible strategy to improve immunogenicity of the 
RG1 epitope by its genetic insertion into the immunogenic DE-surface loop of HPV16 L1 
[49,173,188,189]. Upon expression as a recombinant fusion protein, assembly into 
capsids repetitively displaying RG1 epitopes on the capsid surface (RG1-VLP) is highly 
efficient. Vaccination induced high-titer neutralizing antibodies against HPV16 and 
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improved L2-specific antibodies. Then, available limited in vitro assays demonstrated 
cross-neutralization of mucosal HR HPV18/31/45/52/58, LR HPV HPV6/11, and a single 
genus ȕ-type (HPV5) [49]. This study comprehensively examines RG1-VLP vaccine 
efficacy to cross-protect against all relevant mucosal HR HPVs in vivo and in vitro, 
endurance of protection (an important issue for L2-based vaccine development), and 
induction of cell-mediated immunity. Vaccine efficacy against natural infection was 


















b) Materials and Methods 
 
1) Chimeric RG1-VLP 
Chimeric HPV16 L1–HPV16 L2 (aa 17–36) VLP (RG1-VLP) have been 
generated [49] by the insertion of HPV16 L2 peptide aa 17–36 (RG1) [46] into the DE-
surface loop of HPV16 L1 and expressed in insect cells [7]. 
 
2) Immunization 
NZW rabbits were immunized with 50 ug of RG1-VLP subcutaneously (weeks 0, 
4, 6, and 8, n = 6; NZW nos. 1–6) or 20 ug of RG1-VLP (weeks 0, 3, and 6, n = 4; NZW 
nos. 7–10) (Charles River, Kisslegg, Germany) adjuvanted with alum-MPL (10:1) 
(Sigma Aldrich, St Louis, MO). Sera were drawn at weeks 10 (nos. 1–6) or 8 (nos. 7–10). 
Long-term antibody responses were determined for NZW nos. 1/2 kept at 10 months. 
Sera were drawn before and 14 days after final boost (week 52) and were stored at -20°C. 
For type-specific L1 antisera, a single rabbit each was immunized with 20 ug PsV of 
HPV6/26/34/35/39/43/44/51/52/53/56/ 58/59/66/68/69, or 70, respectively (weeks 0, 3, 
and 6), in complete/ incomplete Freund’s adjuvant. 
 
3) Native virion–based neutralization assays (reverse transcriptase– PCR) 
Native virions HPV2/27/1/4 were extracted from plantar warts; HPV6 from 
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genital warts; HPV26 from a highly differentiated carcinoma [190]; and HPV40 virions 
were provided by Neil Christensen (Hershey, PA) [192]. After mechanical disruption of 
wart tissue by high-speed homogenizer (Fastprep-24, MP Biomedicals, Eschwege, 
Germany) and centrifugation (14,000 r.p.m./4°C/5 minutes), supernatants containing 
virions were used for neutralization assays [188,191]. In brief, 3 × 105 HaCaT 
keratinocytes were infected with virions that were either untreated or preincubated with 
rabbit antisera and incubated overnight. Cellular RNA was reverse transcribed, and 
spliced viral E1^E4 mRNA was identified by 30-cycle nested PCR (95 °C/1 minute, 60 
°C/1 minute, and 72 °C/3 minutes). 
 
4) Murine vaginal challenge 
The intravaginal PsV challenge model (Roberts et al., 2007) was performed with 
slight modification [51]. Female Balb/C mice (groups of 5 or 10) were pretreated with 
3mg of progesterone subcutaneously medroxyprogesterone (Depocou, Pfizer, Vienna, 
Austria), and on day 3 they were passively transferred with 20ml rabbit antiserum: RG1-
VLP (pre) immune serum (rabbits 1, 6, and 10), or sera to L1-VLP of HPV16/31/33/45/6, 
to L1/L2-VLP of HPV18 (J Schiller, NIH, Bethesda, MD), to L1-DNA of HPV59/73, or 
to L1/L2-PSV of HPV26/34/35/39/51/52/53/56/58/66/ 68/69/ or 70, respectively. After 
24hours, vaginal microtrauma was induced by cervical cytobrush, and mice were 
challenged with luciferase-encoding PsV in 3% carboxymethylcellulose. After 3 days, 20 
ul of luciferin (Caliper, Waltham, MA; 7.5 mg ml-1) was applied into the vagina, and 
infection was analyzed by bioluminescence imaging (IVIS 50, Caliper). Data are given 
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with background signal subtracted (mice challenged with carboxymethylcellulose). 
 
5) Statistical methods 
Statistical analysis was performed using Microsoft Excel (heteroscedastic two-
tailed unpaired t-test to evaluate P-values). 
 
6) Consent and approval 
Human sera and tissue samples were collected after written informed consent of 
the patient or the patient’s guardian in accordance with the Ethics Committee of the 
Medical University Vienna (ECS 1327/2012). The study was conducted according to the 
Declaration of Helsinki Principles. 
 
7) Animal welfare 
Animal studies have been approved (BMWF-66.009/0173-1I/3b/ 2011) and 
animal care was in accordance with the guidelines of the Austrian Federal Ministry for 








We have shown previously that vaccination of rabbits and mice with recombinant RG1-
VLP plus alum-MPL (aluminum hydroxide plus 3-O-desacyl-4’-monophosphoryl lipid 
A) adjuvant [49] elicited high-titer neutralizing antibodies to HPV16 and cross-
neutralizing antibodies to pseudovirion (PsV) of the limited number of then available 
mucosal HR HPV18/31/45/52/58, LR HPV6/11, and cutaneous b HPV5. 
 
1) RG1-VLP vaccination induces a robust antibody response against the L2 epitope 
To assess the robustness of the humoral immune responses to RG1-VLP, eight 
additional rabbits were vaccinated either 4 or 3 times (New Zealand White (NZW) nos. 
1–6: 4 × 50 ug and nos. 7–10: 3 × 20 ug) and sera drawn 2 weeks after the last boost. 
Robust antibody responses to L2 (titers of 2,500– 12,500) were detected for both 
vaccination protocols using the 16L2 N-terminal peptide (aa 11–200) as ELISA antigen 
(Figure18). Conversely, reactivity was absent for rabbit antiserum to HPV16 wild-type 




Figure 18.  HPV16 L2 peptide ELISA 
7HQ1=:UDEELWVZHUHLPPXQL]HGZLWKHLWKHUȝJ5*-VLP, week 0, 4, 6 and 8 (n=6); 
RUȝJRI5*-VLP, week 0, 3, 6 (n=4) using Alum-MPL adjuvant. Antisera drawn two 
weeks after the last boost were serially diluted 5-fold and tested in triplicates by ELISA 
using bacterially expressed HPV16 L2-protein (aa 11-200) as antigen. End-point dilution 
revealed robust ELISA titers of 2,500-12,000 in all animals vaccinated with RG1-VLP, 
regardless of immunization scheme. In contrast, a serum from an HPV16 L1-VLP 





2) Antisera to RG1-VLP neutralize distantly related mucosal HPV types in vitro 
The spectrum of cross-neutralization induced by RG1-VLP vaccination was 
further explored by analyzing rabbit antisera (n = 10) in neutralization assays for a large 
panel of genus-a HPV using additional PsV types (Table 3). Similar to findings reported 
previously for rabbits 1/2 (*), the additional eight rabbits’ immune sera contained high-
titer neutralizing antibodies against HPV16 (titers of 10,000–100,000). Broad-spectrum 
cross-neutraOL]DWLRQZDVIRXQGIRUVSHFLHVĮ9 HPV31, 52, 58, 33, 35 (in 2, 5, 9, 6, and 9 
out of VHUDĮ7 HPV18, 45, 39, 59, Į+39
  Į11 HPV73 and 34 (10 and 8/10) (titers fURP WR  EXW QRW IRUĮ6 
HPV 56, 53, and 66. Cross-neutralization beyond mucosal HR types was analyzed for the 
most potent sera nos. 1/2 (TaEOH$SDUWIURP/5+39Į1 HPV32 (causing Heck’s 
disease) was neutralized (titHUVRIZKHUHDV+39Į10) sporadically found in 
genital warts was not neutralized. To narrow the gap between PsV-based in vitro assays 
and natural HPV infection, RG1-VLP-induced neutralizing antibodies were also detected 
using infectious native virions [190]. As shown in Figure 19A, HaCaT cells infected with 
HPV26 virions (lane 2) revealed a specific band corresponding to spliced viral mRNA in 
nested reverse transcriptase–PCR, in contrast to uninfected control cells (lane 1). 
Preincubation of virions with RG1-VLP antiserum (1:400) completely abolished mRNA 
detection, indicating viral neutralization (lane 4), whereas preimmune serum (lane 3), 
mAb RG1 [46] (lane 5), or serum from a Gardasil-vaccinated individual (lane 6) had no 
effect. RG1-VLP antiserum also cross-neutralized LR HPV40 (Figure 19b; lanes 5 and 6) 
and HPV6 virions (Figure 20) at dilutions of 1:100–400. Taken together, the in vitro 
cross-neutralization spectrum of RG1-VLP vaccination includes almost all HR HPVs 
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causing CxCas, as well as LR mucosal types in PsV and native virion–based assays. 
 
 
Table 3.  Cross-neutralization of mucosal HR HPV by RG1-VLP antisera in PBNA in 
vitro 
Abbreviations: alum-MPL, aluminum hydroxide plus 3-O-desacyl-4’-monophosphoryl 
lipid A; HPV, human papillomavirus; HR, high risk; NZW, New Zealand White; PBNA, 
pseudovirion-based neutralization assay; VLP, virus-like particle. Antisera of 10 NZW 
rabbits raised against RG1-VLP were analyzed for cross-neutralization of 20 mucosal HR 
HPV pseudovirions in duplicates using end point serial dilutions of 1:25–1:100,000. 
Neutralization titers were determined as described earlier [49]. Boxed titers indicate sera 






Table 4.  Cross-neutralization of mucosal LR and cutaneous HPV by RG1-VLP antisera 
in vitro 
Abbreviations: BPV1, bovine papillomavirus type 1; HPV, human papillomavirus; LR, 
low risk; VLP, virus-like particle. Antisera of two rabbits (nos. 1 and 2) raised against 
RG1-VLP were tested for cross-neutralization of 4 LR mucosal, 2 genus ȕFXWDQHRXV
common cutaneous HPVs, and nonhuman BPV1 as indicated. Neutralizing titers were 





Figure 19.  In vitro reverse transcriptase–PCR (RT–PCR) neutralization assays using 
native cutaneous and mucosal high-risk (HR) and low-risk (LR) human papillomavirus 
(HPV) virions. 
 HaCaT cells were incubated with native virions of (a) mucosal HR HPV26, (b) mucosal 
LR HPV40, and (c) cutaneous HPV2. Infection was detected by amplification of spliced 
viral mRNA. Cells were either mock treated (cells only) or infected with native virus ( þ ) 
in the absence of serum (no serum), or with virions preincubated with (pre)immune sera 
at indicated dilutions. Neither mAb RG1 nor a human antiserum from a Gardasil-




Figure 20.  In vitro RT-PCR neutralization assays using native mucosal lr HPV6, or 
cutaneous HPV27, HPV4, or HPV1 virions 
Type-specific neutralizing anti-L1 VLP antisera (HPV6, 27) or anti L1-L2 PsV antiserum 
(HPV4), were used as respective controls. Sera of 8 pre-pubertal girls (#1-#8) were used 








3) Antisera to RG1-VLP cross-neutralize prevalent common cutaneous and HR b HPVs 
In immunocompetent individuals with palmoplantar and plane warts, the most 
frequently detected typeV DUH JHQXV Į HPV >@ Ȗ +39 P +39 DQG Į
+39 *HQXV ȕ HPV5/8 have been first identified in patients suffering from 
Epidermodysplasia verruciformis, ZKHUHDV D SRVVLEOH UROH RI ȕ SDSLOORPDYLUXV LQ QRQ-
melanoma skin cancer pathogenesis is still controversial. Thus, rabbit antisera nos. 1/2 
were screened for cross-neutralization against available cutaneous HPVs in pseudovirion-
based neutralization assay (PBNA; Table 4), showing previously reported cross-
neutralization of HPV5 DQG DGGLWLRQDOO\ RI +39 Į DQG +39 ȕ4) (titers of 
 EXW QRW RI +39 Ȗ RU +39 ȕ2). Furthermore, antisera nos. 1 and 2 
cross-neutralized native virions of HPV2 with titers of 800 and 1,600 (Figure 19c, lanes 5 
and 11), and HPV27 at dilution 1:400 (Figure 20). Interestingly, antiserum to HPV2 L1-
VLP neutralized HPV27, as did antiserum to HPV27 L1-VLP (1:400), indicating that 
closely related genotypes HPV2 and HPV27 (Į4) may represent common serotypes 
(antisera to HPV2/27 L1-VLP were a kind gift from L Gissmann, DKFZ, Heidelberg, 
Germany). Neither HPV1 nor HPV4 virions (Figure 20) were cross-neutralized by RG1-
VLP antiserum. Sera of 7/8 prepubertal girls were neutralizing against highly prevalent 
cutaneous HPV1 (Figure 20), indicating robust seroconversion after natural infection, 
whereas serum from a Gardasil-vaccinated individual did not cross-neutralize cutaneous 
HPV4. Moreover, the cross-neutralization spectrum of RG1-VLP vaccine even extends to 




4) RG1-VLP vaccination induces cellular immune responses 
The enzyme-linked immunospot analysis of splenocytes from mice vaccinated with RG1-
VLP or similarly HPV16 L1-VLP showed IFN-Ȗ-producing cells when stimulated with a 
previously described HPV16 L1 cytotoxic T lymphocyte epitope (Figure 21), indicating 
the induction of a strong cellular immune response [194]. In contrast, stimulation of cells 










Figure 21.  INF-ȖELISPOT assay detecting cytotoxic T-cell responses to vaccination 
with RG1-VLP. )HPDOH&%/PLFH[ZHUHYDFFLQDWHGZLWKȝJRI+39/-
VLP, RG1-VLP, or PBS, respectively. Isolated splenocytes were stimulated with serum 
(1), scrambled peptide (2), SEA (3), HPV16 L1 peptide (aa 165-173) (4), HPV16 L2 
RG1 peptide (aa 17-36) (5), or HPV16 L1 plus RG1 peptides combined (6). Spots 
representing IFN-Ȗ SURGXFLQJ FHOOV ZHUH FRXQWHG DQG UHVXOWV Hxpressed as mean 
number/10
6 




5) RG1-VLP antisera efficiently protect mice against experimental vaginal challenge with 
mucosal HPV in vivo 
Given the broad spectrum of HR HPVs cross-neutralized in vitro, vaccine efficacy 
in vivo was determined using an experimental mouse model [61]. As expected, passive 
transfer of RG1-VLP antiserum reduced vaginal infection in mice challenged with 
HPV16 PsV to background levels, similar to HPV16 L1 VLP antiserum (Figure 22a). 
Importantly, mice were also cross-protected from infection with phylogenetically 
diverJHQW W\SHV +39  Į +39 Į +39 Į
+39 Į DQG+39 Į DQG/5+39 ĮDQG+39 Į8) (Figure 
22b and c). Indicative, yet statistically unsignificant, results were obtained for LR HPV44 
Į10). The level of cross-protection by RG1-VLP antiserum was indistinguishable from 
that induced by type-specific antisera to the homologous L1-VLP, respectively, except 
for HPV53/ 43/44, for which protection was recognizably lower. In contrast, HPV16 L1-
VLP antiserum showed predominantly type-restricted protection against homologous 
HPV16, with significant cross-protection against very closely related HPV31/33/35 and 
to a smaller extent against more divergent HPV56/59/6. Detectable in vitro cross-
neutralization titHUV25) were always accompanied by cross-protection in vivo (Tables 3 
and 4). However, RG1-VLP antisera also conferred complete (HPV56) or at least partial 
cross-protection (HPV53/66) in vivo (Figure 22a and b), for which types cross-
neutralization was not detected in vitro, suggesting low sensitivity of current assays. To 
further demonstrate vaccine efficacy irrespective of subtle cross-neutralization titers in 
vitro, antisera nos. 6/10 were selected for in vivo assays. Antisera nos. 6/10 demonstrated 
a narrow cross-neutralization spectrum in vitro for only 6/19 or 3/19 mucosal HR types 
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(Table 3). Although neither of the two sera cross-neutralized HPV31/45 in vitro, both 











Figure 22.  Cross-protection against vaginal challenge with mucosal high-risk (HR) and 
low-risk (LR) human papillomavirus (HPV) in vivo.  
(a–d) In vivo vaginal challenge with mucosal HPV in mice, passively transferred with 
RG1-VLP antiserum. Female Balb/c mice were injected intraperitoneally (i.p.) with 20 
ml of rabbit (A) preimmune serum; (B) RG1-VLP immune serum (serum no. 1) (a, b); 
serum no. 6, no. 10 (c); (C) HPV16 L1-VLP antiserum; or (D) L1 antiserum to the 
respective homologous type. Mice were challenged with pseudovirion (PsV) of (a) 
HPV16; (b) the next 11 most prevalent HR types HPV18, 45, 31, 33, 52, 58, 35, 39, 51, 
59, and 68, and less frequent (<1%) types in cervical cancer (CxCa) HPV56, 73, 26, 53, 
66, 34; LR HPV6, 43, and 44; or (c) high-risk HPV31 and 45. (d) An RG1-VLP rabbit 
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antiserum (no. 1) drawn at week 52 (10 months following the third boost with in vitro 
titer of <25 to HPV58) was analyzed for cross-protection against challenge with HPV58 
(B no. 1, week 52). Antisera to (d, C) HPV16 L1-VLP and (d, D) HPV58 L1/L2 PsV 
drawn 2 weeks after the third boost were used as controls. Luciferase activity in 
bioluminescence imaging (Y axis: average radiance; p/s/cm2/sr) is given with the 
respective background luminescence (unvaccinated mice challenged with 
carboxymethylcellulose (CMC) only) subtracted from all data points. P-values comparing 














5) Induction of long-lasting B-cell memory and cross-protection 
To examine long-term B-cell memory after RG1-VLP vaccination, rabbits 1/2 
were housed for a further 10 months after the fourth immunization and boosted at week 
52 with 50 ug of RG1-VLP (Figure 23). When compared with sera drawn at week 10, 
cross-neutralization titers had declined 1–2 logs (HPV18/31) or beneath the level of 
detection (HPV45/52/58/6/5) in week 52. A similar 2-log decline was observed for 
neutralizing antibodies against HPV16, which are predominantly induced by the L1 
scaffold of RG1-VLP. Importantly, boosting with RG1-VLP raised antibody titers to 
former levels or beyond. To determine whether cross-protection in vivo is also long 
lasting, antiserum drawn at week 52 was analyzed for cross-protection against in vivo 
challenge with HPV58. Although neutralization of HPV58 was no longer detectable in 
vitro at week 52, cross-protection was still conferred in vivo (Figure 22d), yet to a slightly 




Figure 23.  RG1-VLP induced cross-neutralizing antibody titers over time (12 months) 
Two NZW rabbits (#1 and #2) were kept for additional 10 months following the 4th 
immunization with RG1-VLP in Alum-MPL. Sera were drawn before and two weeks 
DIWHU D WK LQMHFWLRQ DW ZHHN ZLWK ȝJ RI DQWLJHQ SOXV $OXP-MPL, and tested by 
PBNA for indicated types. Serum titers are shown and compared to sera obtained at week 










The search for second-generation HPV vaccines is driven by the need to protect 
against the plurality of carcinogenic genital HPV by safe and affordable formulations. 
Because licensed vaccines do not target HR HPVs other than HPV16/18, causing 30% of 
CxCas, cytological screening programs cannot be superseded. This major limitation in 
particular affects developing countries, which bear >85% of the global CxCa burden. 
Moreover, precancerous cervical neoplasia with a substantial disease prevalence and 
morbidity in younger women is even more strongly associated with types other than 
HPV16/18 [195]. To extend protection to the most common oncogenic HPVs, a 
nonavalent L1-VLP vaccine (comprising seven HR and two LR types) is in clinical trials. 
Although such a highly multivalent L1 vaccine is expected to significantly increase the 
breadth of coverage, L2-based vaccines are attractive as single-antigen formulations 
targeting even more mucosal and, additionally, nongenital types. The spectrum of L2-
mediated cross-neutralization by chimeric RG1-VLP has been analyzed by a limited 
number of in vitro assays, whereas the vaccine’s efficacy to confer protection in 
mammals against infection with a broad range of HPVs has not been substantiated so far. 
In a very extensive comparison of HPV16 L1 VLP versus RG1-VLP (plus alum-MPL 
adjuvant) provided herein, RG1-VLP vaccination (cross-) protects with high efficacy in 
vivo against infection with 18 divergent HR types out of 4 different species (a5/7/9/11), 
which cause more than 95% of CxCas worldwide, and also partially protects against the 
remaining four types tested [179]. Mice were protected from vaginal challenge with large 
doses of mucosal PsV despite considerable antiserum dilution (B1:50) into the mouse 
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circulation. Interestingly, undetectable cross-neutralization in vitro did not stringently 
imply incomplete protection in vivo. In line with the recently reported insufficient 
sensitivity of current in vitro assays to detect anti-L2 antibodies, in vivo testing has 
become the gold standard in detecting neutralizing HPV antibodies [108] and 
documenting vaccine efficacy. The results imply that the actual immunogenicity is 
substantially greater than that reflected by the standard in vitro neutralization assay, and 
suggest that this vaccine should have a significant impact not only on reducing the risk of 
CxCa but also on the overall incidence of genital HPV infection, thus providing a major 
advantage to HPV-based screening programs when compared with the current vaccines. 
Complementary in vitro assays were used to more extensively characterize the spectrum 
of cross- neutralization by RG1-VLP vaccination, which was not predicted by L1-based 
classification of papillomaviruses, the site of infection, or host species. In PBNA, 
variable (cross)-neutralization by RG1-VLP antiserum was detected for 17 mucosal HR 
types, whereas cross-protection in vivo was intact for the serum with least potency in 
vitro. Although technically demanding and limited to those few types available from 
productive lesions, neutralization assays using native virions may reflect viral infection 
more authentically than PBNA [196]. Reassuringly, the RG1-VLP antisera neutralized 
lesion-derived virions as well. The RG1-VLP antisera also cross-neutralized LR types 
+39 Į+39 Į+39 Į DQG FXWDQHRXV+39 Į+39 Į
DQG+39ȕEXWQRW+39+39ȖDQG+39ȕ2QFRPSDULQJWKH5*
motifs of all types cross-neutralized, sequence homology to HPV16 RG1 was at least 
60%. Whether this lower threshold of homology necessary for inducing cross-
neutralization holds out in more sensitive in vivo assays needs to be demonstrated. 
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Therefore, RG1-VLP vaccination is expected to protect against a substantial proportion 
of benign papillomas, including both sexually transmitted genital and nongenital skin 
warts. The latter is not only of tremendous clinical importance for the growing group of 
immunocompromised patients (e.g., organ-transplant recipients, HIV patients), but may 
have expanded relevance if these types contribute to the genesis of nonmelanoma skin 
cancers. Because the incidence of common skin warts peaks in early childhood, this 
would provide a rationale for implementing the vaccine into existing childhood programs. 
Various approaches to enhance cross-neutralizing L2 antibodies have been presented over 
the past years, including conjugation of L2 peptides to a T-helper epitope and a Toll-like 
receptor 2 ligand [197], concatenated multimeric L2 peptide vaccination [48], or display 
on bacteriophage [198], adeno-associated virus [113], or HPV L1-VLP 
[49,173,188,189,199]. Favorably, RG1-VLP vaccination plus alum-MPL (as in Cervarix) 
not only elicits robust antibody responses against RG1 in ELISA but also retains high-
level protection against the most important HPV16. Therefore, RG1-VLP vaccination 
should provide strong protection not just against CxCas but also against the even higher 
percentage of noncervical cancers attributable to HPV16. In contrast, in a comprehensive 
direct comparison, HPV16 L1-VLP vaccination protected against HPV16 and 31 and 
only to a lower extent against 35, 39, 56, and 6. Licensed vaccines provide long-term 
protection of at least 8.5 years, and the antibody levels required are still unknown. 
Importantly, sera drawn 12 months after RG1-VLP vaccination completely protected 
mice against vaginal challenge with HR HPV58 in vivo. RG1-VLP holds promise as 
next-generation vaccine with broad efficacy against the vast majority of relevant mucosal 
and additional cutaneous HPVs, provides a rationale for childhood vaccination, and adds 
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economic advantage of a single antigen formulation compared with multivalent L1-VLP 
formulations. As post-licensure data confirm excellent safety profiles for HPV L1-VLP 
vaccines, we infer that RG1-VLP vaccination may prove similarly safe, offering the 

























The efficacy of vaccination with HPV L1 virus-like particles (VLP) for the 
prevention of new infections provides an opportunity to reduce the incidence of HPV-
associated cancers globally if these vaccines can be widely utilized [2,8,10,75,159]. This 
opportunity is particularly dramatic for women who currently lack access to effective 
cytologic screening and intervention programs. Indeed, 85% of the global burden of 
disease occurs in such low income countries [3]. Unfortunately, the current cost of the 
licensed L1 VLP vaccines has proven a significant barrier to their sustained global 
implementation, and this has driven an effort to create a second generation of low cost 
HPV vaccines that require fewer doses to improve access for under-served populations 
[74]. The licensed HPV vaccines target only the two types most commonly found in 
cervical cancer, HPV16 and HPV18 that cause 70% of cases, but there are a dozen other 
types responsible for remaining, 30% of cervical cancer cases [54]. The L1 VLP vaccines 
provide type-restricted protection and, while a variable degree of cross-protection against 
highly related types has been described, there is concern that it is incomplete and may 
wane [11,75]. This has triggered an ongoing clinical effort to develop a nonavalent L1 
VLP vaccine, but its potential to further increase the cost of vaccination against HPV has 
encouraged the development of alternate vaccines based on the more cross-protective 
capsid antigen L2 [74].  
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L2 can be produced at high levels in bacteria and numerous studies demonstrate it 
is a protective antigen although it does not form a VLP [170,187,200,201]. Vaccination 
of rabbits with the N-terminus (residues 94–122, 11–200 or 1–88) of L2 prevents 
papilloma development after experimental challenge with virions but not viral DNA, 
suggesting that protection is mediated by neutralizing antibodies [170,202]. Indeed, 
neutralizing antibodies binding to linear epitopes in HPV16 L2 17–36, 65–81 and 108–
120 have been described [46,111,167]. The development of HPV pseudovirion (PsV) 
technology in which a reporter gene is encapsidated within the papillomavirus L1 and L2 
capsid has greatly facilitated the measurement of neutralizing antibodies, and recently has 
been utilized in a mouse challenge model [61,203]. Passive transfer of the HPV16 L2 17–
36 specific neutralizing antibody RG-SURWHFWHGQDࡇÕYHPLFH IURPFXWDQHRXVFKDOOHQJH
with HPV16 PsVs suggesting that L2-specific neutralizing IgG is sufficient to mediate 
protection [46]. 
Antisera to the N-terminus of L2 broadly cross-neutralizes HPV, although it is 
most effective against the virus type from which the vaccine was derived, and the titers 
induced are significantly lower than those produced by L1 VLP vaccines [44,45]. The 
induction of sustained neutralizing antibody titers for durable/lifetime protection is a 
critical goal and might offer an opportunity to move from an adolescent to childhood 
vaccination schedule to further improve vaccine access. To potentially enhance the level, 
durability and breadth of cross-protection by reinforcing the most conserved epitopes, we 
designed concatenated fusion proteins consisting of the N-terminal protective region of 
L2 derived from multiple medically significant HPV genotypes [48]. This study 
suggested that a pentameric fusion of L2 residues of 11–88 from divergent HPV types 
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could induce a robust humoral response, but another study suggested that inclusion of 
more repeats might be beneficial [204]. Herein we define HPV16 L2 residues 17–36, 32–
51 and 65–81 as protective epitopes, and show an unexpected enhancement of the 






















b) Materials and methods 
 
1) Ethics Statement 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All animal studies were performed with the prior approval of the Animal Care and Use 
Committee of Johns Hopkins University (protocol MO08M19). 
 
2) Antigen preparation 
The L2 multimer constructs 11–88×8, 13–47×15, 11–88×8ǻ DQG –
88×8ǻPADRE were codon optimized for expression in E. coli by lowest free energy 
calculation and synthesized by Blue Heron Inc. The 11–88×8 family constructs were 
cloned with BamHI sites at their N-terminus and XhoI sites at their C terminus into the 
pET28a vector (Novagen), whereas NheI and XhoI were used for 13–47×15. The N-
terminal hexahistidine-tagged recombinant polypeptides were expressed in E. coli BL21 
(Rosetta cells, Novagen) [45]. The recombinant L2 polypeptides were affinity purified by 
binding to a nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen) in 8 M urea (using the 
QiaExpressionist standard purification protocol for denaturing conditions) and then 
dialyzed in cassettes (Pierce) against Dulbecco’s phosphate buffered saline (PBS). Purity 
was monitored by SDS-PAGE and protein concentration determined by bicinchoninic 
acid test (Pierce) using a bovine serum albumen standard. L2 peptides were synthesized 
with a C-terminal cysteine to >90% purity, sequence validated by mass spectrometry and 
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10 mg conjugated with 5 mg keyhole limpet hemocyanin (KLH) protein carrier using 
maleimide (Proteintech) to enhance their immunogenicity [24]. 
Two rabbits were immunized with each KLH-coupled peptide in Freund’s 
adjuvant and boosted on days 14, 28, 35 and 76 using incomplete Freund’s adjuvant and 
exsanguinated at day 56 (Proteintech). 
 
3) Neutralization assays 
The HPV pseudovirion in vitro neutralization assays were performed as described 
earlier and the secreted alkaline phosphatase content in the clarified supernatant was 
determined using the p-Nitrophenyl phosphate tablets (Sigma, St. Louis, MO) dissolved 
in diethanolamine and absorbance measured at 405 nm. Constructs and detailed protocols 
for the preparation of the pseudovirions can be found at http://home.ccr.cancer.gov/lco/. 
Titers were defined as the reciprocal of the highest dilution that caused a 50% reduction 
in A405, and a titer <50 was not considered significant. 
 
4) Animal Studies 
Female Balb/c mice, 4–6 weeks age (NCI Frederick) were vaccinated in groups of 
5 animals three times at two week intervals s.c with 25 ug of antigen (11–88×8, 13–
47×15, 11–88×8ǻ –88×8ǻPADRE) either with Alum alone, or Alum+MPL, 
Alum+CpG 1018 (Dynavax Inc.) or GPI-0100 (Hawaii Biotech Inc.). Serum samples 
144 
 
were obtained by tail vein bleeds two weeks and four months after the final 
immunization. 
 
5) Passive transfer of mice and vaginal challenge with HPV pseudovirus 
Five days before the challenge, female Balb/c mice were injected s.c. with 3 mg 
of medroxyprogesterone (Depo-Provera; Pfizer) to synchronize their estrus cycles. For 
those mice receiving the passively transferred rabbit antiserum, 100 ul of serum was 
administered intraperitoneally 24 hours prior to infection. Each challenge dose comprised 
of 20 ul PsV mixed with 20 ul of 3% carboxymethyl cellulose (CMC). The dose was 
delivered twice into vaginal vault, the first 20 ul just prior to and the second 20 ul just 
after treatment with a cytobrush cell collector. The cytobrush cell collector was inserted 
into the vaginal vault and turned both counter-clockwise and clockwise 15 times while 
the mice were anesthetized. Three days after PsV delivery, the mice were again 
anesthetized and 20 ul of luciferin (7.8 mg/ml) was deposited in the vaginal vault. 
Luciferase signals were acquired for 10 min with a Xenogen IVIS 100 imager, and 
analysis was performed with Living Image 2.5 software. 
 
6) Statistical analysis 
One-way ANOVA and Bonferroni’s multiple comparison tests were performed 





1) Passive transfer with L2 peptide anti-sera protects mice from vaginal HPV16 challenge 
To define protective epitopes within the amino terminus of L2, rabbits were 
vaccinated with KLH-coupled synthetic HPV16 L2 peptides comprising residues 17–36, 
32–51, 47–66, 65–81, 108–120 or as a negative control C-terminal peptide 373–392, each 
formulated initially in CFA and boosted in IFA. The pre- and hyper-immune antisera 
were each tested for reactivity with full length HPV16 L2 protein by ELISA. None of the 
pre-immune sera were reactive whereas the immune sera to HPV16 L2 17–36, 32–51, 
47–66, 65–81, 108–120, and 373–392 exhibited ELISA titers of 6400, 400, 100, 800, 
800, and 6400 respectively. Passive transfer of 0.1 ml/mouse rabbit anti-sera generated 
against HPV16 L2 residues 17–36, 32–51 and 65–SURWHFWHGQDࡇÕYH%DOEFPLFHQ 
against intra-vaginal challenge with HPV16 PsV one day later (p<0.01, p<0.05 and 
p<0.05 respectively, Figure 24). Conversely, passive transfer of 0.1 ml/mouse of antisera 
to HPV16 L2 residues 47–66 (n=10), 108–120 (n=5) or 373–392 (n=5) was not 
significantly protective. A second rabbit immunized with the HPV16 L2 47–66 peptide 
did not produce a detectable titer in the HPV16 L2 protein ELISA and also was not 
protective (not shown), suggesting that this peptide is either poorly immunogenic and/or 
was not presented in the appropriate context for immunization. Passive transfer of rabbit 






Figure 24.  Passive transfer of HPV16 L2 peptide antisera protects mice against vaginal 
challenge with HPV16.  
Mice were injected i.p. with 0.1 ml buffer or rabbit antiserum to KLH-coupled HPV16 
L2 peptides encompassing residues 17–36, residues 32–51, residues 47–66, residues 65–
81, 108–120, residues 373–392, or antiserum to HPV16 L1 VLP. One day later the mice 









2) Antibody responses to different adjuvant formulations of 11–88×8 and 13–47×15 
Recent studies have shown that vaccination with polymeric fusions of L2, each 
unit being derived from a different HPV type, produces a more broadly neutralizing 
response than the monomer, and that increasing the numbers of the fusion epitopes can 
enhance immunogenicity [48,204]. To potentially enhance cross-protection by 
reinforcing the responses to conserved neutralizing epitopes within the medically 
significant Į7, Į9 and Į10 clades [12], we generated two multitype L2 fusion proteins, 
11–88×8 and 13–47×15, by recombinant expression in E. coli [48]. The first, 11–88×8, 
comprised L2 residues, 11–88 of HPV6, HPV16, HPV18, HPV31, HPV39, HPV51, 
HPV56 and HPV73 L2 concatenated to form the ‘11–88×8’ antigen, and the second, 13–
45×15, comprised L2 residues, 13–47 of the fifteen HPV types (HPV6, HPV11, HPV 16, 
HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, 
HPV59, HPV73) that encompass the two most common types in genital warts and the 
thirteen most common oncogenic HPV types. Both proteins were expressed in bacteria 
and affinity purified under denaturing conditions utilizing an N-terminal 6His tag. The 
expression level of 13–45×15 was noticeably higher than 11– 88×8. 
In order to compare the immunogenicity of the 11–88×8 and 13–45×15 antigens, 
mice were immunized three times at two week intervals with either 13–47×15 or 11–
88×8 protein, alone or formulated with alum alone, alum+MPL, alum+CpG 1018, or the 
saponin-based adjuvant GPI-0100. Both the 11–88×8 and 13– 45×15 polypeptides were 
immunogenic and induced antibodies that neutralize key papillomavirus types, including 
HPV16, HPV18, HPV45 and HPV58 (Figure 25). However, the 13– 47×15 protein was 
not as immunogenic as 11–88×8, regardless of the adjuvant used. Amongst the adjuvants 
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tested, GPI-0100 was the most effective, producing titers a log higher than alum and 
either MPL or CpG. The HPV16 neutralization titers at 3 months post vaccination were 
robust and similar to those measured at 2 weeks post immunization for 11–88×8, 







Figure 25.  HPV in vitro neutralization titers of sera of mice vaccinated with 13–47×15 
and 11–88×8 in different adjuvants.  
Balb/c mice were vaccinated three times at 2 week intervals with the indicated 13–47×15 
and 11–88×8 proteins formulated in alum, alum+MPL, alum+CpG or GPI-0100. Sera 
were harvested two weeks later for testing in vitro neutralization titers against HPV16 
(A), HPV18 (B), HPV45 (C) and HPV58 (D) pseudovirions, or HPV16 at 3 months after 



















3) Elimination of residues 45–67 compromises 11–88×8 immunogenicity 
These findings suggested that residues 45–88 contribute significantly to the 
immunogenicity of the construct, consistent with the protective epitope described 
between residues 65–81 (Figure 24). However, residues 47–66 do not appear to be 
immunogenic and antisera to this peptide were not significantly protective (Figure 24), 
suggesting that it might be dispensable from the vaccine construct. Furthermore, while 
the 13–47×15 protein was highly expressed, the 11–88×8 protein was produced at a 
significantly lower level (data not shown) possibly reflecting the hydrophobicity of L2 
between residues 45–67 (IL- QYGSMGVFFGGLGIGTGSGTG). In an effort to focus the 
antibody response on the key protective epitopes by removing potentially competing non-
protective regions, we designed 11– îǻ by removing this region from each unit of the 
11–88×8 protein. The expression level of 11–îǻ was dramatically higher than 11–
88×8 and, unlike the 13–45×15, it still contains the neutralizing epitopes residing with 
residues 65–81. 
While CD4 T cell epitopes are found within E2, E6, E7 and L1 and at this point it 
is unknown where within the L2 capsid protein a potential epitope would be located, if 
any, we postulated the existence of a key T helper epitope might possibly overlap or lie 
within the 45–67 region as a reason for the greater immunogenicity of the 11–88×8 as 
compared with the 11–îǻ polypeptide. Interestingly, an in silico analysis of the 11–
ǻ8 sequence using ProPred predicts that the 45–67 region contains promiscuous MHC 
class II epitopes [206-208]. Thus, in removing this 45–67 region from each unit of 11–
ǻ8, we were concerned that this would also eliminate potentially important epitopes 
recognized by CD4 T helper cells. Therefore, we generated another construct in which 
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the potent and conserved CD4 T helper epitope PADRE (AKFVAAWTLKAAA) was 
fused to the 11–îǻSURWHLQ IRUPLQJ µ–88×8ǻPADRE’. The PADRE epitope was 
chosen because it is recognized in C57BL/6 mice, but not Balb/c mice, and it is broadly 
recognized by human HLA-DR [209,210]. Both the 11–îǻ protein and the 11–
îǻPADRE proteins were expressed in E. coli at noticeably higher levels than 11–
88×8. 
To determine the impact of deleting the 45–67 region upon the immunogenicity of 
11–88×8, immunization studies were performed in Balb/c and C57BL/6 mice with 11–
88×8, 11–88×8ǻRU–îǻ3$DRE using alum+MPL as an adjuvant. The mice were 
immunized three times at two week intervals and sera were obtained two weeks after the 
final immunization. Neutralization assays for HPV16, HPV45, and HPV58 indicated that 
the titers were consistently lower in the 11–îǻ DQG –îǻPADRE immunized 
mice as compared to those vaccinated with 11–88×8. This phenomenon was observed in 
both strains of mice (Figure 3) while the PADRE epitope is only recognized by the 
C57BL/6 mice. This suggests that the reduction in immunogenicity does not reflect a loss 
of a key T helper epitope upon elimination of the 45– 67 region in each subunit of 11–
88×8. Nevertheless, all three immunogens were able to protect both strains of mice from 







Figure 26.  HPV in vitro neutralization titers of sera of Balb/c and C57BL/6 mice 
vaccinated with 11–88×8, 11–îǻ DQG – îǻ3$'5( XVLQJ $OXP03/ DV
adjuvant.  
Balb/c or C57BL/6 mice were vaccinated three times at 2 week intervals with 11–88×8, 
11– îǻRU–îǻ3$'5(–îǻ3XVLQJ$OXP03/DVDGMXYDQW6HUDZHUH
harvested two weeks later and tested for in vitro neutralization titers against HPV16 (A), 











Figure 27.  Vaginal Challenge of Balb/c and C57BL/6 mice vaccinated with 11–88×8, 
11–îǻDQG–îǻ3$'5(–îǻ3) in Alum+MPL.  
Balb/c or C57BL/6 mice were vaccinated three times at 2 week intervals with the 
indicated 11–88×8, 11–îǻ DQG –îǻ3$'5( XVLQJ $OXP03/ DV DGMXYDQW
The mice were vaginally challenged one month later using HPV16 pseudovirions 











4) Antibody to residues 45–67 is not required for protection by 11–88×8 antiserum 
To determine if antibody to residues 45–67 plays a role in the protective response 
elicited by vaccination with 11–88×8, we first sought to confirm that pooled mouse 
antisera to 11–88×8 does contain antibody specific to the 43–67 region. Using ELISA, 
we observed that vaccination with 11–88×8 does induce antibody reactive with 43–67 
peptide at 1:100 dilution, whereas the 11– îǻ antigen does not (as expected since this 
epitope is deleted from this construct) as it exhibits background reactivity (Figure 28A). 
Next, we sought to define which epitopes are critical by blocking neutralization of 
HPV16 pseudovirus by 11–88×8 antisera with overlapping peptides (20mer) that together 
span the entire HPV16 L2 13–90 region. We observe that only mixing of the 11–88×8 
antisera with excess of the first two peptides, corresponding to residues 13–32 and 18–37, 
block the neutralizing response, whereas peptide 23–42 and peptides thereafter had 
minimal impact on in vitro neutralization. This again supports the central role of the 17–
36 region in neutralization and protection. To further rule out a role for the 47–66 region 
in protection, we mixed the 11–88×8 antiserum with excess peptides encompassing the 
47–66 region and compared its protective capacity against HPV16 challenge. Thus 20 ul, 
5 ul or 2 ul of 11–88×8 mouse antiserum was mixed with excess 47–66 peptide, or not, 
and then administered i.p to na ࡇÕYHPLFHPLFHJURXSSULRUWRFKDOOHQJH$VFRQWUROV
additional groups of mice received 200 ug of antibody purified from the rabbit antisera to 
HPV16 L2 17–36, 47–66 or 373–392 (approximately 20-fold higher doses than utilized 
in Figure 24). The pre-incubation of the 47–66 peptide with the 11– 88×8 mouse 
antiserum had no significant impact upon its protective capacity in this model, further 
supporting the notion that antibodies to 47–66 are not effecting protection after 
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vaccination of mice with 11–88×8. Furthermore, the antibody to 17–36 but not that to 








Figure 28.  Peptide blockade of 11–88×8 antiserum.  
A. Sera of Balb/c mice immunized three times with 11–88×8 or 11–îǻ XVLQJ
Alum+MPL as adjuvant were harvested two weeks after the final boost. The antisera 
diluted 1:100 were reacted with microtiter plates coated with 1 mg of two HPV16 L2 
peptides encompassing residues 43–62 and 48–67. After washing, specific reactivity was 
measured by ELISA using peroxidase-linked anti-mouse IgG. B. Pooled sera of Balb/c 
mice immunized three times with 11–88×8 using Alum+MPL as adjuvant were harvested 
either pre-immunization (Pre-bleed) or two weeks after the final boost (68 Sera). The 
antiserum to 11–88×8 was diluted 1:50 in a total volume of 200 ml and incubated with 7 
mg of HPV16 L2 peptide encompassing residues 13–32, 18–37, 23–42, 28–47, 33–52, 
38–57, 43– 62, 48–67, 53–72, 58–77, 63–82 or 71–90 for an hour prior to mixing with 
HPV16 pseudovirions carrying a SEAP reporter for a further hour at ambient temperature 
and subsequent infection of 293TT cells. Infection was measured as optical density, and 
only HPV16 L2 pepitdes 13–32 and 18–37 substantially blocked neutralization by 1:3200 
dilution of antiserum to 11–88×8. C. Sera of Balb/c mice immunized three times with 
11–88×8 using Alum+MPL as adjuvant were harvested two weeks after the final boost 
and pooled (68). The 11–88×8 antiserum was mixed with two HPV16 L2 peptides 
encompassing residues 43–62 and 48–67 (+Peptide) in the same ratios as in B. The 11–
88×8 antiserum was administered i.p. either alone or pre-mixed with peptide in volumes 
RIPOPORUPOWRQDࡇÕYHPLFHLQJURXSVRI6HSDUDWHJURXSVRIPLFHUHFHLYHd 
200 mg each of antibody affinity purified with protein G columns from the sera of rabbits 
hyper-immunized with HPV16 L2 peptides 17–36, 47–66 or 373–392. All groups of mice 
(except the Background group) were subsequently challenged intra-vaginally with 
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HPV16 pseudovirions carrying a luciferase reporter. Infection was assessed by measuring 




















Vaccination studies in several challenge models indicate that the amino terminus 
of L2 has potential as a protective antigen [10]. There are ongoing efforts to map 
potentially protective epitopes by the generation of antisera to synthetic L2 peptides or 
the generation of monoclonal antibodies and testing of their in vitro neutralizing activity 
[45,46,111,167,211,212]. We extend these studies by showing that passive transfer of 
antisera to HPV16 L2 residues 17–36, 32–51, and 65–81 is protective, whereas an 
antiserum to HPV16 L2 108–120 was not protective. These findings are generally 
consistent with prior in vitro neutralization studies, with the exception of the antiserum to 
HPV16 L2 108–120 [212-214]. However, we note that Rubio et al showed that both 
neutralizing and non-neutralizing antibodies can bind to the HPV16 L2 18–38 epitope, 
and thus it is possible that the HPV16 L2 108–120 peptide coupled to KLH utilized here 
for immunization induced only non-neutralizing antibodies despite containing a 
neutralizing epitope. Alternatively, the avidity of the neutralizing antibodies induced in 
the rabbit antiserum to HPV16 L2 108–120 peptide coupled to KLH was insufficient to 
afford protection in vivo at the dilution used (100 ul of serum in ,2 ml plasma volume of a 
mouse suggests ,1:20). We favor the latter possibility since we previously showed that 
this antiserum to HPV16 L2 108–120 peptide at 1:50 can partially neutralize native 
HPV11 virions [188]. 
Vaccination with the 11–88×8 protein induced a robust and broadly neutralizing 
antibody response (11–88×8 antiserum neutralizes eleven HPV genotypes, Kwak K et al, 
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International Papillomavirus Meeting, Montreal, Canada, July 2010, Abstract P-201, 
http://hpv2010.org/main/images/stories/hpv2010_abstracts. pdf) and protected mice from 
vaginal challenge with HPV16. Surprisingly, the 13–47×15 was significantly less 
immunogenic than 11–88×8, and this likely reflects in part the absence of the second 
neutralizing epitope within residues 65–81. Similarly, we previously observed that 17–
36×22 was less immunogenic than 11–88×5 or 11–200×3 [48]. However, 11–îǻ
(from which the 45–67 equivalent region has been eliminated from each unit of L2) was 
also less immunogenic than 11–88×8. Since passive transfer of mice with rabbit HPV16 
L2 47–66 antiserum was not significantly protective against HPV16 challenge and the 
peptide was poorly immunogenic, this implies that 11–îǻ LV QRW OHVV LPPXQRJHQLF
than 11–88×8 because a potent protective epitope within the 45–67 region was deleted. 
However, a recent study defined the epitope for a neutralizing monoclonal antibody 
(Mab24B) between residues 58– 64 [215]. Since the Mab24B antibody was generated in 
Balb/c mice, and our failure to detect neutralizing activity in the L2 47–66 peptide 
antiserum likely reflects its low immunogenicity in rabbits. Nevertheless, when we 
performed blockade studies by mixing individual overlapping 20mer peptides 
encompassing the N-terminus of HPV16 L2 with the mouse antiserum to 11–88×8, only 
peptides encompassing residues 13–32 and 18–37 impacted the neutralizing activity, 
suggesting the protective response is focused on this region in mice. 
An in silico analysis using ProPred suggested that the reduction of 
immunogenicity by elimination of the 45–67 region in each unit of L2 within 11–88×8 
might reflect the loss of CD4 T helper epitope(s). The C57BL/6 mouse strain is known to 
generate strong helper T cell response to PADRE, whereas Balb/c mice do not. Therefore 
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a PADRE epitope was included in the 11– îǻ3$'5(SURWHLQWRGHWHUPLQHLILWFRXOG
complement the loss of T helper epitope(s) in the 45–67 region and restore the 
immunogicity to that of 11–88×8 in C57BL/6 mice [30]. Since the 11–îǻ3$'5(
and 11–îǻ ZHUH ERWK VLPilarly less immunogenic than the 11–88×8 in either 
C57BL/6 or Balb/c mice, this suggests that loss of critical T help is not responsible for 
their lower immunogenicity than 11–88×8. 
Although we note that the L2 multimers are purified under denaturing conditions 
and evidence to date suggests that the L2 neutralizing epitopes are linear, another 
possibility is that the 45–67 region within each unit of L2 contributes to the immunoge- 
nicity of 11–88×8 by maintaining the appropriate spacing, structure or conformation of 
L2 neutralizing epitopes. Thus, while the immunogens are initially purified under 
denaturing conditions in urea, we speculate that the 45–67 region may facilitate the 
folding or association of the L2 multimers under more physiologic conditions (as the urea 
is removed during dialysis) into a structure that better presents the neutralizing epitopes 
to the immune system. Indeed, recent work by Bronnimann et al suggests a structural role 
for the GxxxG motifs in this 45–67 region [216]. 
The observations herein support the use of the, 11–88 region of L2 as an 
appropriate subunit of a multimeric L2 vaccine, but do not fully address the optimal 
number of subunits to include within the construct. Prior studies by Rubio with repeated 
units of HPV16 L2 epitopes and our own work with repeated L2 units derived from 
different HPV types, suggest that more than 3 subunits is optimal, and that there is little 
difference between 5–9 subunits and that greater numbers of repeats are not necessary, 
and possibly detrimental [48,204]. Indeed, the 13–45×15 was less immunogenic than 11–
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îǻ EXW LW LV QRW FOHDU ZKHWKHU LW UHIOHFWV WRR PDQ\ VXEXQLWV SHUKDSV WRR FORVHO\
spaced (17–36×22 was also poorly immunogenic), or the loss of a key neutralization 
epitope between residues 65–81 [111]. An alternative approach to enhance 
immunogenicity is to display these protective L2 epitopes on the surface of virus-like 
particles in immunodominant locations [16,217]. While this complicates the use of 
sequences derived from multiple HPV types to enhance the breadth of cross-protective 
responses, virus display may enhance the strength and duration of the immune response 



















Persistent infection with oncogenic types of human papilloma-virus (HPV) is the 
cause of 5% of cancers worldwide [3]. Therefore, these HPV-associated cancers are 
potentially prevent- able through global implementation of a vaccine that provides 
durable protection against infection by all oncogenic HPVs [54], of which at least a 
dozen types have been identified from within the ĮĮĮĮDQGĮSDSLOORPDYLUXV
species [12]. The licensed HPV vaccines, Cervarix (GSK) and Gardasil (Merck), provide 
protection over at least a decade against the two most common oncogenic HPV types in 
cancer, HPV16 and HPV18, but their efficacy against other oncogenic types is variable 
and of less-certain duration [11,75], and no therapeutic benefit has been demonstrated for 
preexisting infection [218]. Gardasil also targets HPV6 and HPV11 to protect against 
genital warts that, while benign, are associated with significant morbidity and treatment 
costs [159]. The efficacious but type-restricted protection provided by these L1 virus-like 
particle (VLP) vaccines has driven ongoing development of a nonavalent formulation 
(NCT00543543). While this nonavalent vaccine has potential to provide broad protection 
against oncogenic HPV infections, the complexity of its manufacture is likely to further 
drive up costs. Unfortunately, cost remains the principal impediment to broad 
implementation of HPV vaccines, particularly in developing countries which also lack the 
166 
 
resources for an effective national cytologic screening infrastructure and thus bear ~85% 
of cervical cancer cases globally [74]. 
The twin requirements for inexpensive and broadly protective HPV vaccines have 
propelled interest in the minor capsid protein, L2. Vaccination with the amino terminus 
of L2 produced in bacteria protects animals from experimental challenge with either 
animal papillomaviruses or HPV pseudovirions that carry a reporter plasmid 
[46,110,170,187,197]. Passive transfer of either L1 VLP antiserum or L2-specific 
neutralizing antibody is sufficient to protect naive animals from experimental viral 
challenge [21,22,26,46], whereas vaccination with L2 failed to impact existing disease or 
protect against challenge with viral DNA [170,219]. While L1 VLP vaccination induces 
antibodies against conformation-dependent, type-restricted neutralizing epitopes [6,7], 
L2-specific antibodies recognize linear epitopes and can be broadly neutralizing 
[44,45,112]. L1 vaccines are produced in insect cells or Schizosaccharomyces cerevisiae 
yeasts that allow VLP assembly [8,220], whereas L2 can be expressed at high levels in 
bacteria, potentially reducing the cost of manufacture [110,187]. 
Vaccination with L2 induces more broadly neutralizing but lower titer antibodies 
than L1 VLP. Furthermore, L2-induced neutralizing antibody titers are generally higher 
against papillomaviruses most closely related to the type(s) from which the L2 vaccine 
was derived [44]. Therefore, to broaden and enhance the antibody response against 
conserved neutralizing epitopes, we developed polypeptide vaccines comprising 
concatenated protective regions of L2 derived from multiple medically significant HPV 




competition between the subunits with respect to the generation of protective immunity, 
if the lower neutralization titers generally seen with L2 vaccine formulated in alum 
adjuvant are sufficient to render protection against diverse HPV types, whether it is 
necessary to include an L2 unit derived from each phylogenetic clade to achieve broad 
immunity against human papillomaviruses [12], and how the spectrum of L2-based 















b) Materials and Methods 
 
1) Ethics statement  
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All mouse studies were performed with the prior approval of the Animal Care and Use 
Committee of Johns Hopkins University, and rabbit studies were performed with the 
approval of the Animal Ethics committee of Shantha Biotechnics, Hyderabad, India. 
Research using neonatal foreskin keratinocytes was performed with the approval of the 
institutional review board of the University of Alabama, Birmingham. 
 
2) Generation and neutralization of HPV18 virions  
Primary human keratinocytes (PHKs) were recovered from neonatal foreskins 
[221] that were collected from UAB Hospital (Birmingham, AL). PHKs were cultured in 
serum-free medium (K-SFM; Invitrogen, Carlsbad, CA) used at passage one or two for 
the neutralization experiments. HPV18 virions were partially purified from organotypic 
cultures of PHKs containing HPV18 genomic plasmid, and titers were determined by 
using real-time quantitative PCR (qPCR) to measure packaged viral genomes [222]. For 
neutralization studies, 4 × 104 PHKs/well were seeded in 12-well plates and cultured for 
2 days. On day three, after the cell numbers were determined, PHKs were then infected 
with HPV18 virions at a multiplicity of infection (MOI) of 500. Prior to infection, the 
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virions were mixed with different dilutions (1:62,500, 1:12,500, 1:2,500, or 1:500) of 
polyclonal antisera described in Table 5 and raised to Į11-88×8 (animals 1a, 2a), Į11-
88×5 L2, Gardasil (animals 1d, 2d), and L1/L2 VLPs of HPV6, HPV11, HPV16, and 
HPV18 formulated in Freund’s adjuvant anti-L1L2 [13]. Similarly, HPV18 virions were 
mixed with undiluted or diluted (1: 1,250, 1:250, or 1:50) monoclonal antibody RG-1 or 
A-1 prior to addition to PHKs at an MOI of 500. In the nonneutralizing control, the 
virions were mixed with K-SFM prior to infecting PHKs. The cells were incubated for 24 
h at 37°C. The medium was changed, and PHKs were cultured for an additional 3 to 4 
days until 100% confluence. In parallel, uninfected PHKs were similarly cultured as a 
negative control. Total RNAs were extracted with TRIzol (Invitrogen) and treated with 
DNase (Applied Bio-systems, Carlsbad, CA). Five micrograms of total RNA was reverse 
transcribed (Promega, Madison, WI) in a 75 ul reaction mixture. Two microliters of the 
cDNA products was used for 20 cycles of PCR in a 35 ul reaction mixture to amplify the 
ȕ-actin cDNA fragment (642 bp) [223] or for 30 cycles for the spliced HPV18 E1Ê4 
cDNA fragment (211 bp) [223]. 
The primers for the HPV18 E1^E4 transcript are as follows: forward, 
GGTGTGCATCCCAGCAGTAAG (nucleotides [nt] 888 to 908); reverse, 
AGGTCCACAATGCTGCTTCT (nt 3583 to 3602). Fifteen microliters of PCR products 
was used for electrophoresis in 2% agarose gel. The gels were stained with ethidium 
bromide for imaging. 
 
3) Generation of HPV pseudoviruses 
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Pseudoviruses (PsV) were generated as previously described [82]. Briefly, 
plasmid double expression vectors for codon-optimized L1 and L2 genes were 
transfected with either a luciferase or alkaline phosphatase (SEAP) reporter gene plasmid 
into 293TT cells [82] using TransIT-2020 transfection reagent (Mirus). Three days after 
transfection, cell pellets were collected and rinsed with Dulbecco’s modified Eagle 
medium (DMEM) and Dulbecco’s phosphate-buffered saline (DPBS). The pellets were 
resuspended in a small volume of DPBS-Mg (DPBS supplemented with 9.5 mM MgCl2) 
and then transferred into siliconized tubes. Cells were pelleted by low-speed 
centrifugation, and the supernatant was discarded. For PsV maturation, an equal volume 
of lysis buffer (DPBS-Mg supplemented with 0.5% of Brij 58 and 0.2% benzonase) was 
added to the cell pellet, which was incubated at 37°C for 24 h. After maturation, lysates 
were adjusted to 850 mM NaCl and extracted with high-salt buffer (DPBS with 0.8 M 
NaCl). Lysates were clarified by centrifugation at 10,000 × g for 10 min, loaded onto an 
Optiprep step gradient (27, 33, and 39%), and spun at 40,000 rpm in an SW40 rotor for 
16 h at 16°C. After centrifugation, 0.5-ml fractions were collected from the top of the 
gradient. A sample representing each fraction was diluted and tested on 293TT cultures 
[82] for reporter gene expression. Fractions with the highest reporter gene expression 
were pooled and used for the serum neutralization assay and the in vivo challenge 
experiments. 
 
4) Preparation of vaccine antigen 
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We fused L2 sequences corresponding to residues ~11 to 88 of HPV16 L2 [48] of 
5 or 8 differenW Į +39 W\SHV DQG H[SUHVVHG HDFK / PXOWLPHU SURWHLQ LQ D EDFWHULDO
system facilitating inexpensive, robust, and reproducible production. Briefly, the 
multitype LQXFOHRWLGHVHTXHQFHRIĮ-88×8 was codon optimized for Escherichia coli 
expression by lowest free-energy calculation and synthesized at Blue Heron 
Biotechnology, Inc. (Bothell, WA), with 5ƍ = NcoI and 3ƍ = XhoI sites to facilitate 
cloning (detailed description in reference 79). The L2 gene was subcloned into the 
pET28a vector (Novagen, San Diego, CA) for expression in Escherichia coli BL21 
(Rosetta cells; Novagen). The L2 gene for Į-88×5 was PCR amplified using the above-
mentioned plasmid and similarly subcloned into the pET28a vector and transformed to 
BL21 Rosetta cells [79]. The manufacturing process for the production of bulk proteins 
was initiated with a batch fermentation of the recombinant bacteria. Protein expression 
was induced by adding 1 mM isopropyl-D-thiogalactopyranoside to the transformed 
bacterial cells. Following cell harvest, a primary recovery process was performed to 
purify inclusion bodies. Solubilized inclusion bodies were subjected to chromatographic 
separations, and the purified proteins were refolded in vitro. Both vaccine antigens were 
>90% pure when analyzed by SDS-PAGE. Protein estimation was done using absorbance 
at 280 nm, and 250 ug/ml protein was adsorbed onto 1 mg aluminum adjuvant before 
being placed in glass vials. Bulk proteins were tested for impurities arising from the host 
cell, including DNA and bacterial protein levels, and to confirm that bacterial endotoxin 
was <10 EU/ml using the Limulus amebocyte lysate assay. 
 
5) Immunization of mice 
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Inbred 4- to 6-week-old female BALB/c mice (NCI) in groups of 5 or 10 were 
immunized subcutaneously three times at 2-week intervals. The immunogens used were 
25 ug of Į-88×5 in alum or 11-88×8 in alum or one-tenth of the human dose of 
Cervarix or Gardasil. Alum alone and PBS were used as controls for the study. Mice 
were bled 2 weeks after final immunization. 
 
6) Measurement of HPV pseudovirion titers and neutralizing antibodies 
Serum samples collected from each mouse 2 weeks after the final immunization 
were serially diluted 2-fold in culture medium, mixed with an equal volume of HPV 
pseudovirions containing either luciferase or SEAP reporter genes, and incubated at 37°C 
for 2 h. These samples were each added to 293TT cell cultures (3 × 104 cells/well), 
which were then incubated for 72 h [82]. To measure luciferase expression after infection 
of cells with titrated challenge virus preparations, culture media were removed from each 
well and 1× cell culture lysis reagent (CCRL; Promega) was added to lyse the cell 
monolayer for 15 min at room temperature on a rocking platform. A volume of 20 ul of 
the lysate from each well was transferred to a black microtiter plate, followed by the 
addition of 50 ul/well of 1× luciferase substrate (Promega). The plates were scanned with 
the GloMax-Multi detection system (Promega). For SEAP measurement, 40 ul of cell-
free supernatant was collected from each well, mixed with 20 ul of 0.05% CHAPS {3-
[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, heated at 65°C for 30 
min, and then cooled on ice. A volume of 200 ul/well of p-nitrophenyl phosphate (pNPP) 
substrate (2 M diethanolamine with 1 mg/ml of pNPP) was added to each well for color 
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development at ambient temperature, and absorbance data were collected with an 
automatic enzyme-linked immunosorbent assay (ELISA) plate reader (Bio-Rad). Data 
were collected when the absorbance from the wells incubated with only PsV (ODpsv) 
had an optical density at 405 nm (OD405) of >1. The highest dilution of serum that 
resulted in 50% or more reduction in ODpsv was defined as the endpoint neutralization 
titer and expressed as its reciprocal value. 
 
7) Vaginal challenge of mice with HPV pseudovirions 
Four days before challenge, female BALB/c mice were injected subcutaneously 
with 3 mg of medroxyprogesterone (Depo-Provera; Pfizer) to synchronize their estrus 
cycles [61]. Each challenge dose was comprised of 20 ul PsV mixed with 20 ul of 3% 
carboxymethyl cellulose (CMC). The dose was delivered twice into the vaginal vault, 
with the first 20 ul injected just prior to treatment and the second 20 ul injected just after 
treatment with a cytobrush cell collector. The cytobrush cell collector was inserted into 
the vaginal vault and turned both counterclockwise and clockwise 15 times while the 
mice were anesthetized. Three days after PsV delivery, the mice were again anesthetized 
and 20 ul of luciferin (7.8 mg/ml) was deposited in the vaginal vault. Luciferase signals 
were acquired for 10 min with a Xenogen IVIS 100 imager, and analyses were performed 
with Living Image 2.5 software. Each mouse received only a single HPV challenge. 
 
8) Statistical analysis 
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Exploratory statistical analyses are performed to analyze the observed titer data. 
Log transformations were used to achieve normality in residuals for titer data. One-way 
analysis of variance (ANOVA) and pairwise multiple comparisons with the Bonferroni 























1) Design of L2 vaccines 
The licensed HPV vaccines and the nonavalent vaccine under development 
(NCT00543543) target exclusively the oncogenic HPV types within the Į9 and Į7 
species, selected from the most prevalent types found in cervical cancer [54]. 
Nevertheless, a significant fraction of cervical cancers are caused by Į5, Į6, and Į
papillomaviruses, suggesting the value of developing a more broadly targeted HPV 
vaccine based upon L2 multimers. To evaluate the importance of having at least one unit 
derived from each species upon the breadth of protection, we generated a single protein 
(termed Į-88×5) comprising five different units of L2 (amino acid residues ~11 to 88) 
derived from three papilloPDYLUXV VSHFLHV Į Į DQG Į )LJXUH  DQG D VHFRQG
SURWHLQWHUPHGĮ-îFRQWDLQLQJ/UHVLGXHVWRGHULYHGIURPVL[VSHFLHVĮ
ĮĮĮĮDQGĮ)LJXUH$5DWKHUWKDQVHOHFWLQJRQO\WKHPRVWFRPPRQ+39
types present in cervical cancer, the sequences included were intended to cover as much 
of the sequence diversity as possible within two key neutralization epitopes of L2 
residing between residues 17 to 36 and 65 to 81 (Figure 29B). The two multimeric L2 
fusion proteins were expressed without tags in E. coli and purified using conventional 







Figure 29.  Design of L2 vaccines.  
(A) Diagram showing the composition of Į-î DQG Į-88×5 candidate HPV L2 
vaccines with individual subunits derived from different medically significant genotypes 
and several papillomavirus species (color coded). (B) Comparison of sequences within 
the amino terminus of medically significant alpha papillomaviruses by Clustal W with 
color coding by a functional amino acid side chain. The location of the putative furin 
cleavage sites at the amino terminus of each is indicated. The bar shows the region 
utilized in the multimer vaccines, and the two filled regions show neutralizing epitopes 
defined by monoclonal antibodies specific for HPV16 L2, notably residues 17 to 36 by 
RG1 [46], residues 20 to 38 by K4L2 and K18L2, residues 28 to 42 by K8L2, and 
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residues 72 to 78 by K1L2 [167], and residues 69 to 81 by MAb6 [111]. (C) Coomassie-
stained SDS-3$*(JHORI WKHĮ-îODQHDQGĮ-88×8 (lane 2) antigens. MW, 

















2) Neutralizing and protective capacity of L2 multimer antisera 
Two rabbits each were primed with either 50 ug or 200 ug of Į-88×8 in 
complete Freund’s adjuvant (CFA) and boosted twice with the same dose in incomplete 
Freund’s adjuvant (IFA). The immune sera were tested for HPV16, HPV18, HPV31, 
HPV45, and HPV58 pseudovirion neutralizing titers (Table 5), and all were broadly 
QHXWUDOL]LQJ6LPLODUO\VHUXPRIDUDEELWLPPXQL]HGZLWKĮ-88×5 was able to broadly 
neutralize these types, whereas antisera from two rabbits vaccinated with Gardasil 
strongly neutralized HPV18 (which is targeted by the vaccine) and weakly neutralized 
HPV31 and HPV45 (the two types most closely related to HPV16 and HPV18 that are 
included in the vaccine), but no neutralizing activity against HPV58 was detected. 
3DVVLYH WUDQVIHU RI Į-88×8 antiserum completely protected naive mice from vaginal 
challenge with HPV16 and HPV58 pseudovirions (Figure 30A and B), whereas infection 
was robust in the presence of preimmune serum, confirming that the L2-specific 
neutralizing antibodies are sufficient to mediate protection of mice against vaginal 









Table 5.  In vitro neutralization titers of rabbit antisera to candidate HPV vaccines and 
Gardasila 
a Rabbits were vaccinated on days 1, 28, and 42 with the indicated dose of polymeric L2 
constructs in complete Freund’s adjuvant (CFA) with the initial dose and incomplete 
Freund’s adjuvant (IFA) thereafter as described previously [48]. Two additional rabbits 
ZHUHYDFFLQDWHGZLWKRUȝJRI*DUGDVLORQGD\VDQGDQGEORRGVDPSOHV
were collected 1 week after the final vaccination. Individual rabbit identifiers (Rb ID) are 
provided in the second column. Blood was allowed to congeal overnight, and the serum 
was separated by centrifugation and stored at ~20°C until testing for in vitro 
neutralization titers against HPV16, HPV18, HPV31, HPV45, and HPV58 pseudovirions 
(PsV) as described previously [48] or against organotypic raft-derived HPV18 (native) 





Figure 30.  Neutralizing and protective capacity of L2 multimer antisera.  
Passive transfer of rabbit Į11-88×8 antiserum, but not preimmune serum, protects mice 
from vaginal challenge with HPV16 (A) or HPV58 (B) pseudovirus. The dashed line 
indicates the background bioluminescence level without pseudovirion challenge. (C) In 
vitro HPV16 neutralization titers of 6 groups of 10 BALB/c mice that were immunized 
three times at 2-week intervals with PBS alone, alum alone, Į11-88×5 in alum, Į11-88×8 
in alum, or one-tenth of a human dose of either Gardasil or Cervarix for comparison. 
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3) Neutralization of raft-derived HPV18 by L2 and L1 VLP-specific antibodies 
It has been suggested that neutralization of organotypic raft culture-derived HPV 
virions differs from that of HPV pseudovirions [224]. Therefore, we wished to determine 
if Į-88×5 and Į-88×8 antisera were able to neutralize infection of primary human 
keratinocytes by HPV18 derived from organotypic raft culture. HPV18 virions were 
partially purified from organotypic raft cultures, incubated with dilutions of sera from 
vaccinated rabbits, monoclonal antibody RG-1, or an isotype-matched non-neutralizing 
L2-specific monoclonal antibody A1, and then used to infect primary human 
keratinocytes at an MOI of 500. Infection was determined by the detection of early 
spliced E1^E4 viral mRNA by reverse transcription-PCR (RT-PCR). The L2-specific 
neutralizing monoclonal antibody RG-1 reduced HPV18 infection (Figure 31A), whereas 
the isotype-matched control monoclonal antibody A1 had no effect (Figure 31B). Sera 
from rabbits vaccinated with HPV6, -11, -16, or -18 L1 VLP in alum (Gardasil) 
neutralized infection at a dilution of 2,500, and sera from a rabbit that was vaccinated 
with these VLPs in CFA/IFA neutralized HPV18 at a titer of 12,500 [13] (Figure 31B). 
Sera of two rabbits vaccinated ZLWKĮ-88×8 in CFA/IFA neutralized HPV18 at a titer of 
DQGVHUDRIDUDEELWLPPXQL]HGZLWKĮ-88×5 in CFA/IFA neutralized at 12,500 
(Figure 31A and Table 5). For comparison, neutralizing antibody titers of the same sera 
as determined using in vitro infection with HPV18 pseudovirions carrying a reporter 
construct are also shown in Table 5. The differences in titer likely reflect distinct 
methodologies and cell types used in these neutralization assays. 
For a direct comparison of the immunogenicities of Į-88×5, Į-88×8, and the 
licensed HPV vaccines using an adjuvant already licensed for human use, groups of 10 
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BALB/c mice were immunized three times at 2-week intervals with either alum alone, 
Į-88×5 in alum, Į-88×8 in alum, or one-tenth of a human dose of either Gardasil or 
Cervarix. Sera obtained 2 weeks after the final immunization were tested for in vitro 
neutralization titers against HPV16 pseudovirions. The titers in sera of mice vaccinated 
with Cervarix were higher than those vaccinated with Gardasil (P = 0.0022). The HPV16 
QHXWUDOL]DWLRQ WLWHUV LQGXFHGE\Į-îDQGĮ-88×8 were similar (P = 0.3870) and 
two logs lower than those for the licensed HPV vaccines (Figure 30C). There was no 
significant difference between ELISA titers 2 weeks after the final immunization with 
Į-88×5 in alum (2,250 ± 380 [n = 20]) and those at 4 months (1,779 ± 221 [n = 19]; 











Figure 31.  Neutralization of raft-derived HPV18 by L2 and L1 VLP-specific antibodies.  
(A and B) HPV18 virions were partially purified from organotypic cultures of PHKs 
containing the HPV18 genomic plasmids [222]. Primary human keratinocytes (PHKs at 4 
× 104/well of twelve-well plates) were seeded in K-SFM and cultured for 3 days. HPV18 
virions were mixed with undiluted or diluted (1:1,250, 1:250, or 1:50) RG-1 or A1 
hybridoma supernatant or different dilutions (1:62,500, 1:12,500, 1:2,500, or 1:500) of 
polyclonal antiserum Į11-88×8 1a and 2a, Į11-88×5 2a, Gardasil 1b and 2b, or anti-
L1L2, and then added to PHKs at an MOI of 500. The cells were cultured for 4 days until 
reaching confluence. In parallel, uninfected PHKs were similarly cultured as a negative 
control. Purified total RNAs were extracted with TRIzol, treated with DNase, and reverse 
WUDQVFULEHG DQG D ȕ-actin cDNA fragment (642 bp) [223] or the spliced HPV18 E1Ê4 
cDNA fragment (211 bp) was amplified by PCR. The PCR products were analyzed by 
electrophoresis in 2% agarose gel and stained with ethidium bromide for imaging. 
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4) Protection of mice from vaginal HPV challenge after vaccination with L2 based and 
licensed L1 VLP vaccines 
To differentiate the breadth of protection elicited by the L2 based and licensed 
HPV VLP vaccines, 10 groups of 10 mice were immunized three times at 2-week 
intervals with PBS alone, alum alone, Į-88×5 in alum, Į-88×8 in alum, or one-tenth 
of a human dose of either Gardasil or Cervarix for comparison. The mice were 
intravaginally challenged with HPV16 pseudovirus, and 3 days later, infection was 
assessed by measuring luciferase activity. The level of infection in mice vaccinated with 
alum alone was the same as that in mice vaccinated with buffer, whereas mice vaccinated 
with either Gardasil or Cervarix were completely protected, as were mice vaccinated with 
HLWKHUĮ-îRUĮ-88×8 (Figure 32B). 
These studies were extended by vaccinating additional groups of mice as 
described above, and for a positive control, another group of 5 naive mice received 
passive transfer of protective antisera intraperitoneally (i.p.) 1 day prior to challenge, as 
indicated. These groups of vaccinated mice were challenged intravaginally with 
pseudovirions derived from HPV6, HPV26, HPV31, HPV33, HPV35, HPV45, HPV51, 
HPV56, HPV58, or HPV59 (Figure 32). Gardasil, but not Cervarix, provided complete 
protection against HPV6 challenge, because only the former contains HPV6 L1 VLP. 
%RWK Į-î DQG Į-88×8 contain HPV6 L2 residues 11 to 88, and the vaccines 
demonstrated the same level of protection against HPV6 as Gardasil in the mouse 
FKDOOHQJHPRGHO/LNHZLVHĮ-88×5 aQGĮ-88×8 both contain HPV31 L2 and were 
VWURQJO\SURWHFWLYHDJDLQVW+39Į-88×8 contains L2 units derived from HPV51 and 
+39ZKHUHDVĮ-îGRHVQRW:KLOHĮ-88×8 appeared to provide slightly better 
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SURWHFWLRQ DJDLQVW +39 WKDQ Į-88×5, the difference was not significant for either 
HPV51 (P = 0.31) or HPV56 (P = 1.0). For the remaining challenges with virus types 
whose L2 is not represented in either Į-88×5 or Į-88×8, both vaccines provided 
similarly strong protection (no significant difference for HPV26, HPV33, HPV35, 










Figure 32.  Protection of mice from vaginal HPV challenge after vaccination with L2-
based and licensed L1 VLP vaccines.  
For each HPV challenge study, six groups of 10 mice were vaccinated three times at 2-
week intervals with PBS alone, alum alone, Į11-88×5 in alum, Į11-88×8 in alum, or one-
tenth of a human dose of either Gardasil or Cervarix for comparison. If needed as a 
positive control, another group of 5 naive mice received passive transfer of 20 ul antisera 
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i.p. 1 day prior to challenge, including rabbit antisera to HPV31 L1 VLP (D), HPV33 L1 
9/3 ( DQG+39 /9/3 * JHQHUDWHG DV SUHYLRXVO\ GHVFULEHG >@ Į-88×8 
formulated in Freund’s adjuvant (C), or antisera pooled from mice vaccinated 
intramuscularly (i.m.) with HPV58 L1 expression vector (J). New groups of vaccinated 
mice were challenged intravaginally with HPV6 at 2 months after the final immunization 
(A), HPV16 at 1 month after the final immunization (B), HPV26 at 2 months after the 
final immunization (C), HPV31 at 3 months after the final immunization (D), HPV33 at 3 
months after the final immunization (E), HPV35 at 4 months after the final immunization 
(F), HPV45 at 4 months after the final immunization (G), HPV51 at 2 months after the 
final immunization (H), HPV56 at 4 months after the final immunization (I), HPV58 at 4 
months after the final immunization (J), or HPV59 pseudovirions at 7 months after the 













5) Summary of the protection of mice from vaginal HPV challenge obtained after 
vaccination with L2-based and licensed L1 VLP vaccines 
Figure 33 shows that a very high percentage of mice had >90% reduction in 
OXFLIHUDVHVLJQDOGHPRQVWUDWLQJWKDWERWKWKHĮ-îDQGĮ-88×8 vaccines strongly 
protect against members of five medically significant papillomavirus species in the 
mouse vaginal challeQJHPRGHOĮ+39+39Į+39Į+39+39
+39Į+39+39+39+39+39DQGĮ+39*DUGDVLODQG
Cervarix provided some degree of cross-protection against nonvaccine types, notably 
HPV45 and HPV59 (Figure 32 and 33). )RU VHYHUDO JHQRW\SHV YDFFLQDWLRQZLWK Į-
88×5 provided significantly better protection than Cervarix (HPV26, P = 0.0062; HPV35, 
P < 0.0001; HPV51, P < 0.0001; HPV56, P = 0.0007; HPV58, P = 0.0075; HPV6, P < 
0.0001) or Gardasil (HPV26, P < 0.0001; HPV33, P = 0.0002; HPV35, P < 0.0001; 
HPV51, P < 0.0001; HPV56, P = 0.0001; HPV58, P = 0.0069), and similar results were 
REWDLQHGZLWKWKHĮ-88×8 immunogen. Importantly, the protection afforded by the L2 
vaccines persisted at least several months postvaccination in all cases tested, including 7 






Figure 33.  Summary of the protection of mice from vaginal HPV challenge obtained 
after vaccination with L2-based and licensed L1 VLP vaccines.  
The percentage of mice in each vaccine group (n = 10) that exhibited a >90% reduction 
in luciferase signal upon challenge compared to control mice in studies shown in Figure 













Studies of Cervarix and Gardasil demonstrated strong protection against the two 
vaccine-targeted types but only limited protection against persistent infection by most 
other oncogenic HPV types, illustrating the need for broader coverage [11,225]. Indeed, 
clinical efficacy, as measured by persistent infection with an L1-based vaccine like 
Cervarix, against any nonvaccine oncogenic HPV type at 6 and 12 months is 11.3% 
(96.1% confidence interval [CI], 3.7% to 18.3%) and 10.9% (96.1% CI, -0.9% to 21.4%), 
respectively [75], and Malagón et al. suggest that there is some evidence for waning of 
cross-protection with increased follow-up [76,77]. Gardasil exhibits 23.4% (95% CI, 
7.8% to 36.4%) efficacy for protection against CIN1-3 or AIS associated with 10 
nonvaccine oncogenic HPV types, although this is not directly comparable to the above-
mentioned data for Cervarix [11,75]. Both L2-based vaccines provide broad protection in 
mice against vaginal challenge with diverse members of the genus Į papillomaviruses, 
notably at least nine oncogenic HPV types that are responsible for cervical cancer. An 
HPV vaccine that is broadly effective against all members of the Į HPV genus is likely to 
reduce the number of patients with atypical squamous cells of undetermined significance 
(ASCUS), low-grade squamous intraepithelial lesions (LSIL), and high-grade squamous 
intraepithelial lesions (HSIL) that require colposcopy and more-intensive follow-up, 
potentially providing significant cost savings. 
There was no difference in the HPV16 pseudovirion-neutralizing antibody titers 
induced by vaccination with Į11-88×5 or Į11-88×8, but the titers were two orders of 
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magnitude lower than those observed for the licensed HPV vaccines. However, the 
currently used in vitro neutralization assays were recently shown to underestimate the 
protective capacity of L2 antibodies because of differences in the infection process in 
cervicovaginal tissues versus cultured cells [226]. Consistent with this observation, robust 
protection from experimental pseudovirus challenge was observed in mice even 5 to 7 
months postimmunization with the L2 vaccines formulated in alum despite low titers, as 
measured in the conventional neutralization assay used herein, and the use of higher 
doses of pseudovirions in the in vivo assays. These observations suggest that the new 
neutralization assay described by Day et al. [226], or a higher-throughput version, might 
better be used to assay the serum titers of vaccinated patients during the clinical 
development of the L2 multimer vaccine. 
Although vaccination of healthy volunteers with an HPV16 L2E6E7 protein 
(without an adjuvant) has been shown to elicit L2-specific (cross-) neutralizing serum 
antibody responses [227,228], the ability of an alum-formulated L2 vaccine to protect 
patients from natural acquisition of HPV and the duration of protective immune 
responses remain an open question. However, vaccination of healthy volunteers with 
HPV6 L2E7 formulated in alum produced robust serum IgG responses and antigen-
specific T cell proliferative responses, apparently stable at least 6 months after 
vaccination [229], and our mouse challenge studies indicate that protection is maintained 
at least this long. Likewise, cattle maintained protection for 1 year after vaccination with 
L2 [230]. Durability of protection is a critical issue for assessing the need for booster 
immunizations and cost/benefit analyses since HPV vaccines are ideally given several 




Like Gardasil, the L2-based vaccines were also highly effective for protection of 
mice against vaginal challenge with HPV6. HPV6 and HPV11 are the major types found 
in genital warts, but HPV40, HPV42, HPV43, HPV44, etc., also contribute a significant 
fraction of genital warts [231], and rabbit antisera to Į11-88×8 effectively neutralize 
these types (data not shown). While genital warts are benign, they cause significant 
morbidity, and approximately $200 million is spent annually on their treatment in the 
United States alone [232]. 
A broadly protective HPV vaccine may be particularly beneficial to patients with 
HIV infections or who are immunosuppressed following organ transplantation. These 
patients are more prone to infection associated with unusual HPV genotypes not targeted 
by the current HPV vaccines, and the lesions can be more persistent and recalcitrant to 
treatment [233]. 
Based on passive-transfer experiments, protection in the vaginal challenge model 
is mediated by neutralizing antibodies. Importantly, antisera to the L2 vaccines 
effectively neutralized native HPV18 virions derived from organotypic rafts, suggesting 
that the protection does not represent an artifact of the pseudovirion system utilized in 
these studies. Although comparable in endpoint neutralization titers to Gardasil in this 
assay, it is important to note that the L2 vaccines were administered in CFA/IFA rather 
than alum (Table 5). It should also be noted that several animal studies using wart-
derived virus for challenge have demonstrated the capacity of L2-based vaccines to 
protect against BPV4 in the soft palate of cattle, rabbit oral papillomavirus (ROPV) in the 
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oral mucosa of rabbits, and cottontail rabbit papillomavirus (CRPV) in skin [110,187]. 
The Į11-88×5 and Į11-88×8 vaccines induced indistinguishable titers of HPV16-
neutralizing antibodies, suggesting that immunologic competition between units is not a 
significant issue. There was no statistically significant difference in the protection against 
vaginal challenge with any of the 11 different virus types tested that was induced by 
vaccination with Į11-88×5 or Į11- 88×8. These findings suggest that it is not necessary 
to include a unit of L2 derived from each species to achieve broader protection against 
diverse medically significant HPV types than is achieved with the licensed HPV vaccines 
in the mouse vaginal challenge model. 
The current HPV vaccines do not overcome the need for continuing cervical 
cancer screening programs because they do not protect against many oncogenic HPV 
types. The substantial burden to health care systems of maintaining both primary and 
secondary prevention programs might be reduced by a vaccine that provides effective 
protection against all oncogenic HPV types. Further, the introduction of a broadly 
protective vaccine is particularly important in low-resource settings that lack cytologic 
screening, and low cost is an important factor in reaching these populations [74]. The 
findings herein using the mouse vaginal challenge model suggest that Į11-88 L2 
multimer vaccines produced by bacterial expression and formulated in alum (a low-cost 







As there are billions of people who need HPV vaccines in developing countries 
but cannot afford the current licensed vaccines due to their high cost, and because current 
vaccines do not provide complete protection against the 15 known oncogenic HPV types, 
next generation HPV vaccines should be both cost-effective and broadly protective. We 
have generated several vaccine candidates including naked DNA expression vectors 
expressing L1(±L2), and engineered protein-based L2 vaccines as candidate second 
generation vaccines to address this need. DNA vaccines can be manufactured simply and 
are stable at ambient temperature. Immunization with L1-expressing DNA utilizing in 
vivo electroporation induced antibody responses with high neutralization titers 
approaching those elicited by Cervarix and Gardasil. We mixed L1 DNAs from multiple 
different HPV types and immunized mice with the DNA mixture expecting broad 
protection against diverse HPV types. However, when L1 DNAs were mixed together 
reduced neutralization titers were observed with certain combination of types, likely 
resulting from heterotypic L1 interactions that can be observed in co-
immunoprecipitation studies. Vaccination with L1 DNA vaccines of different types at 
different sites resolved this interference. Thus, multivalent vaccination via in vivo 
electroporation optimally requires spatial separation of individual type L1 DNA vaccines, 
although this issue could be ameliorated by inclusion of L2 in each construct. 
Although L1 DNA vectors have potential as an inexpensive and heat stable 
approach to HPV vaccination, injecting L1 DNA of different types at different sites and 
the use of electroporation make this approach complex and costly to apply clinically, and 
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electroporation is also associated with significant local pain. Thus, we next examined the 
potential of the L2 minor capsid protein as an immunogen because it is known to elicit 
broad protection, although L2 immunity is associated with low antibody titers compared 
to L1 VLP vaccines. In an effort to enhance immune presentation of L2, we engineered 
key L2 protective epitopes into diverse antigen forms. Initially, a chimeric L1 capsomer 
was utilized as a platform to display L2 protective epitopes in which the N-terminal 
residues of HPV18, HPV31, and HPV45 L2 were fused in tandem with the C-terminus of 
L1 without compromising its self-assembly into a capsomer. Vaccination with capsomer-
L2 elicited complete protection against HPV16 and HPV18 intravaginal challenge. 
However we could not measure detectable neutralization titers against HPV18, HPV31, 
and HPV45, suggesting that the in vivo intravaginal challenge assay is more sensitive 
than the in vitro neutralization assay and that L2 antibody response elicited by capsomer-
L2 vaccination is weak. 
Next, a key conserved and protective epitope of HPV16 L2 (recognized by the 
RG1 neutralizing monoclonal antibody) was linked to DE surface loop of HPV16 VLP in 
order to display the RG1 epitope (aa 17-36) on the surface of the VLP. We hypothesized 
this would enhance the L2 antibody response as VLP is a more potent platform than 
capsomer, and the epitope was inserted into an immunodominant loop that contributes to 
the structure of a conformational and neutralizing L1 epitope. RG1-VLP generated 
detectable, but somewhat varied, cross-neutralizing antibody titers and complete 
protection against diverse HPV types. Titers were higher against HPV types 
phylogenetically close to HPV16 but low against other types possibly because single 
HPV16 L2 was used as an immunogen. However, it is important to note that the L2-
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specific response was still far weaker than the corresponding L1-specific antibody titers.  
This indicates that the RG1-VLP conformation kept most L1 neutralizing epitopes intact, 
but the presentation of the linear L2 neutralizing epitope was not as efficient as the 
conformational L1 epitope that it replaced. 
We hypothesized from previous results that high neutralization titers to diverse 
HPV types can be achieved when the N-terminus of L2 from multiple HPV types is 
administered fused together as a concatemer, i.e. a linear array as opposed to the three 
dimensional display of L2 in a chimeric VLP. Thus, we generated L2×8 fusing protective 
domains comprising L2 residues 11-88 derived from eight different HPV subtypes. 
Neutralization titers elicited by L2×8 given in alum+MPL adjuvant were robust against 
vaccine and even non-vaccine HPV types, although still lower seen with L1 VLP 
vaccines. Complete protection was also observed against numerous HPV types including 
high and low risk types, suggesting L2×8 has potential as a candidate prophylactic HPV 
vaccine to provide broad immunity. However, the yield of L2×8 upon recombinant 
expression and column chromatography was low because of llow expression levels and 
substantial degradation during production in E. coli. 
We eliminated the hydrophobic region at N-WHUPLQXVRI//îǻ WRHQKDQFH
the yield, as consecutive hydrophobic residues appeared contribute to protein aggregation 
and degradation. Although the yield was considerably increased after removal, 
neutralization titers eliciteGE\YDFFLQDWLRQZLWK/îǻZHUHVLJQLILFDQWO\GHFUHDVHGE\
about ten-fold) compared to L2x8. Since this might reflect the deletion of a key CD4 T 
helper epitope (and because in silico analysis predicted that the deleted hydrophobic 
region contains promiscuous MHC class II epitopes), we attempted to complement this 
198 
 
ORVV YLD IXVLRQ RI WKH NQRZQ SURPLVFXRXV &' 7 KHOSHU HSLWRSH 3$'5( WR /îǻ
protein and thus rescue immunogenicity. Neutralization assays of antisera indicated that 
titers were not recovered afWHU DGGLWLRQ RI 3$'5( WR /îǻ FRQVWUXFW LPSO\LQJ WKDW
reduction of immunogenicity by elimination of hydrophobic region was not because of 
loss of CD4 helper epitope but possibly because of other reasons, such as changes in the 
structure of the epitope. 
We postulated that decreasing the number of L2 repeats in the L2 multimer would 
improve yield while maintaining immunogenicity, as there would be a lesser number of 
hydrophobic regions in the L2 multimer in this case. A truncated derivatives of L2×8 
with the last three units deleted (L2×5) was produced at a significantly higher yield and 
with less evidence of degradation. Further vaccine efficacy was measured to examine if 
the L2×5 multimer elicits comparable neutralization titers and protection to the L2×8 
vaccine. Fortunately, a significant increase in protein yield in E. coli was observed after 
truncation, and L2×5 elicited robust antibody responses with high neutralization titers and 
potent protection against diverse HPV types with similar efficacy to the L2×8 vaccine.  
These results suggest that L2×5 is a promising candidate second generation HPV vaccine. 
In conclusion, the current prophylactic HPV vaccines do not overcome the need 
for continued pap-smear screening because of the type-restricted protection properties of 
these vaccines, and their high price limits access of the vaccine to people in developing 
countries. To overcome the disadvantages of current vaccines, we examined several 
inexpensive and broadly protective next generation HPV vaccine candidates including L1 
DNA and engineered L2 protein vaccines. After thorough evaluation, we concluded that 
the L2×5 and RG1-VLP are the best candidates and suggest that they warrant further 
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testing in early phase trials. It will be important to optimize the immunogenicity of L2 in 
patients by use of an appropriate adjuvant because of the need for durable protection, but 
given the priority for safety, initial efforts will focus on these L2 vaccines formulated in 
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